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Let every dawn be to you as the beginning of life, and every setting sun be to you 
as its close. Then let every one of these short lives leave its sure record of some 










XP is considered a disease of failed repair of direct UVR-induced DNA 
photoproducts, leading to severe sunburn, extremely high rates of skin cancer, 
and death in young adulthood from complications relating to malignancy and 
neurodegeneration. Most experiments in the literature on XP cells, both for 
diagnosis and interpretation of photobiological processes, have used non-solar 
UVC radiation. 
 
Discernable differences in clinical phenotype have emerged from long-term 
follow-up of XP patients in the UK National XP clinic. The development of a 
sunburn severity score revealed that XP-C, XP-E and XP-V patients have normal 
sunburn reactions; a cohort of milder XP-A patients has been identified, arising 
from a likely founder mutation yielding less than 5% read-through of normal 
XPA protein. Deep phenotyping, including the development of ocular and 
neurological severity scores, has resulted in precise correlation of XP phenotype 
with the causal mutation, enabling the development of personalized prognostic 
advice for XP patients worldwide. 
 
Based on XP phenotype patterns, molecular experiments were conducted on skin 
fibroblasts from a range of XP complementation groups using environmentally 
relevant 385nm UVA-1 compared with 254nm UVC. UVA-1 was a more 
effective inducer of MMP mRNA and protein than UVC, by a mechanism 
independent of CPD. MMP upregulation was proportional with ROS generation, 
and this effect was attenuated when vitamin E was added to cell culture, 
providing indirect evidence that UVA-1-induced ROS was the main cause of 
MMP upregulation. 
 
The effects of UVA in XP literature have been largely ignored; studies here 
highlight that XP is a disease of impaired defenses against direct and indirect 
UVR-induced damage, which may explain sunburn, photoageing, skin cancer 
and neurological phenotype.  
 
These studies demonstrate the importance of translational research in this rare 
genetic disease. Photoprotection from solar-UVA, together with antioxidants, 
may provide a future gold standard for photoageing in the general population. 
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Abbreviations 
*OH  Hydoxyl radical 
1O2  Singlet oxygen species 
6-4PP  pyrimidine-pyrimidone (6-4) photoproducts 
8-OxoGua 8-oxo-7,8-dihydro-2'-deoxyguanosine 
ACTH  Adrenocorticotropic hormone 
AP-1  Activator protein 1 
BCC  Basal cell carcinoma 
BER  Base excision repair 
CHS  Contact hypersensitivity 
CIE  Commission Internationale de L’Eclairage (CIE), 
CPD  Cyclobutane pyrimidine dimers 
Ct  Cycle threshold 
cyPudNs 8,5′ -cyclopurine-2′ -deoxynucleosides 
DAPI  4',6-diamidino-2-phenylindole 
DEJ  Dermo-epidermal junction 
DEPC  Diethyl pyrocarbonate 
DHS  Delayed hypersensitivity 
DNA  Deoxyribonucleic acid 
DT  Delayed tanning 
ECM  Extracellular matrix 
ERCC  Excision repair cross-complementation group 
FBS  Fetal bovine serum 
GG-NER Global genome nucleotide excision repair 
GPX  Glutathione peroxidase 
HO-1  Heme oxygenase 1 
HPLC  High-performance liquid chromatography 
IL-1  Interleukin 1 
IPD  Intermediate pigment darkening 
KEAP-1  Kelch-like-ECH-associated protein 1 
KC  Keratinocyte cancer 
LC  Langerhans cells 
MAPK  Mitogen-activated protein kinase 
MED  Minimal erythema dose 
miRNA microRNA 
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MM  Malignant melanoma 
MMP  Matrix metalloproteinase 
mRNA  Messenger ribonucleic acid 
NER  Nucleotide excision repair 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NQO-1 NAD(P)H dehydrogenase. quinone 1 
NRF-2  Nuclear factor erythroid-2-related factor 2 
O2*
-  Superoxide radical 
OGG-1 8-oxoguanine DNA glycosylase 
PBS  Phosphate buffered saline 
PBST  Phosphate buffered saline + tween20 
PCR  Polymerase chain reaction 
Polη  DNA polymerase η 
PPD  Persistent pigment darkening 
qRT-PCR quantitative reverse transcription polymerase chain reaction 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species 
RPA  Replication protein A 
SCC  Squamous cell carcinoma 
SED  Standard erythema dose 
SOD  Superoxide dismutase 
SPF  Sun-protection factor 
SSR  Solar-simulated radiation 
SSS  Sunburn severity score 
T4N5  T4 endonuclease V 
TC-NER Transcription-coupled nucleotide excision repair 
TF11H  Transcription factor 11 human 
TGF-β  Transforming growth factor beta 
Th  T-helper lymphocytes 
TIMP  Tissue inhibitor of metalloproteinase 
TLS  Translesional synthesis 
TNF-α  Tumour necrosis factor alpha 
UDS  Unscheduled DNA synthesis 
UVA-1 Ultraviolet A-1 radiation  
UVB  Ultraviolet B radiation  
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UVC  Ultraviolet C radiation 
UVR  Ultraviolet radiation 
XP  Xeroderma pigmentosum 
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1.1. Ultraviolet radiation (UVR) 
Ultraviolet radiation (UVR) is a relatively short waveband within the 
electromagnetic spectrum. Depending on wavelength, UVR can be subdivided 
into UVC (100-280nm), UVB (280-315nm), UVA-2 (315-340 nm) and UVA-1 
(340-400nm) (Commission Internationale de l’Eclairage (International 
Commission on Illumination (CIE), 2014). At its highest, the sun emits a 
maximum of ~95% UVA and ~5% UVB; all UVC is absorbed in the atmosphere 
by ozone (O3), dioxygen (O2) and water vapor (H2O) (Chou et al., 1996). 
However, the ratio of UVA: UVB depends on the height of the sun above the 
horizon, known as the solar zenith angle. The higher the sun, the greater the 
UVB intensity.  
 
1.2. UVR penetration of the skin 
The different wavelengths of UVR have different penetration depths within the 
skin. Wavelengths above ~300nm (UVA and UVB) reach the basal layer of the 
epidermis, containing keratinocytes and fibroblasts (Figure 1.2.1). The longer 
UVA waveband has the greatest penetration depth (Figure 1.2.2, Agache and 
Humbert, 2004). Absorption of UVR photons within the skin is strongly 
dependent on wavelength and specific wavelengths give rise to different 
photobiological efficiencies, which has led to the concept of “action spectrum” 
for a given photobiological outcome (Young, 1997).  The absorption of UVR 
photons by different cellular chromophores results in various acute and long-




Figure 1.2.1: Morphology of human skin in a normal adult skin biopsy (scale bar = 50μm). 
Haematoxylin and eosin (H&E) staining showing the epidermis containing 
keratinocytes, the dermis containing fibroblasts and a cross section of a blood vessel 





Figure 1.2.2: Penetration depth of optical radiation (adapted from Figure 48.2, page 472, 
“Measuring the Skin” Agache & Humbert, 2004).  
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1.3. Acute effects of UVR 
1.3.1. Erythema (sunburn) 
UVR absorption by chromophores in epidermal keratinocytes can result in 
erythema (sunburn). Clinically, sunburn is recognised as a confluent, well-
demarcated, erythematous, sometimes oedematous and tender reaction, caused 
by vasodilation and inflammation. Histologically sunburn is recognised by 
apoptotic keratinocytes (known as sunburn cells (SBC), Young, 1987) within 
the epidermis. The sunburn response is mediated by local histamine and 
prostaglandin release, as well as other pro-inflammatory cytokines (Gilchrest et 
al., 1981, Barr et al., 1999, Brink et al., 2000). 
 
Erythema intensity is determined by the total UVR dose delivered to the skin 
(UVR dose = irradiance x time), therefore low intensity (irradiance) over a long 
time period has an equal effect to high irradiance over a short time period, a 
relationship known as reciprocity (Meanwell & Diffey, 1989). Erythema 
intensity and duration are also a function of UVR wavelength (Bachem, 1955, 
Gange et al., 1987, Hruza and Pentland, 1993); erythema induced by UVC starts 
to resolve within 3 hours of exposure, however UVB and UVA-induced 
erythema may last for days. This phenomenon may be explained by wavelength 
penetration and therefore chromophore absorbance within the skin (Figure 1.2.2 
and see section 1.5). 
 
UVR-induced erythema is strongly dependent on the amount of constitutive skin 
pigmentation; moderate to dark pigmentation requires a 3 to 30 fold higher UVR 
exposure dose compared to fairer skin, respectively (Höningsmann, 2002, 
Fajuyigbe & Young, 2016).  
 
For any given individual (regardless of skin pigmentation) the lowest dose of 
UVR that causes clearly demarcated erythema is termed the minimal erythema 
dose (MED, Harrison & Young, 2002). Through consolidation of data from 
previous studies, a reference erythema action spectrum has been established 
(Figure 1.3.1) indicating that UVB is orders of magnitude more effective at 
inducing erythema (per unit dose in J/m2) than UVA (Diffey et al., 1984, 
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McKinlay & Diffey, 1987). For example, the median MED at 300nm (UVB) is 
0.025J/cm2, whereas that at 360nm (UVA) it is 32J/cm2 (Young, 1998). 
 
 
Figure 1.3.1: Reference action spectrum for UVR-induced erythema in human skin, as accepted by 
the CIE. 
 
Erythema induced by UVA and UVB has a biphasic response, although the time 
frames differ significantly (Hruza & Pentland, 1993); UVB induces an 
immediate phase lasting a few minutes, followed by a prolonged phase peaking 
12-24 hours after exposure and resolving by 72 hours (Gilchrest et al., 1981). 
2.5 MED UVA induces erythema immediately, peaking at 8 hours and persisting 
for 24-48 hours, strongly dependent on dose (Kaidbey & Kligman, 1979, 
Gilchrest et al., 1983). For both UVA and UVB the immediate-phase response 
has been histologically characterized as vasodilatation of the dermal vasculature 
(Ramsey & Challoner, 1976). The prolonged phase demonstrates more 
significant dermal injury; sunburn cells appear with UVB-induced erythema, 
although they are not apparent with UVA (Soter, 1990). Instead UVA-induced 
erythema causes a dense mononuclear cell infiltrate, with severe vascular and 
endothelial damage, dermal leakage of red blood cells and fibrin deposition 
(Kumakiri et al., 1977). 
 
Erythema is used as the end-point for many photobiological studies involving 
the skin (Höningsmann, 2002). Given the subjectivity of assessing individual 
MED, more recent biological/epidemiological studies on UVR use dose 
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measurements in standard erythemal doses (SED, Diffey et al., 1997), defined 
as a fixed dose of 100J/m2 of a spectrum that is biologically weighted by the 
CIE erythema action spectrum (Figure 1.3.1). Therefore the SED can be used to 
compare erythema induced by different spectral UVR sources (Harrison & 
Young, 2002).  
 
1.3.2. Changes in skin melanin 
There is a biphasic response in pigmentation after UVR exposure that includes 
immediate pigment darkening (IPD), persistent pigment darkening (PPD) and 
delayed tanning (DT). IPD occurs immediately after UVR and involves 
oxidation of existing melanin and redistribution of melanosomes (Tadokoro et 
al., 2005, Young, 2006). IPD peaks at 2 hours after UVR exposure and 
subsequently fades or, at doses of greater than 10J/cm2 UVA, it is followed by 
PPD (Bissonnette et al., 2000). DT is associated with an increase in the number 
and activity of melanocytes, resulting in de novo melanin synthesis. This 
pathway is activated by α-melanocyte stimulating hormone (α-MSH) and 
adrenocorticotrophic hormone (ACTH) synthesized by epidermal melanocyte 
and keratinocytes (Im et al., 1998).  
 
The differing wavelength penetration depths of UVA exert varying effects on 
melanin distribution; long wave UVA-1 irradiation stimulates basal layer 
melanocytes whereas shorter UVA-2 results in the transfer of melanosomes to 
epidermal keratinocytes (Matsumura & Ananthaswamy, 2002).  
 
Melanin is a chromophore for UVR (Figure 1.3.2) that is integral to its 
photoprotective properties. This has been demonstrated in vivo showing modest 





Figure 1.3.2: Spectral absorbance of melanin: a) constitutive melanin; b) UVB-induced melanin 
and c) UVA-induced melanin (Young 1997). 
 
1.3.3. Immunosuppression 
UVR exposure at erythema-inducing doses (i.e. mainly UVB) mediates 
suppression of T-lymphocyte populations, leading to immunosuppression 
(Morison et al., 1978). Histological examination of skin shows a transient 
reduction in epidermal Langerhans cells (LC) 4 hours after irradiation (Gilchrest 
et al., 1981). LC function within the adaptive immune system to present antigens 
to CD4+ T-helper (Th) lymphocytes (Simon et al., 1990); the number of Th 
reduces significantly after UVR exposure (Rivers et al., 1989).  
 
Clinically UVR-induced immunosuppression manifests as a reduction in the 
cutaneous effect of normal contact hypersensitivity (CHS) and delayed 
hypersensitivity (DHS) responses, which is directly proportional to the 
induction of skin erythema (Kelly et al., 2000). As UVB only penetrates through 
to the epidermis (Figure 1.2.2), the molecular mechanisms of 
immunosuppression have been proposed to occur through different 
photoreceptors: Trans-urocanic acid (trans-UCA) is found in the stratum 
corneum, and isomerises to its cis form through absorption of UVB irradiation 
(see Figure 1.5.1B), mediating suppression of CHS (Noonan et al., 1988, 
Noonan & De Fabo, 1992, Norval et al., 1989, Hart et al., 1997). UVR-induced 
DNA damage may also act as a photoreceptor; prevention of the UVR-induced 
suppressive CHS response occurred by repairing UVR-induced DNA damage 
using photoreactivating enzymes (Applegate et al., 1989) and T4 endonuclease 
enzymes (Kripke et al., 1992). 
 
UVR-mediated immunosuppression to a range of antigens has been investigated 
both locally and systemically (Kripke, 1984). Evidence for systemic 
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immunosuppression has been demonstrated in mice exposed to high UVR doses, 
as CHS is not induced at unirradiated sites (Noonan et al., 1983). In addition 
UVR has been shown to induce long-term antigen-specific immunologic 
tolerance: contact antigens applied to UVR-irradiated skin did not induce CHS, 
either at the time of irradiation or weeks later (Toews et al., 1980). 
 
Topical application of immunomodulating drugs that activate or restore the local 
skin immune response, such as imiquimod and interferon, have been used 
successfully to treat both pre-cancerous and cancerous skin lesions (Urosevic & 
Dummer 2002, Tyring et al., 2002), implying an accountability of UVR- 
immunosuppression in photocarcinogenesis.  
 
In contrast to pathogenesis, immunosuppression arising from UVR has been 
exploited as a treatment for diseases that result from immunological over-
activity; phototherapy using both UVA and UVB can be used to treat a wide 
range of immune-mediated dermatological conditions such as psoriasis, atopic 




1.3.4. Vitamin D 
Vitamin D is a fat-soluble steroid hormone essential for calcium homeostasis; 
vitamin D deficiency has been associated with development of autoimmune 
diseases, carcinogenesis, cardiovascular and infectious disease, schizophrenia 
and type 2 diabetes (Wacker & Holick, 2013). Interestingly, prospective studies 
have shown impressive reductions in both acute and chronic health disorders 
with increasing vitamin D levels, however interventional randomised controlled 
trials supplementing vitamin D have shown little or no effect (Autier et al., 
2014) and hence the associations between improving disease outcomes and 
increasing serum vitamin D may not be causal.  
 
The skin is the main source of vitamin D; exposure to one MED in a tanning 
bed is equivalent to 20,000IU of ergocalciferol (oral vitamin D2) (Holick, 2008). 
UVB irradiation of the skin is absorbed by 7-dehydrocholesterol (provitamin D) 
within the cytoplasm of epidermal keratinocytes and results in the formation of 
previtamin D3. Previtamin D3 undergoes temperature-dependent transformation 
into biologically inert vitamin D3
 (Holick et al., 1987). Shortly after its 
formation, inert cellular vitamin D3 is released from skin cells into the 
extracellular space, diffusing into the dermal capillary bed where it binds to 
vitamin D-binding protein (Haddad et al., 1993). Active vitamin D3 requires two 
hydroxylation steps, initially to 25(OH) vitamin D3 (occurring mainly in the 
liver) and subsequently to active 1,25(OH)2 vitamin D3 (mainly in the kidney), 
however vitamin D hydroxylation enzymes are also found in other organs, 
including the skin (Bikle, 2014). 1,25(OH)2 vitamin D3 binds to the vitamin D 
receptor expressed on many different cell types, exerting intranuclear effects on 
the transcription of a wide range of genes (Holick, 1987).  
 
The action spectra for erythema and previtamin D synthesis overlap in the UVB 
range (Springbett et al., 2010, CIE, 2006), therefore sunscreens designed to 
absorb UVB may reduce the capacity of the skin to produce vitamin D3 by the 
same proportion (Holick, 2007). Longitudinal, randomised controlled studies 
have shown that vitamin D levels increased by the same amounts in both people 
who applied sunscreen and in those who did not (Marks et al., 1995, Farrerons 
et al., 1998, Norval & Wulf, 2009). This may be in part due to erratic application 
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of sunscreen at less than the recommended dose of 2mg/cm2 (Bech-Thomsen & 
Wulf, 1992, Wulf et al., 1997, Autier et al., 2001) however by default, 
sunscreens will allow a fractional (1/sun-protection factor (SPF)) penetration of 
incident UVB photons and perhaps the use of sunscreens (with inadequate 
application) may even encourage more sun exposure, thereby increasing vitamin 
D levels (Kimlin et al., 2007). People with photosensitive disorders who practice 
strict sun-avoidance will most likely become vitamin D deficient unless they are 
supplemented with oral vitamin D. This is of particular importance in patients 
who have developed malignant melanoma as lower vitamin D levels are 
associated with an increase in relapse rate (Newton-Bishop et al., 2009). It has 
been argued that the global burden of disease resulting from vitamin D 
deficiency is far greater than that resulting from overexposure to sunlight (Lucas 
et al., 2008). 
 
1.4. Long-term effects of UVR 
1.4.1. Photoageing 
Photoageing (extrinsic skin ageing) comprises specific clinical, histological and 
functional features of chronic UVR-exposed skin (Berneburg et al., 2000). 
Clinically, chronic UVR exposure leads to dry, leathery skin, with coarse 
wrinkles and increased skin fragility, occurring at an earlier age than intrinsic 
(chronological) skin ageing (Berneburg et al., 2000). Histologically this is 
associated with a loss of dermal architecture through a reduction in skin collagen 
and elastin fibres (solar elastosis) occurring within the dermal extracellular 
matrix (ECM). These ECM fibrous proteins originate from dermal fibroblasts in 




Figure 1.4.1: Cellular and extracellular components of young skin: dermal fibroblasts synthesize 
the ECM, composed of collagens, elastic fibre-associated proteins and proteoglycans. 
Fibrillar collagens (I and III) are abundant in the papillary and deep reticular dermis. 
The distribution of collagen VII is confined to anchoring fibrils at the dermal-
epidermal junction (DEJ). The elastic fibre system has a highly ordered architecture: 
perpendicularly oriented fibrillin microfibrils at the DEJ merge with elastin-rich 
elastic fibres in the reticular dermis (from Naylor et al., 2011). 
 
Functionally the loss of collagen and elastin fibres leads to a reduction in skin 
tensile and mechanical strength, elasticity and hydration, through 
glycosaminoglycan degradation (Gosline et al., 2002, Waller and Maibach, 
2006). The pattern of ECM protein degradation differs in photoageing compared 
to intrinsic ageing of skin (see Figure 1.4.2). The major structural ECM protein 
is type 1 collagen (Nimni, 1983), abundant in skin connective tissue. The half-




Figure 1.4.2: ECM remodeling in intrinsically and extrinsically aged skin. Dermal collagens, 
elastic fibres and glycosaminoglycans (visualised with picrosirrius red, Miller’s 
elastin and periodic acid staining respectively) all undergo significant, yet differential 
remodelling in extrinsically and intrinsically aged skin. Extrinsically aged 
(photoaged) skin shows a reduction in fibrillar collagen staining and loss of collagen 
VII from DEJ. Later stages of photoageing are characterised by disorganised elastic 
fibre protein accumulation throughout the dermis, known as solar elastosis. 
Intrinsically aged skin shows atrophy of dermal collagens in the reticular dermis and 
in the elastic fibre system at the DEJ. Glycosaminoglycans, which are lost in 
intrinsically aged skin, accumulate in disorganised aggregates in extrinsically aged 
skin (adapted from Naylor et al., 2011). 
 
The mechanism of photoageing is proposed to occur through upregulation of 
matrix metalloproteinase (MMP) enzymes (Scharffetter et al., 1991, Fisher et 
al., 1996, 2001, 2002, Lahmann & Young, 2001, Dong et al., 2008, Tewari et 
al., 2012, Kim et al., 2013). MMP comprise collagenases (e.g. MMP-1, MMP-
8, MMP-13), gelatinases (e.g. MMP-2, MMP-9) stromelysins (e.g. MMP-3, 
MMP-10, MMP-11) and metalloelastases (e.g. MMP-12). MMP-12 has a 
crucial role in the development of solar elastosis (Ashworth et al., 1999, Taddese 
et al., 2009) as well as activating pro-MMP-1 (Chakraborti et al., 2003). Figure 
1.4.3 lists the MMP that are upregulated by either UVA and/or UVB 
(Pittayapruek et al., 2016). 
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Figure 1.4.3:  Role of UVA and UVB in photoageing induced by MMP (Pittayapruek et al., 2016). 
 
Once activated, MMP may be subsequently inhibited by tissue inhibitors of 
metalloproteinases (TIMP); TIMP-1 and TIMP-3 are the main general inhibitors 
(Brew & Nagase, 2010). In vivo studies, typically with acute UVR exposure, 
suggest that epidermal keratinocytes are the main source of skin MMP  (Quan 
et al., 2009, Tewari et al., 2014), however in vitro studies show that dermal 
fibroblasts may also be an important producer of MMP (Fagot et al., 2002, 
2004). Many studies on photoageing have demonstrated the role of UVR 
exposure in upregulation of MMP, however the pathway through which this 
occurs is still the subject of debate and may be in part due to the UVR 
wavelength penetrations depths in the skin, and varying action spectra for 
different MMP.  
 
There are currently two main schools of thought: on one hand, UVR-induced 
DNA damage, such as cyclobutane pyrimidine dimers (CPD see section 1.5.2), 
have been shown to increase levels of MMP-1 and this has been supported by 
in vitro studies of normal fibroblasts showing that exogenous endonuclease 
(T4N5) enhancement of CPD repair results in a reduction of MMP-1 at the 
mRNA and protein level (Dong et al., 2008). On the other hand, UVA is known 
to be a major cause of oxidative stress, generating reactive oxygen species 
(ROS), causing upregulation of MMP-1 both in vitro and in vivo (Scharffeter et 
al., 1991, Scharffeter-Kochanek et al., 1993). ROS activate the mitogen-
activated protein kinase (MAPK) pathway (see Figure 1.4.4) leading to 
signalling of activator protein-1 (AP-1) (Angel et al., 1987, Fisher et al., 2002). 
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AP-1 is essential to regulating transcription of MMP-1 (Stein et al., 1989). AP-
1 activity causes inhibition of transforming growth factor beta (TGF-β) by 
downregulating its receptor and also interfering with its transcriptional 
activation of collagens I and III (Quan et al., 2001, 2002, 2004).  
 
 
Figure 1.4.4: How UVR initiates MMP upregulation via ROS (schematic diagram from  
Pittayapruek et al., 2016). 
 
Tying these two schools of thought together, a recent paper has shown that the 
chemiexcitation of melanin produces “dark CPD” (CPD caused without direct 
absorption of a UVR photon), with a peak at 3 hours after UVR exposure (Premi 
et al., 2015). These CPD are formed as a consequence of the combination of 
UVR-induced reactive oxygen and nitrogen species and could be potentially 
contributing to MMP upregulation. 
 
1.4.2. Skin cancer 
The most common skin cancers are keratinocyte cancers (KC) (previously 
termed non-melanoma skin cancers (NMSC) comprising squamous cell (SCC) 
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and basal cell (BCC) carcinomas) and malignant melanoma (MM), with MM 
accounting for 2% of all cancer-related deaths (Cancer Research UK, 2015). KC 
incidence rates continue to rise with advancing age in countries with high 
Caucasian populations, particularly Northern European and Nordic countries 
(Asgari et al., 2015, Rudolph et al., 2015, Sella et al., 2015, Rogers et al., 2015, 
Abbas & Kalia, 2016, Callens et al., 2016), contributing to a significant disease 
and therefore economic burden (Guy et al., 2015, Gordon et al., 2015, Doran et 
al., 2015).  
 
The increased rate of skin cancer incidence in the last 50 years, coupled with its 
development at predominantly UVR-exposed sites, linked the cause of 
melanoma to childhood blistering sunburn, and adult chronic cumulative UVR 
exposure to the development of KC in the general population (Glass & Hoover, 
1989).  
 
The mechanism of photocarcinogenesis arises from mutations in one or a 
combination of tumour-suppressor genes (e.g. p53), proto-oncogenes (e.g. ras) 
and DNA repair genes, explained in further detail in section 1.9.8. p53 is known 
as the ‘guardian of the genome’ (Lane, 1992); if DNA damage is induced, p53 
then has a critical role inducing cell cycle arrest and activating programmed cell 
death (Hartwell & Weinhart, 1989). Mutations in p53 have been identified in 
normal skin at UVR-exposed sites (Nakazawa et al., 1994, Jonason et al., 1996) 
in precancerous skin lesions such as actinic keratosis (Brash et al., 2005), KC 
(Campbell et al., 1993, Ziegler et al., 1994, Benjamin & Ananthaswamy, 2007) 
and in MM (Stretch et al., 1991, Lassam et al., 1993, Albino et al., 1994; see 




The metastatic potential of both MM and KC begins with local degradation at 
the dermo-epidermal junction (DEJ) and ECM surrounding the skin cancer by 
MMP (Kleiner & Stetler-Stevenson, 1999). In MM, UVR-induced cytokines 
such as tumour necrosis factor alpha (TNF-α) and interleukins can also activate 
MMP leading to invasion and metastasis (Shellman et al., 2006). 
 
1.5. Molecular mechanisms of UVR-induced damage 
The biological effects of UVR can be classified into those caused by either direct 
damage (through direct absorption of a UVR photon by the chromophore, e.g. 
DNA) or indirect damage as a consequence of UVR excitation of cellular 
chromophores to generate ROS that attack important biomolecules.   
 
1.5.1. Indirect damage from UVR 
ROS or ‘free radicals’ are generated by both indirect and direct mechanisms, 
termed types I and II photosensitised oxidation, respectively (Foote, 1991). In 
type I, an endogenous chromophore absorbs the UVA photon to form a triplet 
energy state. This highly reactive molecule then interacts with other surrounding 
substrates to produce ROS, e.g. a superoxide anion radical (O2*
-) or a hydroxyl 
radical (*OH). In type II, direct energy transfer to an oxygen molecule results 
in a singlet oxygen species (1O2). 
 
Indirect DNA damage occurs through excitation of cellular chromophores such 
as porphyrin, heme and bilirubin, as well as fluorophores in extracellular matrix 
proteins, all of which absorb in the UVA range (Wondrak et al., 2006). 
Absorption of UVR photons by flavins and porphyrins can lead to a 
‘photosensitization effect’, a cause of photosensitive disorders (Smith et al., 
2012). Other chromophores absorbing in the UVA range are melanin and 
products of melanogenesis (see Figure 1.5.1C and D; Young, 1997).  
 
ROS are generated from normal aerobic metabolism, as well as from exposure 
to environmental stresses such as UVR and ionizing radiation. When the 
production of ROS exceeds its breakdown or detoxification, the balance shifts 
towards accumulation of ROS, leading to oxidative stress. Oxidative stress is 
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defined as a “disturbance in the balance between the production of ROS and 
antioxidant defenses” (Betteridge, 2000). Tissue damage caused by oxidative 
stress has been implicated in mechanisms of ageing, carcinogenesis and 




Figure 1.5.1: Absorbance of cellular chromophores (Young, 1997), with added lines marking the 
UVA-1 range (340-400nm): A: absorption spectra of calf thymus DNA, L-tyrosine 
and L-tryptophan; B: absorption spectrum of trans-UCA acid, with peak absorption 
at 268nm; C: absorption spectra of melanogenesis products: 5,6-dihydroxyindole 
(DHI), 5-S-cysteinyldopa (5SCD), and 5,6-dihyroxyindole-2-carboxylic acid 
(DHICA); D: apparent absorbance spectra of constitutive melanin in human skin in 
vivo determined by reflectance spectroscopy. 
 
UVR-induced ROS in the form of nitric oxide (NO*) and peroxynitrite radicals 
are implicated in the mechanisms of skin erythema and inflammation (Hruza 
and Pentland, 1993, Deliconstantinos et al., 1995 and 1996). ROS-mediated 
inflammation occurs through activation of transcription factors such as nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-κB) and AP-1 
(Abeyama et al., 2000, Rittie & Fisher, 2002). ROS-induced lipid peroxidation 
has been linked to an increase in lipid mediators such as prostaglandins, which 
are associated with erythema (Logani and Davies, 1980, McCall et al., 1987, 
Wills, 1996). Lipid peroxidation has been demonstrated in an irradiated 
epidermis, together with depletion of natural antioxidants ubiquinone and 
vitamin E (Witt et al., 1991).  
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ROS can cause severe damage to DNA through oxidation of bases, forming 
bulky and non-bulky DNA lesions and single strand DNA breaks (Peak & Peak, 
1991, Kielbassa et al., 1997, Cadet et al., 2009, Cadet, 2011). *OH and 1O2 
generated close to DNA can cause mutations through changing the structure of 
purine and pyrimidine bases, e.g. the formation of 8-oxo-7,8-dihydro-2'-
deoxyguanosine (8-oxoGua) (Demple & Harrison, 1994, Halliwell, 1994). 8-
oxoGua are highly mutagenic if left unrepaired (Le Page et al., 1995). 
 
DNA damaged by *OH causes the removal of hydrogen from the 5-carbon (C-
5) position of 2-deoxyribose; this C-5 sugar radical can add to the 8-carbon (C-
8) of adenine or guanine to generate a cyclopurine deoxynucleoside: 5’,8-cyclo-
2-deoxyadenosine (see Figure 1.5.2) (Kuraoka et al., 2000). Formation of a 
covalent bond between a purine C-8 and the deoxyribose-phosphate backbone 
causes local distortion of the DNA structure. These lesions cannot be removed 
by DNA glycosylases (see section 1.7) and cause interruption of other cellular 
processes.  
 
Figure 1.5.2: Oxidatively-induced DNA lesions: cyclopurine deoxynucleosides (taken from 
Kuraoka et al., 2000): The 5’R and 5’S diastereoisomers of 5’,8-cyclo-2’-
deoxyadenosine in DNA damaged by *OH. In these lesions there are two covalent 
linkages of the purine base to the sugar-phosphate backbone. 
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The higher the metabolic rate of a cell, for example in neurons, the greater 
amount of oxygen is required and therefore more significant DNA damage may 
occur by oxidative stress. A reduced DNA repair capacity means DNA damage 
is left unrepaired, which can result in increased oxidative nucleotide damage 
(Hayashi, 2008), which if left unrepaired can adversely affect cell function and 
integrity (Cortat et al., 2013).  
 
1.5.2. Direct damage from UVR 
DNA is a major chromophore for UVR photons, absorbing maximally around 
260nm (UVC) (Sutherland & Griffin, 1981) but with an absorption tail in the 
UVB and UVA regions (Figure 1.5.1A, Young, 1997). It is established that 
those wavelengths preferentially absorbed by DNA correspond to those that are 
also the most potent inducers of cell death, mutation and erythema (Mitchell, 
1993). There is strong evidence that DNA is the chromophore for erythema as 
the action spectra for erythema and DNA are similar (Young 1998).  
 
Direct absorption of a UVR photon by a DNA molecule may lead to the 
formation of covalent bonds between adjacent bases to form photoproducts. 
These photoproducts consist mainly of CPD or pyrimidine (6-4) pyrimidine 
photoproducts (6-4PP) (Varghese & Patrick, 1969, Cadet et al., 2005). In order 
of frequency, CPDs form between two adjacent thymines (TT) > cytosine-
thymine (CT) > cytosine-cytosine (CC) (Giglia-Mari & Sarasin, 2003).  
 
Photoproducts cause severe local distortion of DNA (Mitchell, 1993, Kim et al., 
1995), leading to interruption and/or cessation of many processes integral to 
cellular function (Gentile et al., 2003). Replication machinery is unable to 
bypass 6-4PP (Nakajima et al., 2004), which may trigger apoptosis if these 
lesions are unrepaired (de Lima-Bessa et al., 2008), whereas bypassing of CPD 
for DNA replication can occur through DNA polymerase η (Polη, Masutani et 




The biological effects induced by CPD are slightly different to those induced by 
6-4PP; CPD form at approximately five times the frequency of 6-4 PP (Ravanat 
et al., 2001) and are attributed to be the main cause of lasting DNA damage (Lo 
et al., 2005), implicated in mechanisms of mutagenesis, carcinogenesis and 
apoptosis. CPD cause transcription arrest as they represent a physical blockage 
of the transcription machinery (Donahue et al., 1994). Persistence of CPD in the 
genome can lead to acquired mutations (see Figure 1.5.3) and ultimately tumour 
development (Brash et al., 1991) or cell death (Batista et al., 2009). 6-4PP are 
responsible for only a limited role in mutagenesis in mouse models (You et al., 
2001). 6-4 PP are repaired up to five times faster than CPD, with up to 90% 
removal in the first 4h after UVR exposure (Young et al., 1996, Bykov et al., 
1999, Riou et al., 2004,), suggesting a higher toxicity of these lesions compared 
to CPD (de Lima-Bessa et al., 2008). 
 
Studies on UVR-induced mutagenesis in cultured cells have identified a “UVR-
signature mutation”, namely C to T transitions and CC to TT tandem mutations 
(see Figure 1.5.3), occurring opposite the site of a CPD and are very rarely found 
after exposure to any mutagenic agent other than UVR. These mutations have 







Figure 1.5.3: How CPD cause mutations during DNA replication: direct absorption of UVR 
photons by adjacent DNA bases (thymines and/or cytosines) disrupts the hydrogen 
bond between base pairs, forming a covalent bond between the adjacent bases, known 
as a photoproduct or ‘CPD’. During cell replication when DNA strands separate, if a 
CPD is formed on a transcribed strand, DNA polymerase may substitute AA (instead 
of GG) opposite a CPD between CC, meaning at the next replication, the substituted 
AA will pair with TT, leading to CC to TT tandem mutations. 
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1.6. DNA repair 
In organisms ranging from bacteria to humans, photoproducts are removed from 
DNA through the nucleotide excision repair pathway (NER) (see Figure 1.6.1), 
a mechanism based on excision of the oligonucleotides containing the 
photoproduct, followed by insertion of new bases into the gap. NER relies on 
the integral function of 30 ‘excision repair proteins’, including the seven 
xeroderma pigmentosum (XP) proteins; XPA to XPG. A biallelic mutation in 
any of the genes coding for NER proteins will lead to abnormal or truncated 
proteins and therefore impaired NER. The main NER-deficient syndromes are 
xeroderma pigmentosum (XP), cockayne syndrome (CS) and 




Figure 1.6.1: A scheme for NER, showing the roles of XP proteins. For simplicity, other proteins 
involved have not been included. In GG-NER, XPE and XPC are involved in damage 
recognition; TFIIH containing XPB and XPD are recruited and open out the DNA 
structure in the vicinity of the damage. XPA verifies the damaged structure prior to 
dual incisions by XPF-ERCC1 and XPG. After the damaged section has been 
removed DNA polymerases and ligases fill in the gap. In TC-NER, blockage of RNA 
polymerase by the damage is the recognition signal. Proteins CSB and CSA, defective 
in Cockayne Syndrome, are recruited and these in turn recruit TFIIH to enable the 
rest of the NER process to proceed. 
 
NER consists of two sub-pathways (see Figure 1.6.1), which are activated 
depending on the location of the photoproduct. Global genome repair (GG-
NER) is a relatively slow scanning of the entire genome; XPE (also named DNA 
damage binding protein 2) and its partner protein DDB1 (DNA damage binding 
protein 1) bind to the photoproduct (Scrima et al., 2008) and recruit XPC in 
complex with Centrin 2 and stabilised by HR23B (Araki et al., 2001), which 
recognises and binds to the distortion affecting the strand opposite the 
photoproduct (Min & Pavletich, 2007). GG-NER is responsible for repair of 
both strands of actively and non-actively transcribed genes. If photoproducts are 
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located on the transcribed strand of DNA, transcription-coupled NER (TC-
NER) is activated for repair. Here, RNA polymerase II stalls at the site of the 
photoproducts and recognition of this and recruitment of subsequent NER 
proteins is mediated by the Cockayne syndrome proteins, CSA and CSB. 
Defects in either of these proteins result in Cockayne Syndrome, rather than XP.  
 
The two NER sub-pathways then converge to form a common pathway, where 
TFIIH, a complex containing 10 polypeptides including the helicases XPB and 
XPD, is recruited to open up and unwind DNA around the site of the 
photoproduct (Schaeffer et al., 1993, 1994, Roy et al., 1994). XPA and RPA 
(replication protein A) bind to verify that all the proteins are in the correct 
position and to define sites for excision. RPA is crucial for full DNA unwinding 
around the site of the lesion, as well as coordinating all NER nucleases (de Laat 
et al., 1999).  The heterodimeric nucleases ERCC1/XPF and XPG cleave the 
damaged DNA strand 5’ and 3’ to the damage respectively (Sijbers et al., 1996, 
Mu et al., 1997). An approximately 30-nucleotide fragment containing the 
damaged nucleotides is then excised and the resulting gap filled in by DNA 
polymerases δ, ε, κ and PCNA, using the undamaged strand as template (Budd 
& Campbell, 1995, 1997). The DNA polymerisation that fills in the gap is 
known as unscheduled DNA synthesis (UDS).  
 
The XPC/HR23B complex has a higher affinity for 6-4PPs than CPD 
(Kusumoto et al., 2001) and GG-NER repair of CPD is almost entirely absent 
in mouse models (Bohr et al., 1985, Hanawalt et al., 2001). XPD functions in 
both NER and in basal transcription. Therefore mutations in XPD can result not 
just in XP, but also in TTD and XP/CS overlap syndromes (Taylor et al., 1997). 





1.7. Repair of oxidative damage 
Historically, DNA glycosylases and endonucleases, functioning through base 
excision repair (BER), were understood to be the main repair pathway for 
oxidatively induced DNA damage (Mitra et al., 2001). 8-oxoGua are repaired 
by BER through the activity of 8-oxoguanine DNA glycosylase (OGG-1) 
(Aburatani et al. 1997); OGG-1 knockout mice are highly susceptible to UVB-
induced skin cancer (Kunisada et al., 2005). Another oxidatively modified 
guanine residue, 7,8-Dihydro-8-oxo’-deoxyguanosine (8-oxo-dG) is released 
from DNA during repair of chemically-induced damage by OGG-1 (Leanderson 
et al., 1988, Loft et al., 1993). Recent studies have shown that both 8-oxoGua 
and 8-oxo-dG can function as biologically active molecules, scavenging ROS 
and thereby exerting endogenous antioxidant effects in solution, after their 
release from DNA (Ock et al., 2011). This has been demonstrated in vivo, 
showing potent protection of UVB-induced inflammation by 8-oxo-dG (Lee et 
al., 2013). Apurinic/apyrimidinic endonuclease-1 (APE-1) is another essential 
BER protein cleaving at the site of oxidative damage and participating in redox 
regulation of NFκB and AP-1 (Mitra et al., 2007).  
 
For many years, the NER pathway was considered specific to repairing CPD, 
however more recently it has been shown that NER is required to repair 
oxidative lesions (Shafirovich et al., 2016). Work done by Reardon et al. in 1997 
showed that the NER pathway was in part responsible for repair of 8-oxoGua. 
Later on, NER was also demonstrated to repair 5’,8-cyclo-2-deoxyadenosine 
(Kuraoka et al., 2000). XPC has been shown to physically interact with APE-1, 
regulating both its activity and the activity and expression of OGG-1 (de Melo 
et al., 2016). There is in vivo evidence of the role of XPC in removal of 
oxidatively-induced damage as after oxidant exposure XPC-deficient cells are 
defective in the removal of 8,5’-cyclopurine 2’-deoxynucleosides. This may 
occur because XPC is required in the recognition step for NER or through 
stimulation of OGG-1 catalytic activity (D’Errico et al., 2006). 8,5-cyclopurine 
deoxynucleotides result from the reaction of *OH with DNA (Henle et al., 1996) 
and are repaired by NER (Brooks, et al., 2000), which may explain why 
neurodegeneration is a recognised feature of TC-NER-impaired syndromes.  
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1.8. Cellular antioxidant defense 
In addition to specific repair of oxidative stress-induced lesions, a wide range of 
naturally occurring cellular antioxidants exist grouped into small molecules, 
protein chelators, and enzymes. Glutathione is the main molecular antioxidant 
within skin cells, however this is destroyed by UVA (Connor & Wheeler, 1987, 
Tyrrell, 1994). Vitamins C and E are the most ubiquitous chain-breaking 
antioxidant molecules within epidermis and dermis, acting as ROS scavengers 
by preventing propagation of free radicals. Vitamin C is water-soluble, whereas 
vitamin E is lipophilic, scavenging oxygen radicals in the cell membrane and 
acting as a defense against membrane peroxidation (Niki, 1987). Vitamin E is 
regenerated through the action of ascorbate, which reduces the vitamin E radical 
(Golumbic & Mattil, 1941). Peroxyredoxins are protein chelators reducing 
ROS-induced peroxynitrite and scavenging other free radicals (Ding et al., 
2017). Antioxidant enzymes include endogenous antioxidant scavengers such 
as superoxide dismutase (SOD), glutathione peroxidase (GPX), catalase and 
NAD(P)H dehydrogenase. quinone 1 (NQO-1), a cytosolic enzyme that reduces 
quinone to hydroxyquinone, therefore lowering rate of ROS generation 
(Halliwell, 1994, Dinkova-Kostova & Talalay, 2010) 
 
In 1989, a 32-kDa protein and was found to be significantly increased maximally 
2-4 hours after broad spectrum UVA and visible (330-450nm) irradiation; this 
was identified as the enzyme HO-1 (heme oxygenase 1) (Keyse & Tyrrell, 
1989). HO-1 converts free heme, a molecule with pro-oxidant effects, into iron, 
carbon monoxide and biliverdin (Tenhunen et al., 1969).  
 
HO-1 is an integral part of the cellular response to ROS induced by UVA (Keyse 
& Tyrrell, 1989). HO-1 release is triggered in the presence of heme that is 
released by destruction of heme-containing proteins by UVA (Kvam et al., 
1999). Activation of HO-1 gene transcription is initiated by 1O2 generated by 
UVA (see Figure 1.8.1) (Basu-Modak & Tyrrell, 1993). ROS peroxidation of 
lipids results in membrane destabilisation that is detrimental to cell integrity and 
may lead to cell death. Lipid peroxidation leads to accumulation of 4-
hydroxynonenal as an end product, which is also a powerful activator of HO-1 
(Basu-Modak et al. 1996). Increasing levels of HO-1 lead to a reduction in the 
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amount of cellular heme thereby reducing cellular pro-oxidants. HO-1 is 
therefore considered an important contributor to cellular antioxidant defense 
(Keyse & Tyrrell, 1989, Keyse et al., 1990).  
 
Figure 1.8.1: Transcriptional activation of heme oxygenase 1 by UVA; UVA-induced singlet 
oxygen and heme release leads to activation of HO-1 (Tyrrell, 2004). 
 
NRF-2 (nuclear factor erythroid-2-related factor 2) is a transcription factor that 
functions as an important activator of antioxidant genes, including HO-1 (see 
Figure 1.8.2, Gorrini et al., 2013). NRF-2 activates two superoxide dismutase 
genes (SOD-1 and SOD-2) as well as GPX. Increasing the natural levels of 
NRF-2 is currently being tested as a treatment in cardiovascular and 
neurodegenerative disorders, where inflammation and oxidative stress are key 




Figure 1.8.2: Antioxidant pathways controlled by NRF-2 (Gorrini et al., 2013).  
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1.9. Xeroderma pigmentosum 
1.9.1. History of XP 
Nearly 140 years ago, the term “xeroderma” was first used by Moriz Kaposi for 
patients with dry, wrinkled, parchment-like skin, to characterize a rare disease 
he had noted in two patients; one with severely pigmented skin in predominantly 
sun-exposed areas (face, neck, shoulders and arms), the other, aged 10 years, 
also had dry, thin skin, without the noted pigmentation, but within one year 
developed a fissured tumour of the nose. Kaposi described XP as a condition 
existing from childhood that never improved either spontaneously or as a result 
of any treatment (von Hebra et al., 1874).  
 
 
Figure 1.9.1:  Image of a girl with XP: A Practical Treatise on Diseases of the Skin for use by 
Students and Practitioners. Dr. James Nevins Hyde, 1909. 
 
In 1883, Albert Neisser made the link between XP and neurodegeneration. In 
1932, two Italian physicians, De Sanctis and Cacchione (De Sanctis C, 1932), 
reported a “xerodermic idiomacy” in which three XP patients also had 
neurological and other physical abnormalities: microcephaly with progressive 
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mental deficiency, retarded growth and sexual development, hearing loss, 
choreoathetosis, ataxia and eventual quadriparesis with Achilles-tendon 
shortening. The term “De Sanctis Cacchione Syndrome” was used to describe 
XP patients with severe neurodegeneration, but it is now no longer in use. In 
1965, Reed et al. described XP with choreoathetoid neurological complications 
in a Caucasian brother and sister, and two Japanese brothers. A review by the 
National Institute of Health (NIH) described all the neurological abnormalities 
identified in XP patients (Kraemer et al., 1987) and commented that the type of 
neurodegeneration detected can be found in many degenerative and hereditary 
disorders of the nervous system of non-XP patients, usually correlating with 
distinctive pathological findings (Reed et al., 1969); however postmortem 
cerebral examination of XP patients failed to reveal any unique morphological 
or cellular abnormality, other than neuronal cell loss (Robbins et al., 2002).  
 
In 1968, James Cleaver showed that whereas fibroblasts from normal adult skin 
were able to repair damage induced by UVC, cultured fibroblasts from XP 
patients had a marked reduction in, or absence of, DNA repair (measured by 
unscheduled DNA synthesis (UDS) using incorporation of tritiated thymidine 
and autoradiographic grain counting). Epstein et al. confirmed this in vivo in 
1970. In 1971-2, the spectrum of clinical symptoms in XP prompted studies into 
the genetic heterogeneity using XP fibroblast cell fusion techniques. Each XP 
fibroblast was known to be deficient in repairing UVR-induced DNA damage. 
Fusing XP fibroblasts from two separate donors enabled a heterokaryon to be 
formed (a cell containing nuclei from different donors in a common cytoplasm). 
This heterokaryon exhibited normal DNA repair, implying that separately each 
cell supplied what the other lacked and therefore the defects in each cell were 
genetically different. This ultimately led to identification of seven separate XP 
‘complementation groups’ deficient in NER, designated XP-A to XP-G, 
depending on the representative protein that lacks and therefore the gene that is 
mutated (XPA to XPG) (de Weerd-Kastelein et al., 1972, de Weerd-Kastelein et 
al., 1974, Kraemer et al., 1975a, Kraemer et al., 1975b, Arase et al., 1979, 
Kleijer et al., 1979).  
 
A separate group of XP patients with normal NER in lymphocytes and in 
fibroblasts was reported and later designated as ‘XP-variant’ (XP-V) (Burk et 
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al., 1971). Their cells showed normal levels of DNA repair after UVC exposure 
and it was assumed that the defect must lie elsewhere. Indeed, in 1975 it was 
discovered that XP-V cells were defective in replicating DNA after UVC, 
suggesting a defect in translesion synthesis (TLS), a DNA post-replication 
repair pathway (Lehmann et al., 1975). In 1999 the specific mutation in Polη 
required for translesion TLS, was identified in XP-V (Masutani et al. 1999). 
During DNA replication, the normal function of Polη is essential to replicate 
DNA past a photoproduct, as the rate of cell replication often exceeds the rate 




Figure 1.9.2: The role of DNA polymerase η: DNA replication, carried out by DNA polymerases 
δ or ε is blocked by a UVR lesion and in many cases reinitiates beyond the lesion. 
The resulting gap is filled in by DNA polymerase η, which is deficient in XP-variant. 
1.9.2. XP classification 
XP is an autosomal recessive disorder, arising from mutations in both alleles of 
the XP gene affected. There are eight complementation groups associated with 
a diagnosis of XP and these are assigned depending on the causative mutation 
(see Table 1.9.1). 80% of XP patients have abnormal NER. All of these are 
deficient in GG-NER. XP-C and XP-E patients are competent for TC-NER, 





Table 1.9.1: XP classification: genes, chromosomal locations and protein products in different XP 
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6p21.1 713 Polymerase TLS 
 
1.9.3. XP diagnosis 
Initially the diagnosis of XP may be made on clinical examination: A young 
child may be brought to the paediatric department with bright, confluent 
erythema over all sun-exposed sites, or with lentigines at an unusually early age 
in sun-exposed areas. In the former case, the clinician assessing the child may 
suspect a skin allergy, drug reaction or even in some cases sunburn caused by 
parental neglect. After all differentials have been excluded, the clinician would 
then request cellular tests to assess for defective DNA repair. This requires a 4 
mm punch biopsy of the skin taken from an unexposed site (e.g. buttock area). 
This specimen is used to generate cultured skin fibroblasts in which UDS is 
measured at a single time point (usually four hours) after 20J/m2 254nm UVC 
irradiation. This functional assay measures the quantity of tritiated thymidine 
incorporated within DNA after irradiation (Stefanini et al., 1976) or of 
fluorescence-labelled EdU (5-ethynyl-2′-deoxyuridine, an alkyne-conjugated 
nucleoside analogue (Limsirichaikul et al., 2009). Liquid scintillation to detect 
the level of tritiated thymidine incorporation or cellular fluorescence imaging 
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and quantification to detect EdU is then used to measure the amount of UDS, 
proportional to the level of DNA repair occurring in this 4-hour period. Results 
are calculated as a percentage compared to total repair occurring in control (non-
XP) cells, normalized at 100% repair capacity. I was involved in establishing a 
protocol using immunofluorescence quantification for UDS measurements (Jia 
et al., 2015). 
 
Typically a reduced level of UDS confirms a diagnosis of XP. Mutational 
analysis to assign complementation group and define pathogenic mutation(s) in 
the affected gene(s) is then performed. Using next-generation sequencing 
techniques, a platform of DNA repair genes can be used for rapid identification 
of both complementation group and mutation analysis.  
 
Diagnosis of XP-V is different as XP-V cells have normal levels of UDS. 
However, UVR-exposed XP-V cells show an exquisite sensitivity to caffeine, 
which impairs their survival (Arlett et al., 1975, Lehmann et al., 1977). 
Therefore, if XP-V is suspected, cultured fibroblasts are incubated in caffeine 
for a few days and their viability is compared to that of normal cells. If UDS is 
normal and post-UV sensitivity to caffeine is detected, a diagnosis of XP-V is 
confirmed (Broughton et al., 2002). 
 
All the diagnostic procedures require specialised laboratories and technical 
skills and are therefore often not available in poorer countries, in which there 
may be high incidences of XP. 
 
1.9.4. Epidemiology of XP 
XP has been reported to affect all ethnic groups worldwide. It affects men and 
women in equal ratio, in the recognized pattern of autosomal recessive 
inheritance. Amid Indian and Middle Eastern areas incidence is quoted at 
1:10,000-30,000 (Khatri et al., 1999, Fazaa et al., 2001, Moussaid et al., 2004, 
Zghal et al., 2005). In Japan, incidence is reported as 1:20,000 – 100,000 
(Moriwaki & Kraemer, 2001, Hirai et al., 2006) and in Western Europe it has 
been estimated at 2.3:1,000,000 births (Kleijer et al., 2008). The incidence of 
XP in Japan appears ten times higher than Western countries; approximately 
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60% of XP patients in Japan belong to the XP-A complementation group, twice 
the proportion seen in other countries (Fassihi, 2013). 90% of patients are 
homozygous for an XPA founder mutation, carried by 1% of the Japanese 
population (Hirai et al., 2006). In 2010, it was reported that 85% of XP families 
in the Maghreb region (Algeria, Tunisia and Morocco) carried a founder 
mutation in the XPC gene (Tamura et al., 2010, Soufir et al., 2010). More 
recently it has been reported that 1 in 5000 individuals of the black Mahori 
population in the Comoro Islands have XP-C. This is linked to another founder 
mutation (Cartault et al., 2011). In the latter regions consanguineous marriages 
are quite common, resulting in higher frequencies of homozygous mutations in 
genes corresponding to rare genetic disorders. 
 
In addition to founder mutations, mutations in XP genes may arise 
independently at genetically unstable parts of the genome, known as “mutation 
hotspots”. These have been described in the XPD gene and are known to be 
present in unrelated XP patients from around the world (Lehmann, 2001). 
 
1.9.5. Clinical features 
The inability to repair UVR-induced damage leads to the main historical, 
textbook clinical manifestations of XP: severe and exaggerated sunburn 
reactions on minimal sun exposure, increased lentigines and pigmentary change, 
an overwhelming increased risk of skin cancer and ocular abnormalities. 
Cutaneous clinical features of XP patients are largely determined by the 
cumulative amount of UVR exposure at sun-exposed sites (skin and eyes) and 
therefore also by age of the patient at diagnosis and timing of photoprotection 
initiation. Approximately one-third of patients develop progressive neurological 
degeneration (Kraemer et al., 1987). The median lifespan is 32 years, with death 
resulting mainly from metastatic melanoma and neurological degeneration 
(Bradford et al., 2011). These features are further detailed in the sections below. 
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1.9.6. Sunburn in XP 
Patients with XP may suffer with severe and prolonged sunburn on minimal sun 
exposure, often lasting more than 7 days (see Figure 1.9.3). Action spectra for 
UVR-induced erythema are reported to be similar to that for CPD formation 
(Young et al., 1998) and therefore the mechanism of increased severity of 
sunburn has been attributed to failure of CPD repair in XP patients. This is 
supported by evidence that sunburn severity can be reduced with topical 
application of liposomes containing the DNA excision repair enzyme T4 
endonuclease (Wolf et al., 1995), which preferentially recognizes CPD; in 
mammals dose-response suppression of UVR-induced erythema has been 
demonstrated in opossums (Monodelphis domestica) if CPD are removed by 
photo-reactivation (Ley, 1985). 
 
Figure 1.9.3: Severe and exaggerated sunburn in two XP patients: Left: XP-D patients after 10 
minutes of UK winter sun; Right: XP-A patient three weeks after 1 hour of spring sun 
exposure. 
 
Before the advent of the UK national XP clinic, XP was considered a disease in 
which all affected patients were afflicted with severe and exaggerated sunburn 
reactions. However with a growing cohort of XP patients under longer term 
follow-up, it became clear that this was not the case for all XP patients and so I 




1.9.7. Photoageing in XP  
XP patients have been noted clinically to have a significantly earlier age of onset 
of photoaged skin compared to non-XP individuals of the same age (Horiki et 
al., 2000, H. Fassihi, personal communication). Studies have been conducted on 
mouse models showing that UVB-induced signs of photoageing (e.g. elastic 
fibre accumulation) are more easily induced in XPA knockout mice compared 
to wild type mice (Horiki et al., 2000). Premature skin ageing has been 
demonstrated in XPC knockout mice (Hosseini et al., 2015), as XPC is known 
to have a role in repairing oxidatively-induced DNA damage.  
 
To date, there has been no investigation on the molecular mechanisms for 
photoageing in XP patients.  
 
1.9.8. Skin cancer in XP 
XP patients have an over 10,000-fold increased risk of developing KC and a 
2000-fold increased risk of MM in patients under 20 years, compared to the 
average population (Bradford et al., 2011). The median age at diagnosis of first 
KC is between 8 and 9 years, significantly younger than the median age at 
diagnosis of first MM, at age 22 years (Kraemer et al., 1987, Bradford et al., 
2011). This is an inverse pattern to what is observed in the general population, 
where younger patients are more likely to present with MM and older patients 
with KC (Glass & Hoover, 1989).  
 
There is a significantly higher level of the UVR signature mutations in XP skin 
tumours compared to those found in non-XP, sporadic skin cancers (Giglia-Mari 
& Sarasin, 2003). Analysis of the p53 gene in skin tumours from XP patients 
has described classical UVR-induced signature mutations in the DNA (Brash et 
al., 1991), indicating that the high level of p53 mutations found in these tumours 
are caused directly by unrepaired UVR-induced DNA photoproducts (Daya-
Grosjean & Sarasin, 2005). UVR exposure to the oral cavity in XP patients can 
result in mucocutaneous malignancy, most commonly seen as SCC of the tip of 
the tongue (Kraemer et al., 1984).  
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In addition to skin cancer, the XP-C patient group seems to be at a greater risk 
of developing other forms of malignancy unrelated to UVR, particularly 
neurological cancers (DiGiovanna et al., 1998, Kraemer et al., 1994). This 
patient group is reported to occasionally develop pyogenic granulomas and 
multinodular thyroid carcinomas (Hadj-Rabia et al., 2013). 
 
Topical application of DNA repair enzymes to UVR-damaged skin of XP 
patients was shown to reduce the rate of precancerous and cancerous lesion 
development during one year of treatment, thereby further implicating 
unrepaired DNA damage as cause of KC (Yarosh et al., 2001). 
 
1.9.9. Neurodegeneration 
The inability of XP patients to repair UVR-induced DNA damage explains the 
skin changes in these patients (lentigines, severe sunburn and skin cancers), 
however the neurodegeneration, seen in only 30% of patients, is harder to 
explain. Accumulation of unrepaired oxidative damage in neurons may induce 
neuronal loss and subsequent neurodegeneration (Brooks et al., 2000, Marietta 
et al., 2002, Brooks, 2002, Reardon et al., 1997). An efficient DNA repair 
mechanism is required to maintain the functional integrity of neuronal cells; 
hence an accelerated ageing process may reflect abnormal DNA repair (Kraemer 
et al., 1987). 
 
The mechanism for neuronal DNA repair was consolidated by studies on 
different cell lines: It has previously been shown that pluripotent cells can repair 
both strands of the active and non-active transcribed genes (GG-NER and TC-
NER both functioning). If these pluripotent cells are differentiated into neuronal 
cells, the ability to repair non-actively transcribed genes (attributed to GG-NER) 
is removed, however the repair of actively transcribed genes is preserved. Most 
importantly, the repair of the non-transcribed strand of active genes was 
surprisingly proficient. TC-NER relates to repair of the actively transcribed 
DNA strand only; therefore it cannot be responsible for repair of the non-
transcribed strand. This repair process in differentiated neuronal cells, 
conserving repair of both strands in actively transcribed genes, was initially 
termed “differentiation-associated repair” (DAR) (Nouspikel & Hanawalt, 
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2000). Of note, these neuronal cells had elevated levels of mRNAs encoding 
ERCC1, XPF and XPG. These three proteins are crucial for the incision process 
of NER. Subsequent studies into DAR have proved that DAR is actually a subset 
of GG-NER operating only in transcriptionally active domains of the genome 
and hence it was re-named “domain-associated repair” (Nouspikel et al., 2006).  
 
Although the requirement for NER in skin to repair UVR-induced damage has 
long been acknowledged, the process for which NER is required in neuronal 
DNA repair was only identified in the last two decades; Brooks et al. showed 
that DNA from neuronal cells, exposed to endogenous oxygen radicals, produce 
cyclopurines (cPu) (cyclo-2′ -deoxyadenosine and 5′(S)-8,5′ -cyclo-2′ -
deoxyguanosine), which were removed by NER (Brooks et al., 2000, 2002). The 
presence of a single cPu lesion on a transcribed DNA strand of a reporter gene 
strongly reduced gene expression in XP-A cells. It was suggested that neuronal 
death resulted from accumulation of these unrepaired cPus. Later cPus were re-
named as 8,5′ -cyclopurine-2′ -deoxynucleosides or “cyPudNs” (Brooks, 2008). 
The biological properties of cyPudNs are very similar to other substrates of NER 
such as CPD. cyPudNs have been shown to block gene expression in XP cells, 
a biological effect that is compatible with causing neurodegeneration (Marietta 
et al., 2002, Brooks et al., 2000).  
 
1.9.10. Ocular disease 
There are three ways in which the eyes can be affected in XP:  
(1) UVR exposure resulting in DNA damage of the eyelids and periocular skin 
(2) UVR exposure resulting in DNA damage of the ocular surface 
(3) Ocular manifestations of neurodegeneration 
 
Photophobia is the earliest presenting ophthalmic symptom of XP (Kraemer et 
al., 1987). Damage to the eyelids and periocular skin can result in the 
development of cicatricial skin changes as well as skin cancers, which require 
excision (Brooks et al., 2013). The ocular surface (conjunctiva and cornea) can 
develop UVR-related damage including dry eye, conjunctival injection and 
inflammation (without infection), as well as the development of premature 
pingueculae and pterygia. Prolonged corneal exposure can result in corneal 
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scarring and visual impairment.  Ocular surface cancers (mainly SCC) have also 
been reported in patients with significant UVR exposure and poor ocular 
photoprotection (Gaasterland et al., 1982). Patients with XP-related 
neurodegeneration develop neuro-ophthalmological features, including sluggish 
pupils, nystagmus and strabismus.  
 
I have recently co-authored a paper describing ophthalmological disease 
features that are specific to XP (Lim et al., 2017). 
 
1.10. XP National Commissioning Group (XP NCG) 
A nationally funded service for patients with XP was established in 2010 at 
Guy’s and St. Thomas’ NHS Foundation Trust. This followed a preceding five 
years of ad hoc clinics, which identified the need for management by a team of 
specialists. Since April 2010, patients with a confirmed diagnosis of XP have 
been invited to attend the multidisciplinary clinic for review by dermatology, 
ophthalmology, neurology, clinical psychology and clinical genetics. In 
addition, there are two specialist nurses available to provide outreach services 
and help run the clinic. More than 100 patients with a confirmed diagnosis of 
XP are under regular review and follow-up. This has enabled a careful and 
detailed assessment and long-term follow-up of XP patients. The creation of the 
XP NCG has resulted in the collection of many different clinical variables 
associated specifically with XP. It has enabled deep-phenotyping of individual 




1.11. Thesis aims 
In this thesis I studied the clinical, molecular and cellular effects of UVR on a 
large cohort of XP patients and their cells in vitro across complementation 
groups. I collected clinical, genetic and laboratory data on XP and non-XP 
individuals. The specific aims are described below: 
 
1) To establish the relationship between genotype and phenotype 
variation in XP from acute and long-term effects of solar UVR 
exposure: 
a) To identify the genetic basis of sensitivity to sunburn in XP: 
I noticed that not all XP patients suffered the textbook description of 
severe and prolonged sunburn reactions, therefore I attempted to further 
delineate these differences by devising a sunburn severity score to 
objectively assess sunburn in both control and XP patients. This led to 
my first paper in chapter 2, defining sunburn reactions in XP patients, 
correlated to their complementation group. 
 
 b) To determine if a milder XP phenotype could be explained by their 
specific mutation:  
I collected clinical and genetic information on a case series of 12 milder 
XP-A patients, all of whom shared the same cryptic splice site mutation. 
This sparked the identification of specific genotype-phenotype 
correlations in XP patients and provided the first tentative reassurance 
of longevity in patients with this mutation, who may have otherwise 
have relied on a historic XP-A prognosis (Kraemer et al., 1987, Anttinen 
et al., 2008) 
 
 c) To assess for patterns in XP disease severity:  
I collected deep phenotypic and genotypic data on 89 XP patients 
registered with the UK national XP service. Using systemic analysis, I 
correlated data relating to skin, brain and eyes with the pathological 




Laboratory materials and methods are explained in chapter 5. 
 
2) To determine if MMP are more significantly upregulated in XP 
compared to control cells, as a possible explanation for their early 
photoageing:  
 I decided to explore the mechanism of photoageing by measuring MMP 
and oxidative stress mRNA and protein upregulation after UVR in XP 
and control cell lines. I wanted to understand if variations in the clinical 
severity of XP photoageing could be explained by MMP mRNA and 
protein expression. In chapter 6, I used two very different UVR sources 
(385nm UVA-1 vs. 254nm UVC) to clarify the biological effect of 
wavelength on the induction of MMP and oxidative stress mRNA and 
protein expression. 
 
3) To explore if the rate of CPD repair was a factor influencing KC 
development in XP: 
 I wanted to understand if the variation in development of skin cancer 
may correspond to varying DNA repair rates between XP 
complementation groups. In chapter 7, part A, I measured the rate of 
repair of CPD (induced directly by 254nm UVC) in control and XP 
fibroblasts over a 48-hour period. I wanted to ascertain if a slower rate 
of repair was occurring over this time, which may contribute to the 
differences in skin cancer development identified in earlier chapters.  
 
4) To understand the trigger for MMP upregulation in XP and control 
cells, using UVR spectral extremes and an antioxidant:  
 In chapter 7, part B, I used two very different spectral sources to induce 
damage and stimulate DNA repair in XP and control cells. I sought to 
ascertain if longer wavelength UVA-1 could induce CPD in XP and 
control fibroblast cultures at specific time points up to 24 hours after 
irradiation. I wanted to understand if there was a possible relationship 
between the MMP mRNA and protein upregulation identified in chapter 
6 and CPD or ROS generation. I performed simultaneous irradiation of 
control and XP fibroblasts with 254nm UVC and 385nm UVA-1, 
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followed by CPD staining at regular time points up to 24 hours after 
irradiation. I subsequently performed identical irradiation steps and 
measured the level of ROS generated for up to two hours after 
irradiation, to identify if there were differences in ROS levels between 








2. XP & sunburn
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2.1. Introduction 
Prior to 2013, there was no formal grading system for sunburn severity in XP 
patients or even for people with other skin photosensitivity disorders. After the 
formation of the UK National XP clinic, with an ever-increasing XP patient 
cohort, it has become possible and important to more carefully document 
previously indiscernible differences in sunburn phenotype between XP 
complementation groups. 
 
I set out to formally assess sunburn severity reactions in XP patients and controls 
(non-XP) by devising a short, objective questionnaire incorporating a scoring 
system from 0-3 points. I used the data I obtained from the results of the 
questionnaire to measure differences in sunburn severity score, neurology and 
skin cancer rates between the different XP complementation groups. 
 
By examining an initial cohort of sixty XP patients, I showed that those with a 
defect in TC-NER (XP-A, XP-B, XP-D, XP-F and XP-G) had the classical 
severe sunburn reactions on minimal sun exposure, whereas those patients with 
preserved TC-NER (XP-C, XP-E and XP-V) had normal sunburn reactions for 
their skin type. I identified abnormal neurological findings in 40% of the cohort, 
affecting the same groups as those suffering from severe sunburn. This suggested 
that impaired TC-NER is a pathological mechanism involved in both severe 
sunburn and neurodegeneration. I also identified an earlier age of onset of KC 
than MM in XP groups compared to the general population, suggesting DNA 
repair deficiency is more significant for KC development than for MM. 
 
Here I present my paper, published in the British Journal of Dermatology, 
detailing the data I collected on sunburn severity, skin cancer and 






































XP-A patients are considered to have one of the severest forms of XP as they 
classically develop severe sunburn, skin cancer and early onset 
neurodegeneration.  Over 20 different mutations have been identified in the XPA 
gene (States et al., 1998, Takahashi et al., 2010).  
 
The XPA protein is required for damage verification in the NER pathway; it 
contains zinc finger domains that bind to DNA (see Figure 3.1.1) and it interacts 
physically with several other NER proteins (Tanaka et al., 1990). 
 
 
Figure 3.1.1: Map of XPA gene and protein function. XPA interacts with other NER proteins at the 
site of DNA damage through three main domains: RPA-interacting domain, TF11H-
interacting domain and a DNA-binding domain containing zinc finger subunits 
(Hilton et al., 2014, Fadda, 2016). XPA recruits ERCC1 (in complex with XPF) to 
the site of DNA damage. Mutations described in the literature are marked: the 
majority occur within the DNA-binding domain. RPA: replication protein A; ERCC1: 
excision repair cross-complementation group 1 protein; TFIIH: transcription factor 
11 human. 
 
I collected phenotypic data on all XP-A patients under long-term follow-up with 
the UK National XP clinic. I identified 12/19 patients with unusually mild XP 
clinical features: Notably these patients had a later age of XP diagnosis than the 
more severe phenotype XP-A patients; none had developed the classical, early-
onset neurodegeneration. Skin cancer developed in only four of the twelve 
patients and the earliest age of first skin cancer onset was 22 years, surprisingly 
later than described in chapter 2 (although this may be because 8 new mild XP-
A patients were diagnosed since the previous data collection). 
 
These 12 milder XP-A patients were all homozygous for c.555+8A>G, a cryptic 
splice-site mutation in intron 4 of the XPA gene. 95% of the mRNA created from 
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this mutation will result in abnormal XPA protein however there is 5% read-
through of normal mRNA and therefore some normal XPA protein, detected in 
immunoblots performed on protein extracts from cells of these patients. This 
low level of normal XPA protein may be capable of repairing oxidatively-
induced DNA damage through NER (measured as 5-15% UDS) that may be able 
to prevent neurodegeneration from occurring. Sunburn severity for these 
patients ranged from normal to severe and therefore it is likely that this low level 
of normal XPA protein is not sufficient to protect against acute UVR-induced 
damage. 
 
All 12 patients included here originate from a 950km stretch of land around the 
Northern India/ Pakistan/Afghanistan borders, suggesting a founder mutation 
existing in this population.  
 
Here, I present my paper, published in the Journal of Investigative Dermatology, 
highlighting the importance of detailed genotype-phenotype correlations in 



















Since the advent of the UK National XP Clinic, it has become evident that XP 
patients, in different complementation groups and within the same group, do not 
share the classical textbook phenotype of severe sunburn, skin cancer 
development and neurodegeneration. 
 
In 2014, I undertook the collection of over 50 sets of data variables from all 89 
patients registered with UK National XP clinic. I collected phenotypic data end-
points relating to three main systems: dermatological, ophthalmological and 
neurological and I correlated these with the pathological XP mutations. In 
collaboration with consultant ophthalmology and neurology colleagues, I helped 
to devise a points-based severity score for these systems, in order to more 
objectively assess severity for each XP patient. 
 
Here I present my jointly first-named author paper with my secondary 
supervisor, published in Proceedings of the National Academy of Sciences of 
the United States of America. It is the largest reported cohort of XP patients in 
whom genotype-phenotype correlations for every XP complementation group 
have been performed.  
 
This detailed analysis of XP clinical and genetic features further adds to the 
library of personalized prognostic information available for the management of 












































In this chapter, I describe the laboratory materials and methods I used to conduct 
in vitro experiments assessing UVR-induced damage from long wavelength 
385nm UVA-1 and short wavelength 254nm UVC.  
5.2. Cell culture 
In Tables 5.2.1, 5.2.2 and 5.2.3, I have listed the reagents, culture solutions and 
equipment used in all fibroblast culture experiments described in chapters 6 and 
7. 
 
Table 5.2.1: Cell culture reagents 
Item Supplier Cat number 
DMEM, high glucose, pyruvate, no glutamine Thermofisher Scientific 21969035 
Fetal Bovine Serum (FBS) Thermofisher Scientific 26140079 
L-Glutamine Thermofisher Scientific 25030081 
Penicillin - Streptomycin Thermofisher Scientific 10378016 
Phosphate Buffered Saline (PBS) pH 7.4 Thermofisher Scientific 10010056 
TrypLE™ Express (1x), no phenol red Thermofisher Scientific 12604013 
 
Table 5.2.2: Cell culture solutions 
Solutions Contents 
Full media (10% FBS) 500ml DMEM + 50ml FBS + 5ml penicillin-streptomycin + 5ml L-
Glutamine  
Starved media (0.5% FBS) 500ml DMEM + 2.5ml FBS + 5ml penicillin-streptomycin + 5ml L-
Glutamine 
 
Table 5.2.3: Cell culture equipment 
Item Supplier Cat number 
12 well Advanced TC™ treated plate with lid Greiner Bio-One 662960 
Biopette Multichannel (8) pipette 50-300μl  Bioline Reagents Ltd P4808-300 
Cell scraper small 18mm blade Corning 734-1527  
CELLSTAR™ 12 well Tissue culture treated plate with lid Greiner Bio-One 665180 
Corning® 15mL PP Centrifuge Tubes with cap Sterile Corning 430790 
Corning® cell culture flasks Sigma CLS3814-24EA 
Pip Accs Reagent Reservoir 25ml pk100 Gilson F267660 
Plastic bottom black wall 96 well plate PerkinElmer 6005182 
Vacuum Pump Integra 158 320 
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5.3. Reagents and solutions 
In Tables 5.3.1 and 5.3.2, I have listed the reagents and solutions used for 
viability experiments, the CPD repair assay and oxidative stress experiments 
with vitamin E. 
 
Table 5.3.1: Reagents 
Item Supplier Cat number 
alamarBlue® Fisher Scientific Ltd 10161053 
DAPI Cell Signaling Technology 4083S 
DEPC-treated water Invitrogen 10636503 
Formaldehyde solution 37% VWR International 437533W 
Hydrochloric acid 37%  VWR International 20252.324 
Normal goat serum Dako X090710-8 
Triton-X Promega UK Ltd H5142 
Tween20 2B Scientific  BSB0045 
Vitamin E (α-tocopherol, >= 95.5%) Sigma-Aldrich Co Ltd 258024-5G 
 
Table 5.3.2: Solutions 
Solutions 
2N HCl 16.7ml of 37% HCl + 83.3ml H20 
 
10% FBS*   500μl FBS + 4.5ml PBS  
DAPI stock solution 0.1mg/ml 1mg DAPI in 1000uL PBS (1mg/ml). 100μl aliquots 
DAPI 20ng/ml in PBS* 1:1000 (1μl stock per ml required) 
0.05% PBST 250μl tween20 in 500mL PBS. Store at room 
temperature for 6 months 
* make new each time 
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5.4. Antibodies, probes and kits 
In Tables 5.4.1 and 5.4.2, I have listed the antibodies used in the CPD assays, 
and the probes and kits used for mRNA extraction, protein measurement by 
ELISA and reactive oxygen species measurement. 
 
Table 5.4.1: Antibodies and probes 
Item Supplier Cat number 
Anti-CPD Monoclonal Antibody (Clone TDM-2)  2B Scientific NM-DND-001  
Alexa Fluor 488® Goat anti- mouse IgG (H+L) 1:200 Life Technologies A11029 
Human Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) Endogenous Control 
Thermofisher Scientific 4326317E 
Human apurinic/apyrimidinic endonuclease-1 (APE-1) Thermofisher Scientific Hs00172396_m1 
Human heme oxygenase 1 (HO-1) Thermofisher Scientific Hs01110250_m1  
Human matrix metalloproteinase 1 (MMP-1) Thermofisher Scientific Hs00899658_m1 
Human matrix metalloproteinase 10 (MMP-10) Thermofisher Scientific Hs00233987_m1 
Human matrix metalloproteinase 12 (MMP-12) Thermofisher Scientific Hs00159178_m1 
Human NAD(P)H dehydrogenase. quinone 1 (NQO-1) Thermofisher Scientific Hs01045993_g1  
Human nuclear factor erythroid-2-related factor 2 (NRF-2) Thermofisher Scientific Hs00975961_g1 
Human 8-oxoguanine DNA glycosylase (OGG-1) Thermofisher Scientific Hs00213454_m1 
Human superoxide dismutase 2 (SOD-2) Thermofisher Scientific Hs00167309_m1 
Human tissue inhibitor of metalloproteinase 1 (TIMP-1) Thermofisher Scientific Hs00171558_m1 
Human tissue inhibitor of metalloproteinase 1 (TIMP-3) Thermofisher Scientific Hs00165949_m1 
TaqMan Gene Expression Master Mix Thermofisher Scientific 4369514 
 
Table 5.4.2: Molecular biology kits 
Item Supplier Cat number 
DCFDA Cellular ROS Detection Assay Kit Abcam ab113851 
ELISA MMP-1 assay kit Thermofisher Scientific EHMMP1CL 
ELISA MMP-10 assay kit Thermofisher Scientific EHMMP10 
ELISA MMP-12 assay kit Elabscience E-EL-H0133 
High-Capacity cDNA Reverse Transcription Kit Thermofisher Scientific 4368814 






5.5. Vitamin E 
Vitamin E (α-tocopherol) was used as an antioxidant in experiments to 
determine the effect of oxidative stress after UVR. Vitamin E solution was 
prepared using a stock solution of 10mM (molecular weight 430.717g/mol; 
10mM stock prepared with 0.043g vitamin E solution dissolved in 10ml 100% 
ethanol). Serial dilutions of the stock solution were performed to yield 
concentrations as low as 0.0001mM for viability experiments (see section 
6.17.1). Ultimately, 0.1mM vitamin E concentration was prepared with 100μl 
of 10mM vitamin E stock solution in 10ml of 10% media or PBS (for incubation 
or irradiation purposes, respectively).  
 
5.6. UVR sources 
Two UVR sources were used in these laboratory experiments, a 254nm source 
(UVC) and a 385nm source (UVA-1). 254nm UVC has been used in the 
mainstay of experiments in the literature on XP. Notably, repair of UVC-
induced damage (measured as UDS) is still used to confirm a diagnosis of XP 
(see section 1.9.3). UVC-induced damage occurs in a matter of seconds after 
exposure, providing an efficient method by which to study DNA repair in vitro. 
A metal box was designed to house a 6-Watt Phillips TUV linear T4 tube 
emitting UVC radiation at 254nm wavelength (see Figure 5.6.1 and Figure 5.6.2 
for the emission spectrum).  
 
Despite the greater physiological relevance of UVA, there have been very few 
experiments in the literature examining its effect on XP cells. There is a breadth 
of published work to identify the effects of UVA in normal skin cells, however 
very few of these studies use spectrally pure UVA-1 (no contamination of 
UVB). The 385nm source (Loctite LED flood systems) is spectrally pure and 
has an irradiation surface of 97mm x 96mm, consisting of 144 LEDs (see Figure 
5.6.3). Spectral irradiance of this source is shown in Figure 5.6.4 and spectral 





Figure 5.6.1:  254nm UVC source box containing a 6-Watt 254nm UVC bulb; designed by my 
father, Ranjit Singh Nagi and me in August 2014, built by the Medical Physics 









 Figure 5.6.3:  Loctite LED Flood system 385nm UVA-1 source irradiating a 12-well plate. 
 
 
Figure 5.6.4:  Spectral irradiance of the 385nm UVA-1 source. 
  












Table 5.6.1: Spectral waveband analysis of the 385nm UVA-1 source. 
Source Region Wavelengths (nm) % Total Irradiance 
385nm UVC 250-280 0.00 
UVB 280-315 0.00 
UVA-2 315-340 0.00 
UVA-1 340-400 94.82 
Visible 400-500 5.18 
Total 280-500 100.00 
 
5.7. Dosimetry 
Spectral irradiance of the 385nm source was measured at a 40cm distance 
using a DM120BC double monochromator spectroradiometer (Bentham 
Instruments, Reading, UK) with an integration sphere calibrated by the Centre 
for Radiation, Chemical and Environmental Hazards (CRCE), Public Health 
England (PHE) against a UK National Standard. Irradiance was routinely 
measured using a spectroradiometrically-calibrated Loctite UVA/Vis 
radiometer (Loctite, Henkel Ltd, UK), with a typical irradiance of 
125mW/cm2. 11 minutes of 385nm UVA-1 irradiation gave a dose of 
52.5J/cm2. 
 
The irradiance of the 254nm UVC source was measured using an International 
Light ILT1400 radiometer attached to a UVC photodetector sensor. The 
radiometer gave irradiance readings in μW/cm2, which was used to calculate 
the exposure time to achieve a given dose in J/m2. Irradiance measurements 
were taken within the UVC box to establish the output at different distances 
away from the bulb (see Figure 5.7.1). At 25cm distance from the source, with 
an irradiance of 18.9μW/cm2, this equated to 0.189 J/m2/second. So, to give a 
dose of 10J/m2 at this distance (10/0.189), exposure to irradiation was given 




Figure 5.7.1:  Irradiance of 254nm UVC source box. 
 
5.8. XP tissue samples and cell culture 
All XP patients gave written and verbal consent to allow their skin biopsies 
(taken at the time of their XP diagnosis) to be used for the purposes of research, 
in accordance with protocols approved by the Research Ethics Committee of 
Guy’s and St. Thomas’ Hospitals NHS Foundation Trust, London (reference 
12/LO/0325). The studies were done following the Declaration of Helsinki. 
These biopsies were initially sent to our collaborator (Professor Alan Lehmann) 
laboratory at the Genome Damage and Stability Centre, University of Sussex, 
where fibroblast cultures from the skin biopsies of both XP patients and controls 
(non-XP) were established and then sent to Guy’s Hospital for the purpose of 
this research.  
 
Cells were received in confluent live culture and grown in DMEM 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 5% 
penicillin/streptomycin and 5% L-glutamine. All cells regularly tested negative 
for mycoplasma. Cells were maintained in a humidified incubator at 37°C with 
5% CO2 and 95% air, passaged once per week (ratio 1:5). All experiments 
described here were carried out in cells between passages 2 and 15. 
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5.9. Tissue culture of skin fibroblast cells 
Table 5.9.1 lists the consecutive steps required for culturing, counting and 
plating fibroblasts for the different in vitro experiments described. 
 
Table 5.9.1: Tissue culture protocol.  
Method 
Step 1 Warm media, PBS and TrypLE™ in water bath at 37°C for 10 minutes 
Step 2 Aspirate media from 75cm2 flasks 
Step 3 Wash with 5ml PBS, aspirate and discard 
Step 4 Add 3ml TrypLE™ and incubate at 37°C with 5% CO2 for 15-20 minutes, or until cells are 
suspended 
Step 5 Add 4ml media to flask containing TrypLE™ and agitate gently 
Step 6 Aspirate 7ml solution mix and transfer to sterile 15ml tube 
Step 7 Spin in centrifuge at 1000G for 5 minutes; cells will form pellet 
Step 8 Aspirate supernatant, leaving pellet intact 
Step 9 Tap tube firmly to re-suspend pellet in remaining solution 
Step 10 Add 5ml media and mix thoroughly with cell suspension 
Step 11 Label well-plate with cell line 
Step 12 Add between 100μl and 1ml media solution per well (depending on well diameter) 
Step 13 Take 10μl of cell suspension and add to haemocytometer with coverslip 
Step 14 Count number of cells in each of four squares; calculate average and multiply by 10,000 
e.g. average value = 24, therefore 240,000 cells per ml (1000μl) 
Calculate volume of cell suspension required to plate required number of cells per well: 
e.g. 10,000 cells in 1000/24 = 41.67μl (or 100,000 cells in 416.7μl) 
 
Step 15 Add calculated volume of cell suspension to wells containing media 
Step 16 Transfer remaining cell suspension in 15ml tubes to 75cm2 flasks containing fresh media 
(final volume 15ml) 




5.10. Cell viability 
Cell viability was performed using the alamarBlue® cell viability assay 
measured 24 hours post UVR irradiation. Viable cells maintain a reducing 
environment within the cell cytosol; resazurin is the active ingredient of 
alamarBlue® assay; it is a cell-permeable, non-toxic, blue compound that is 
reduced to resorufin within viable cells. This is highly fluorescent and hence 
measurement of fluorescence intensity is directly proportional to cell viability.  
 
Cells were plated at a concentration of 10,000 cells per well in a 96-well plate 
(see protocol in Table 5.9.1), laid out according to UV irradiation conditions 
(see Figure 5.13.1). 22.5 hours after UV irradiation, media was aspirated from 
each well and replaced with 100μl of alamarBlue® solution dissolved in 
warmed, full (10% FBS) media (at a ratio of 1:10) into each well that contained 
cells. The plate was then incubated at 37oC with 5% CO2 for 1.5 hours 
(protected from light), in order to establish viability 24 hours after irradiation. 
Fluorescence intensity was measured using an excitation wavelength of 540–
570nm (peak excitation is 570nm) and reading the emission at 580–610nm 
(peak emission is 585nm) with a Spectra Max 384 Plus spectrophotometer 
(Molecular Devices; California, USA). Each condition was tested in triplicate. 
The fluorescence intensity measured in unirradiated (UV-) cells was 
normalized to 100%, so for irradiated cells, viability was calculated as a 
percentage of the unirradiated value. Viability of XP and control fibroblasts 
was determined over a range of 385nm UVA-1 and 254nm UVC doses, over 
different time periods (see chapter 6, section 6.4 and chapter 7, section 7.3). 
 
5.10.1. Viability with vitamin E 
Control and XP fibroblasts were plated in a 96-well plate at a concentration of 
10,000 cells per well in full media and left overnight to adhere. The next day 
cells were treated with varying doses of vitamin E (see section 5.5), ranging 
from 1mM to 0.0001mM in warmed full media (1% ethanol in full media was 
used as a control). Plates were returned to the incubator for 24 hours. After 22.5 
hours, media was aspirated from each well and full media containing 1:10 
alamarBlue® was added to each well for 1.5 hours. The fluorescence intensity 
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of each well was measured and cell viability for vitamin E was calculated as a 
percentage of the control value.  
 
5.11. CPD repair methods 
An immunofluorescence protocol using an anti-CPD IgG2a mouse monoclonal 
antibody (TDM2, Cosmobio, Japan) coupled to a secondary Alexa Fluor 488® 
goat anti-mouse IgG antibody, was adapted from commercially available 
protocols and previous studies (Kobayashi et al., 2001, see Table 5.11.1). 
 
Control and XP fibroblasts were plated in three black-walled 96-well plates on 
day 1, at a concentration of 10,000 cells per well in full media, using 4 wells 
per condition and 1 plate per time point (see Figure 5.11.1). Cells were left 
overnight to adhere. After 12-16 hours, the medium was removed and replaced 
with warmed starved media (containing 0.5% FBS) for 48 hours before the 
experiment, to reduce cell replication. The three 96-well plates were labelled as 
48-hour (48h), 24-hour (24h) and immediate (0h) plates, according to times of 
scheduled irradiations, in order to establish the rate of CPD repair. 
 
5.11.1. UVC (254nm) irradiation steps for CPD repair rate 
On day 4, the 48h plate was removed from the incubator and wells were washed 
once with warmed PBS (200μl/well). PBS was removed from wells on left hand 
side of each plate and aluminum foil was used to cover the wells on the right 
side of the plate (still containing PBS). The left side of each plate was exposed 
to 10J/m2 of 254nm UVC, delivered by UVC source box in Figure 5.7.1. PBS 
was removed from the unirradiated wells and warmed fresh starved media was 
restored to all wells. The plate was then returned to the incubator. The same 
irradiation steps were repeated on day 5 for the 24h plate and day 6 for the 0h 
plate.  
 
5.11.2. CPD immunofluorescence staining methods 
On day 6, after irradiation of the 0h plate, the 24h and 48h plates were removed 
from the incubator. Wells in all 3 plates were washed once in warmed PBS 
(200μl/well) and then fixing solution containing 2% p-formaldehyde in 0.5% 
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Triton-X in PBS was added to each well (100μl/well). The plate was transferred 
to the fridge (4oC) for 30 minutes. Following 3 successive washes in PBS, the 
plates were simultaneously treated with 2N hydrochloric (HCl) acid 
(100μl/well) to denature DNA, followed by a blocking buffer (100μl/well) and 
then a buffer containing the anti-CPD antibody (1:1000), 0.1% Triton-X and 
1.5% goat serum (50μl/well). All 3 plates containing the antibody buffer were 
covered entirely in aluminium foil and placed in the fridge overnight. On day 7 
the plates were removed from the fridge and left on a shaker at room 
temperature for 30 minutes. The antibody buffer was then removed and all wells 
washed extensively with 0.05% PBST (200μl/well). Then a buffer containing 
the secondary antibody (50μl/well), Alexa Fluor 488® goat anti-mouse IgG 
(1:200) was added to each well and the plates were returned to foil encasing on 
the shaker at room temperature for an hour. This secondary antibody buffer was 
subsequently removed and following further washes with 0.05% PBST 
(200μl/well), a solution containing DAPI in PBS at a concentration of 100ng/ml 
was added to each well for 20 minutes (50μl/well). This was then removed and 
wells were washed once more with PBS. 200μl of PBS was left in all wells to 
avoid cells drying out during image acquisition. 
 
 
Figure 5.11.1: Diagram of the CPD staining protocol. 
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5.11.3. CPD staining protocol 
Table 5.11.1: CPD staining protocol 
 Method Temperature Time 
Day 1 
Grow each cell line to confluence in 75cm2 flask 
Wash cells, trypsinise, spin and count  
Plate in full media 10,000 cells per well in 3x 96-well plates (for 0h, 
24h, 48h) 
8 wells per cell line (4 UV-, 4 UV+) 











Day 2 Aspirate media from all wells, replace with starved media 
(200μl/well) 
37°C 2 days 
Day 4 
Take 48h plate out of incubator and wash all wells once with warmed 
PBS (200μl/well) 
Aspirate PBS from UV+ wells 
Cover the UV- wells with aluminium foil  
Irradiate UV+ wells with 254nm UVC at 10J/m2 
Aspirate PBS from UV- wells, replace with starved media 
(200μl/well) 
  
Day 5 Repeat irradiation steps on Day 5 and Day 6 for 24h and 0h plates   
Day 6 
Fix with 2% p-formaldehyde in 0.5% triton X in PBS (100μl/well) 
Wash cells 3x with PBS (200μl/well) 
Denature DNA with 2N HCl (100μl/well) 
Wash cells 1x with PBS (200μl/well) 
Block with 20% goat serum in washing buffer containing 0.1% Triton 
(100μl/well) 
Add primary antibody (1:1000) in washing buffer containing 1.5% 


















Wash cells 3x with 0.05% PBST (200μl/ well) 
Add secondary antibody (1:200) in washing buffer containing 1.5% 
goat serum in PBS (50μl/well) 
Wash 3x with 0.05% PBST (200μl/well) 












Wash 3x with PBS (200μl/well) 
Leave in PBS 200μl per well 
Store at 4°C in dark (stable for 2 months) 
Take fluorescent pictures at 10x optical zoom, Alexa Fluor 488®  
channel 4000ms, DAPI 2000ms 








5.12. CPD quantification and measurement of repair rate 
Immediately after the CPD immunofluorescence staining protocol, wells in all 
3 plates were photographed using Zeiss microscope Axiovision Z1 camera at 
10x optical zoom. Two-channel .zvi images were created; channel 1 (355nm) 
for DAPI exposed at 2000ms and channel 2 (450nm) at 3200ms for Alexa Fluor 
488® (absorbing at 495nm, fluorescence emission at 519nm). 4 images were 
taken per well; data were collected from 4 UV- (unirradiated) wells and 4 UV+ 
(254nm UVC-irradiated) wells per cell line, giving 32 images per cell line, 16 
per condition (UV-/UV+). The .zvi files were converted into .tiff files for each 
channel (c1 and c2). Cell profiler (Carpenter et al., 2006) a free, open-source 
cell image analysis software, was used to identify and quantify fluorescence 
intensity, using a specified pipeline to measure the average integrated intensity 
of Alexa Fluor 488® (proportional to CPD quantity) defined by every nucleus 
in each image (see Figure 5.12.1) and plotted in arbitrary units (a.u.). Data were 
exported as an Excel file and the average value of nuclear integrated intensity 
of Alexa Fluor 488® for 16 images was calculated for each cell line, in each 
condition, over the three time-points. The difference between UV- and UV+ 
wells for each cell line, at each time point, enabled quantification of CPD. This 
was then converted to percentage repair as a proportion of 0h plate data, to 





Figure 5.12.1:  Cell profiler image analysis software: each image was re-sized and converted to grey-
scale; nuclei were identified by DAPI (blue- channel 1) and Alexa Fluor 488®  
(green- channel 2), before integrated intensity of green in each nucleus was measured 
and exported into an excel file. 
 
5.13. CPD staining; 385nm UVA-1 vs. 254nm UVC 
The same method for CPD immunostaining was used as described above, 
however the plate layout and irradiation steps were different (see Figure 5.13.1).  
5.13.1. Concurrent 385nm UVA-1 and 254nm UVC irradiation steps 
On day 1, control and XP fibroblasts were plated at a concentration of 10,000 
cells per well, in full media, into six black-walled 96-well plates. On day 2, full 
media was aspirated from wells in all plates and replaced with warmed starved 
media (200μl/well). On day 3, media was aspirated from all wells of plate 1 (24-
hour time point) and washed once with warmed PBS (200μl/well). Fresh PBS 
(200μl/well) was then added to each well before UV irradiations.   
 
The first six wells of each row were irradiated with 52.5J/cm2 or 105J/cm2 of 
385nm UVA-1 for 11 or 22 minutes, respectively (the remaining wells were 
covered in foil during this time). Immediately after this, the UVA-1 irradiated 
wells were covered and the adjacent three wells were irradiated with 10J/m2 
254nm UVC. PBS was then aspirated from all wells and replaced with warmed 
starved media (200μl/well) and the plate was returned to the incubator for 24 
hours.  
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After 12 hours, plate 2 was irradiated. Six hours before the 24-hour time point, 
plate 3 was irradiated. Three hours before the 24-hour time point, plate 4 was 
irradiated and lastly one hour before the 24-hour time point, plate 5 was 
irradiated. At the 24-hour time point, plate 6 was irradiated and then all six plates 
underwent the CPD staining protocol (see Table 5.11.1).  This enabled three 
wells per condition, per time point for each cell line used (XP or control). Whole 
experiments (six plates) were repeated twice for each cell line tested. Results 




Figure 5.13.1: Layout for CPD quantification after 385nm UVA-1 and 254nm UVC. 
 
5.14. MMP RT-PCR 
XP and control cells were plated in 12-well plates (1 plate per condition: 
unirradiated; 385nm UVA-1; 254nm UVC) at a concentration of 100,000 cells 
per well in full media and left overnight to adhere. The next day wells in plates 
for irradiation were washed with 1ml of warmed PBS, which was aspirated 
before another 1ml of fresh PBS was added to each well. Irradiation steps were 
performed consecutively for separate plates, designated either for 385nm UVA-
1 or 254nm UVC irradiation. After irradiation, PBS was aspirated from all wells 
and 1ml of warmed full media was transferred into each well. Plates were 
returned to the incubator for varying time points prior to RNA extraction.  
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5.14.1. RNA extraction 
Total RNA samples were obtained from XP cells using the mirVANA™ 
miRNA isolation kit with phenol (as per the manufacturer’s protocol). Each well 
was washed once with 1ml PBS. With the plate on ice, 600μl lysis buffer was 
added to each well. One cell scraper per well was used to create a homogenised 
solution of lysis buffer and cells. This was transferred to individually labelled 
1.5ml Eppendorf tubes on ice. 60μl of homogenate additive was added to each 
sample and left on ice for 10 minutes. Then 600μl of acid phenol was added to 
each sample and vortexed. The samples were transferred to a centrifuge and 
spun at 10,000G for 5 minutes. This created an upper aqueous layer containing 
RNA in each sample, which was aspirated and transferred to fresh separate 
Eppendorf tubes. 100% ethanol solution (1.25% of the volume of aspirate) was 
then added to each Eppendorf containing RNA solution. This ethanol/aspirate 
solution was transferred to a filter housed in a sterile Eppendorf tube (provided 
by the mirVANA™ miRNA isolation kit) in 700μl aliquots. The tubes were 
spun at 10,000G for 30 seconds to pass the solution through the filter. The 
solution accumulating beneath the filter after centrifugation was discarded and 
the remainder of ethanol/aspirate solution was transferred to the filter before the 
tubes were spun again. After two further wash steps, the filters were transferred 
to fresh sterile Eppendorf tubes and RNA was eluted in 30μl of DEPC-treated 
(nuclease-free) water. The tubes were spun at 10,000G for 30 seconds and then 
the filters were removed and discarded. RNA concentration was determined 
using a NanoDrop™ spectrophotometer (ND1000 UV-Vis spectrophotometer 




5.14.2. Reverse transcription polymerase chain reaction (RT-PCR) 
200ng RNA (dissolved in 20μl of DEPC-treated water) was added to a 20μl 
mixture of high capacity cDNA reverse transcription kit (see Table 5.14.1) to 
create 40μl of sample cDNA in separate PCR tubes (1 tube per cell line, per 
condition). The PCR tubes were gently spun and then loaded on to thermocycler 
(GeneAmp. PCR System 9700, Applied Biosystems by Life Technologies, 
Carlsbad, USA) using the following thermal cycling conditions: 25°C for 10 
minutes, 37°C for 120 minutes, 85°C for 5 minutes, then cooling at 4°C. 
 
Table 5.14.1: cDNA reverse transcription mixture 
cDNA Reverse Transcription Kit Volume (μl) 
10x RT buffer 4 
25x dNTP mix (100mM) 1.6 
10x Random Primers 4 
Multiscribe reverse transcriptase 2 
DEPC-treated water 8.4 
Total 20 
 
5.14.3. Real Time (quantitative) PCR (qRT-PCR) 
qRT-PCR was performed using Taqman Gene Expression Assays, according to 
the manufacturer’s protocol, using TaqMan FAM-labelled (6-
carboxyfluorescein) DNA probes and VIC-labelled GAPDH as the endogenous 
control. Probes used are listed in Table 5.4.1. 
 
The reactions were performed using Taqman PCR master mix (see Table 5.14.2; 
1μl of sample cDNA was added to 19μl of master mix in each well of a 96-well 
microAMP PCR plate) and analysed by Real-Time PCR. Each sample was run 
in duplicate. The plate was analysed using an ABI prism 7900 HT sequence 
detection system (Applied Biosystems). The following thermal cycling 
conditions were used for 40 cycles of denaturation: 95°C for 15 seconds, 
annealing and extension at 60°C for 1 min. 
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The expression levels of genes of interest (GI) were calculated relative to 
GAPDH amplification, using the ΔΔ Cycles threshold (Ct) value. This was 
determined by subtracting the average Ct GAPDH value from the average Ct GI 
value, to give an overall fold change for GI mRNA expression. Relative 
quantification was calculated by 2 −ΔΔCt. 
 
Table 5.14.2: Master mix for qRT-PCR. 
Master mix for RT-PCR Volume (μl) 
2x Gene expression master mix 10 
GAPDH (endogenous control) 1 
Gene probe of interest 1 
cDNA 1 





5.15. ELISA to measure MMP protein 
Cells were plated as for MMP mRNA experiments (100,000 cells per well in 
12-well plates). Each plate represented one condition (unirradiated; 385nm 
UVA-1 or 254nm UVC irradiation; pre-incubation or post-incubation with 
vitamin E). Immediately prior to RNA extraction, 1ml of supernatant from each 
condition was aspirated from each well containing cells and placed in a 1.5ml 
Eppendorf tube on ice. These samples were spun at 1200G for 10 minutes. 700μl 
of supernatant was subsequently aspirated from the tubes, placed into fresh 
Eppendorf tubes and stored at -20°C until required for ELISA experiments.  
 
Table 5.15.1: ELISA protocol 
 Method Temperature Time 
Step 1 




Add 100μl of standard, blank, or sample per well into the 
bottom of the micro ELISA plate well. Seal the plate and place 
on a shaker  
21°C 150 mins 
Step 3 Aspirate each well and wash four times with wash buffer   
Step 4 
Add 100μl of biotinylated antibody to each well. Cover plate 
and place on shaker 
21°C 60 mins 
Step 5 Aspirate each well and wash four times with wash buffer   
Step 6 Add 100μl of Streptavidin- HRP reagent to each well. Cover 
and place on shaker  
21°C 45 mins 
Step 7 Repeat the wash process four times as conducted in step 4   
Step 8 Add 100μl of TMB substrate solution to each well and keep 
plate in dark 
21°C 15 mins 
Step 9 




Measure absorbance of each well using a micro-plate reader set 





ELISA experiments were performed as per the manufacturer’s protocol (Human 
MMP-1 and Human MMP-10 ELISA kits, Thermo ScientificTM, Human MMP-
12 ELISA kit, Elabscience, see Table 5.15.1). All samples and reagents were 
thawed on ice. 100μl of standard, blank, or sample was added to the 96-well 
ELISA microplate provided by the kit (see Figure 5.15.1 for layout).  Samples 
were assayed in duplicate and performed as per the protocol in Table 5.15.1. 
Preliminary ELISA experiments showed the level of MMP-1 to be above the 
highest standard concentration; a subsequent dilution experiment ascertained an 
optimal supernatant dilution factor of 10. MMP-10 and MMP-12 samples were 
not diluted.  After adding standards and samples, the plate was incubated for 2.5 
hours at room temperature with gentle shaking. The plate was then washed four 
times with wash buffer before 100μl of biotinylated antibody (1:80) was added 
to each well. The plate was incubated for an hour at room temperature. After a 
further wash step, 100μl of Streptavidin-HRP solution (1:440) was added and 
the plate was incubated for 45 minutes at room temperature. The plate was 
washed a further four times and then 100μl of TMB substrate was added for 30 
minutes at room temperature in the dark. 50μl of stop solution was added to each 
well and the plate was read immediately with a Spectra Max 384 Plus 
spectrophotometer (Molecular Devices; California, USA) with absorbance set 
at 450nm and 550nm. 550nm values were subtracted from 450nm values and a 
standard curve was generated. Results were calculated using a four-parameter 
logistic curve fit and for diluted samples (MMP-1) the values obtained were 




Figure 5.15.1: 96-well ELISA microplate layout assaying supernatant samples from 385nm UVA-1 
and 254nm UVC irradiation experiments. 
 
5.16. ROS detection assay 
The DCFDA Cellular ROS Detection Assay Kit (Abcam) uses the reagent 2’,7’–
dichlorofluorescin diacetate (DCFDA) for quantitative measurement of cellular 
ROS (hydroxyl, peroxyl and other species). DCFDA is a fluorogenic dye that 
diffuses into cells and is subsequently deacetylated by cellular esterases. 
DCFDA is later oxidized by ROS into 2’, 7’ –dichlorofluorescein (DCF). DCF 
emits fluorescence that can be measured by spectroscopy, with an excitation 
spectrum at 495nm and emission spectrum at 529nm. ROS can be quantified for 
up to 6 hours (the time period for which intracellular DCFDA is stable). 
 
XP and control fibroblast cells were plated at a concentration of 25,000 cells per 
well in full media, in a black-walled, clear bottom 96-well plate, one row per 
cell line, allowing three columns per condition: positive control (Tert-Butyl 
Hydrogen Peroxide solution (TBHT)), negative control (unirradiated), 
52.5J/cm2 385nm UVA-1, 10J/m2 254nm UVC and 1 column unstained (without 
DCFDA) to measure background (see Figure 5.16.1). 
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Table 5.16.1: DCFDA ROS staining protocol 
 Method Temperature Time 
Step 1 
Grow each cell line to confluence in 75 cm2 flask 
Wash cells, trypsinise, spin and count  
Plate in full media 25,000 cells per well in a black-walled, clear bottom 96-well 
plate. Leave overnight for cells to adhere 
37°C  
Step 2 Aspirate media from each well, add 100μl buffer solution per well 21°C 
 
 
Step 3 Aspirate buffer; add DCFDA solution (25nM concentration, 100μl/well) 37°C 45 mins 
Step 4 
Aspirate DCFDA solution; add TBHT solution (200nM, 100μl/well) into 
positive control wells 
Add buffer solution into remaining wells (100μl/well) 
Add 0.1mM vitamin E solution in PBS to one column of 385nm UVA-1 and 
254nm UVC-treated cells (100μl/well) 
21°C 60 mins 
Step 5 
Cover positive, negative, UVC and unstained wells with aluminium foil 
Irradiate remaining designated wells with 52.5J/m2 385nm UVA-1  
Cover UVA-1-treated wells; uncover UVC wells and treat with 254nm 10J/m2 
UVC 
  
Step 6 Determine fluorescence intensity between 485 and 535nm in plate reader at 





Cells were left overnight to adhere. The next day media was aspirated, wells 
were washed once in 1x Buffer (provided by the kit) and 100μl of 25nM 
concentration DCFDA solution was added to each well before incubation for 45 
minutes at 37oC, 5% CO2. 
 
Following this, DCFDA solution was removed. 100μl of 200nM concentration 
Tert-Butyl Hydrogen Peroxide (TBHT) solution was added to the positive 
control wells and 100μl 1x Buffer added to all remaining wells. For vitamin E-
treated experiments, 0.1mM vitamin E in PBS was added to one column of 
UVA-1 and one column of UVC-treated cells. The plate was then incubated for 
1 hour in the dark at 37oC, 5% CO2. Subsequently all wells in the plate except 
those designated for UVA-1 irradiation were covered in aluminium foil and the 
plate was irradiated by the 385nm source. Next, the UVA-1 wells were covered 
and then UVC wells irradiated. Measurements were taken immediately after 
UVC irradiation and at two-minute intervals up to 2 hours after irradiation. 
Fluorescence absorbance was measured by a plate reader (Spectra Max 384 Plus 
spectrophotometer, Molecular Devices; California, USA). DCFDA is excited by 
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the 488nm laser, detected at 535nm. Results were calculated as 
excitation/emission (adjusting for background unstained, untreated cells).  
 
5.17. Statistical analysis 
All statistical analyses described here were conducted using GraphPad Prism 
software. 
 
5.17.1. Analysis of MMP mRNA expression 
Background levels of MMP and oxidative stress mRNA expression were 
compared using the Kruskal-Wallis test for analysis of variance (ANOVA) and 
Dunn’s multiple comparisons test to compare background mRNA fold change 
in XP groups with that of controls. 
 
I used two-way ANOVA to compare MMP and oxidative stress mRNA 
expression after 385nm UVA-1 and 254nm UVC between all cell lines. I used 
ordinary one-way ANOVA to compare MMP expression in three groups: 
controls, TC-NER-preserved and TC-NER-impaired XP cell lines. 
 
I used the paired t-test to compare unirradiated MMP mRNA expression in all 
cell lines without vitamin E compared to either pre- or post-incubation (with 
sham irradiation). I used two-way ANOVA to assess the effect of pre- and post-
254nm UVC irradiation incubation with vitamin E on all cell lines. 
 
5.17.2. Analysis of CPD repair after 10J/m2 254nm UVC 
Mean fluorescence intensity in arbitrary units (a.u.) (proportional to CPD) from 
each time point (0, 24 and 48 hours) was plotted on a graph. I used linear 
regression to compare the slopes across all cell lines (control and XP). 
 
5.17.3. Analysis of CPD staining after 385nm UVA-1 vs. 254nm UVC 
I plotted mean fluorescence intensity in a.u. from each time point (0, 3, 6, 12 
and 24 hours) and each condition (unirradiated, 385nm UVA-1 at two 
incremental doses and 254nm UVC) on a graph (one graph per cell line) and I 
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used linear regression to interpolate a standard curve for each condition. I 
compared the slopes generated in each condition for a significant deviation from 
zero.  
 
I performed one-way ANOVA to compare CPD generation across time points 
and two-way ANOVA to assess individual time point difference significance 
between irradiated, unirradiated and unstained cells. 
 
5.17.4. Analysis of ROS generation by DCFDA assay 
Data were analysed by two-way ANOVA comparing total ROS generation over 
a 2-hour period, under the same experimental conditions as for CPD staining 
above. Mean differences in ROS generation between positive controls, 385nm 
UVA-1-irradiated, 254nm UVC-irradiated and unirradiated cells was 
calculated. Differences between 385nm UVA-1 and 385nm UVA-1 + vitamin 
E were calculated using paired t-test analysis of Log10 fluorescence intensity of 








6. MMP & oxidative stress 




XP patients appear more significantly photoaged, which may be related to their 
NER defect; a role for unrepaired CPD has been demonstrated in the 
upregulation of MMP-1 mRNA and protein in human epidermal keratinocytes 
(Dong et al., 2008). Mouse models have demonstrated early age development 
of photoageing in XPA and XPC knockouts (Horiki et al., 2000, Hosseini et al., 
2015), but few studies have been performed on human XP cells. 
6.2. Photoageing mechanisms 
I sought to examine if, in the context of deficient NER, XP fibroblasts would 
upregulate MMP-1 more significantly after 254nm UVC irradiation (inducing 
mainly CPD) or UVA-1 irradiation (inducing mainly ROS). I performed 
experiments measuring mRNA and protein expression for MMP-1, MMP-10 
and MMP-12 after 385nm UVA-1 and 254nm UVC irradiation in parallel. I 
selected these particular enzymes as MMP-1 and MMP-12 (a collagenase and a 
metalloelastase associated with mechanisms of photoageing, respectively) are 
both significantly upregulated after UVR exposure (Scharffeter et al., 1991, 
Brennan et al., 2003, Tewari et al., 2014). MMP-10 (stromelysin-2) has a role 
in activation of pro-MMP-1 and it also degrades elastin, gelatin, proteoglycans, 
and collagen types III and IV (Murphy et al., 1991, Kerkelä et al., 2001); MMP-
10 is involved in tumour progression and inflammation via ECM degradation 
(Kadeh et al., 2016). 
 
I hypothesized that there may be an increased expression of oxidative and 
antioxidant genes after 385nm UVA-1 irradiation of XP cells. I examined the 
effect of UVA-1 on the expression of HO-1, SOD-2, NAD(P)H- dehydrogenase 
quinone 1 (NQO-1), NRF-2, APE-1 and OGG-1. In order to establish if 
oxidative stress contributed to the development of UVR-induced photoageing, I 
aimed to correlate the level of oxidative stress gene expression with MMP 
expression after UVA-1. 
 
In order to further clarify the role of oxidative stress in the development of 
photoageing, I examined the effect of adding vitamin E to media surrounding 
XP and control fibroblasts. Vitamin E is a naturally occurring cellular 
 127 
antioxidant that has dampening effects on UVR-mediated free-radical damage 
in the skin (Nachbar & Korting, 1995, Jurkiewicz et al., 1995). The addition of 
vitamin E to cells prior to UVR exposure has also been shown to prevent CPD 
formation (Hochberg et al., 2006, Premi et al., 2015). The effect of pre and post-
irradiation incubation with vitamin E on the generation of oxidized purines and 
CPD in spontaneously immortalized keratinocytes (HaCat) has been 
investigated by a previous PhD student in our lab (Antony Young, personal 
communication). I used pre- and post-irradiation incubation with vitamin E to 
determine if the effects on MMP expression after UVR were as a result of direct-
photochemical or indirectly-induced generation of CPD/ ROS. 
 
6.3. Cell lines 
Fibroblasts from XP-A, XP-C, XP-D, XP-E, XP-F and XP-G patients were used 
for these experiments (see Table 6.3.1 and Figure 6.3.1), selected based on their 
similarity in current clinical age, in an attempt to reduce any differences in 
intrinsic (chronological) skin ageing.  Where possible, more than one patient 
within each XP complementation group was used (e.g. XP-C and XP-D) to see 
if variations in mutation affected the expression of genes of interest here. 
Control fibroblasts (48BR and 1BR) were kindly provided by Professor Alan 
Lehmann’s lab in the Genome Damage and Stability Centre, University of 
Sussex, Falmer. These control cells had been confirmed as non-XP and had been 
provided from skin biopsies of historical university students (age < 24 years, no 




Table 6.3.1: XP lines used to measure MMP and oxidative stress gene expression.  

















XP114BR XP-A c.682C>T p.(Arg228X) 25 22 8 3 n/a n/a 0 
XP22BR XP-C c.658C>T p.(Arg220X) 39 19 13 0 11 BCC 7 
XP6BI XP-C c.1243C>T p.(Arg415X) 27 5 13 0 22 BCC 5 
XP135LO XP-D c.2047C>T p.(Arg683Trp) 35 8 25 3 13 BCC 51 
XP16BR XP-D c.2047C>T p.(Arg683Trp) 
c.1847G>A p.(Arg616Pro) 
22 1 16 3 14 BCC 1 
XP98BR XP-E c.161G>A p.(Tyr54X) 63 48 68 1 15 BCC >200 
XP24BR XP-F c.1765C>T p.(Arg589Trp) 
c.2395C>T p.(Arg799Trp) 
49 30 4 2 n/a n/a 0 




Figure 6.3.1: Face views of some of the XP patients showing clinical appearance of photoageing 
with lentigines and fine wrinkling in sun-exposed areas: cell lines used in following 
experiments from: 1:XP-A (XP114BR); 2 and 3: XP-C (XP22BR, XP6BI); 4: XP-D 
(XP16BR); 5: XP-F (XP24BR); 6: XP-G (XP55BR).  
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6.4. Viability 
Initially, I performed viability experiments (see chapter 5, section 5.10) on all 
XP and control cells, using a range of 385nm UVA-1 and 254nm UVC doses, 
to determine the optimal experimental conditions. It was apparent that normal 
fibroblasts had a higher resistance to both 385nm UVA-1 and 254nm UVC 
irradiation than XP fibroblasts. 
6.4.1. Viability with 385nm UVA-1: dose-response 
Five repeat viability experiments (Figure 6.4.1) were performed 24 hours after 
incremental doses of 385nm UVA-1 on control and XP fibroblasts (Table 6.3.1). 
Pooled results across all cell lines: after 26.25J/cm2 mean viability (±SEM) was 
90.45% (±3.27); after 52.5J/cm2 it was 67.04% (±4.48) and after 105J/cm2 it 
reduced to 54.88% (±4.18). I went on to perform dose-response MMP mRNA 
expression studies using these three doses of 385nm UVA-1 in all cell lines. 
 
 
Figure 6.4.1: Dose-response cell viability 24 hours after 385nm UVA-1 irradiation; mean ±SEM 
of five separate experiments on XP and control cells with incremental UVA-1 doses.  
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6.4.2. Viability with 254nm UVC: dose-response 
Five repeat viability experiments (Figure 6.4.2) were performed at various doses 
of 254nm UVC on control and XP fibroblasts. Pooled results across all cell lines: 
after 20J/m2, mean viability (±SEM) was 96.25% (±5.33); after 10J/m2 viability 
was 96.33% (±3.38) and after 5J/m2 it was 99.45% (±2.75).  I went on to perform 
dose-response MMP mRNA expression studies using these three doses of 
254nm UVC in all cell lines. 
 
 
Figure 6.4.2: Dose-response cell viability 24 hours after 254nm UVC irradiation; mean  ±SEM of 
five separate experiments on XP and control cells with incremental UVC doses. 
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6.5. Background MMP and oxidative stress mRNA expression  
I used qRT-PCR to establish the background mRNA expression levels of 5 
genes involved in skin remodelling: MMP-1, MMP-10, MMP-12, TIMP-1 and 
TIMP-3, and six oxidative stress genes NQO-1, SOD-2, APE-1, OGG-1, NRF-
2 and HO-1 in XP and control cells. Results were obtained as Ct values, relating 
to the number of cycles before the threshold level is reached (see chapter 5, 
section 5.14.3); therefore the lower the Ct value, the higher the mRNA 
expression level. Results were plotted as 100-Ct value comparing background 
mRNA expression levels of these genes (Figure 6.5.1 and Figure 6.5.2). 
Background MMP-1 mRNA expression in XP-C and XP-E cells was 
significantly lower than in control cells (p<0.0001). Background MMP-10 
mRNA expression was significantly lower in XP-E (p=0.0002) and background 
MMP-12 mRNA expression was significantly lower in XP-D and XP-G cells 
compared to control cells (p<0.0001), using Dunn’s multiple comparisons test. 
There was no difference in TIMP or oxidative stress background mRNA 
expression levels between XP and control cells (Figure 6.5.2). 
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Figure 6.5.1: Background MMP and TIMP mRNA expression presented as 100-Ct value; mean 
±SEM of a minimum of two experiments: MMP-1, MMP-10, MMP-12, TIMP-1 and 
TIMP-3 unirradiated mRNA values. P values stated relate to * for XP groups in which 
background mRNA fold change was significantly different compared to control cells, 




Figure 6.5.2:  Background oxidative stress mRNA expression presented as 100-Ct value; mean 
±SEM of a minimum of two experiments: NQO-1, SOD-2, APE-1, OGG-1, NRF-2 
and HO-1 unirradiated mRNA values. There was no significant difference between 
XP and control cells, analysed by one-way ANOVA (p>0.05). 
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6.6. Quality of mRNA extraction 
Figure 6.6.1 below shows an example of the mRNA quality extracted from XP 
and control fibroblasts in 20 samples, measured by the NanoDrop™ 
spectrophotometer.  The graphs indicate 260nm/230nm ratios fell between 1.25 




Figure 6.6.1: mRNA concentration of extracted RNA measured by the NanoDrop™ 
spectrophotometer for 20 samples obtained in March 2017. 
 
 
Prior to assessing MMP mRNA expression in a larger number of XP cell lines, 
smaller preliminary experiments were undertaken in a smaller number of cell 
lines to establish the optimum dose and time points at which to measure fold 
change in mRNA expression and protein levels after 385nm UVA-1 and after 
254nm UVC irradiation. Results are plotted for gene expression as mRNA fold 
change after being normalized for GAPDH mRNA expression. 
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6.7. MMP mRNA expression; 385nm UVA-1 dose-response 
Figure 6.7.1 shows that MMP-1, MMP-10 and MMP-12 mRNA expression 
increased with incremental doses of 385nm UVA-1 after 24 hours. Results are 
plotted for one control and four XP cell lines. Despite optimal viability with 
26.25J/cm2, this dose resulted in very small mRNA fold change for all MMP, 
compared to 52.5J/cm2. 
 
Figure 6.7.1: MMP mRNA expression; 385nm UVA-1 dose-response after irradiation with 
incremental doses in one control and four XP cell lines at 24 hours; mean  ±SEM of 
four experiments: A: MMP-1, B: MMP-10, C: MMP-12 mRNA fold change. 
 136 
6.8. MMP mRNA expression; 385nm UVA-1 time-response 
Figure 6.8.1 shows the time course for induction of MMP-1, 10 and 12 mRNA 
after 105J/cm2 385nm UVA-1 irradiation. MMP mRNA expression peaks 
between 12 and 24 hours after irradiation. However this dose resulted in low 
cell viability (average 54.9%, see Figure 6.4.1) and therefore it seemed more 
appropriate to use a dose of 52.5J/cm2 for all 385nm UVA-1 MMP mRNA and 
protein expression experiments.  
 
Figure 6.8.1: MMP mRNA expression; 385nm UVA-1 time-response after irradiation in one 
control and four XP cell lines with 105J/cm2; mean ±SEM of two experiments: A: 
MMP-1; B1: MMP-10 mRNA fold change in all 5 lines together; B2: MMP-10 
mRNA fold change, plotted without XP-A; C1: MMP-12 mRNA fold change in all 5 
lines; C2: MMP-12 mRNA fold change, plotted without control. 
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6.9. MMP mRNA expression; 254nm UVC dose-response 
MMP-1, MMP-10 and MMP-12 mRNA expression peaked 24 hours after a dose 
of 10J/m2 254nm UVC. There was a dose-dependent increase in mRNA 
expression from 0-10J/m2, however the effect reduced at higher doses (20J/m2) 
for all three genes (see Figure 6.9.1). 
 
Figure 6.9.1: MMP mRNA expression; 254nm UVC dose-response after irradiation; mean ±SEM 
of four experiments with one control and four XP cell lines at 24 hours; A: MMP-1; 
B: MMP-10; C: MMP-12 mRNA fold change. 
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6.10. MMP mRNA expression; 254nm UVC time-response 
MMP-1 and MMP-10 mRNA expression peaked at around 48 hours post 
irradiation with 10J/m2 254nm UVC, however the MMP-12 mRNA expression 
peaks varied between 12 and 48 hours (see Figure 6.10.1). The optimal time-
point at which to compare all MMP mRNA expression after 385nm UVA-1 
versus 254nm UVC seemed to be 24 hours after irradiation. 
 
Figure 6.10.1: MMP mRNA expression; 254nm UVC time-response after irradiation with 10J/m2; 
mean ±SEM of two experiments with one control and three XP cell lines; A: MMP-
1; B: MMP-10; C: MMP-12 mRNA fold change. 
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6.11. Oxidative stress mRNA expression 
6.11.1. Oxidative stress mRNA expression; dose and time response 
Initial experiments measuring HO-1 mRNA expression 24 hours after 10J/m2 
254nm UVC showed a downregulation of HO-1 in TC-NER-impaired XP 
groups (Figure 6.11.1). Subsequent experiments measuring HO-1 mRNA 
expression 24 hours after 52.5J/cm2 385nm UVA-1 showed peaks in XP-E (TC-
NER-preserved) and XP-D (TC-NER-impaired) cells (Figure 6.11.2). 
 
 
Figure 6.11.1: HO-1 mRNA expression; 10J/m2 254nm UVC after 24 hours in one control and six 
XP cell lines; mean ±SEM of two experiments in control, XP-F and XP-G cells, one 
preliminary experiment with XP-A, XP-C and XP-E cells. 
 
Figure 6.11.2: HO-1 mRNA expression; 385nm UVA-1 dose-response after irradiation; mean 
±SEM of two experiments with one control and four XP cell lines at 24 hours. 
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SOD-2 mRNA expression did not change significantly at any time point up to 
48 hours after incremental doses of 385nm UVA-1 irradiation in XP or control 
cells (see Figure 6.11.3). 
 
Figure 6.11.3: SOD-2 mRNA expression over time (top panel), with incremental 385nm UVA-1 
doses after 24 hours (middle panel) and across cell lines at 24 hours (bottom panel); 
mean ±SEM of three experiments with two control and seven XP cell lines.   
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NQO-1 mRNA expression did not change significantly after incremental doses 
of 385nm UVA-1 irradiation in control cells, although there was a small fold 




Figure 6.11.4: NQO-1 mRNA expression over time (top panel) with incremental 385nm UVA-1 
doses after 24 hours (middle panel) and across cell lines after 24 hours (bottom panel); 
mean ±SEM of three experiments with two control and seven XP cell lines.  
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There was no significant change in NRF-2, APE-1 or OGG-1 mRNA expression 
at any time point up to 48 hours after 385nm UVA-1 irradiation in control or XP 
cells (p>0.05 by one way ANOVA, see Figure 6.11.5). 
 
 
Figure 6.11.5: Other oxidative stress gene expression at different time points after 52.5J/m2 385nm 
UVA-1; mean ±SEM of three experiments (except 48 hour time point; one 
experiment) with one control and three XP cell lines. A: NRF-2, B: APE-1 and C: 
OGG-1 mRNA expression at 24 hours. P values refer to one-way ANOVA, 
comparing mRNA fold change of each gene, between groups, over time. 
 
Following these preliminary experiments, MMP and HO-1 mRNA expression 
was measured in 2 control and 6-8 XP cell lines. 
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6.12. MMP mRNA expression; 385nm UVA-1 vs. 254nm UVC 
MMP-1, MMP-10 and MMP-12 mRNA were all more significantly upregulated 
24 hours after 385nm UVA-1 compared to 254nm UVC irradiation in both 
control and XP cells; (MMP-1 and MMP-12: p <0.0001; MMP-10 p= 0.001, by 
two-way ANOVA, see Figure 6.12.1). This was despite a higher overall cell 
viability after 10J/m2 254nm UVC irradiation compared to 52.5J/cm2 385nm 
UVA-1 (96.33% vs. 67.04%, respectively).  
 
Following 52.5J/cm2 385nm UVA-1, MMP-1 mRNA fold change was 
approximately 6 times greater for all cells than after 254nm UVC irradiation. 
Mean (±SEM) MMP-1 mRNA fold change in control cells was 14.05 (±2.37) 
after 385nm UVA-1, compared to 2.49 (±0.37) after 254nm UVC. In XP cells, 
mean MMP-1 mRNA fold change after 385nm UVA-1 was 26.57 (±7.97), 
compared to 4.71 (±0.86) after 254nm UVC. Assessing for differences between 
XP groups, MMP-1 mRNA fold change appeared to be highest in XP-A, XP-C, 
XP-D, XP-E and XP-G (see Figure 6.12.1A).  
 
Under the same exposure conditions as above, MMP-10 mRNA expression fold 
change was approximately doubled following 385nm UVA-1 irradiation 
compared to 254nm UVC. Mean (±SEM) MMP-10 mRNA fold change in 
control cells was 11.67 (±3.30) after 385nm UVA-1, compared to 4.58 (±1.48) 
after 254nm UVC. In XP cells, mean MMP-10 mRNA fold change after 385nm 
UVA-1 was 15.2 (±5.01), compared to 6.60 (±1.84) after 254nm UVC (see 
Figure 6.12.1B). 
 
Mean (±SEM) MMP-12 mRNA fold change in control cells was 12.5 (±5.01) 
after 385nm UVA-1, similar to the mRNA change after 254nm UVC (15.05 
(±2.60)). In XP cells fold change was 13.91 (±4.30) after 385nm UVA-1, 
approximately three times greater than fold change after 254nm UVC (4.72 
(±1.00), see Figure 6.12.1C). 
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Figure 6.12.1: MMP expression; 385nm UVA-1 vs. 254nm UVC; mean ±SEM of six separate 
experiments in two control and eight XP cell lines 24h after 52.5J/cm2 385nm UVA-
1 or 10J/m2 254nm UVC at 24 hours: A: MMP-1; B: MMP-10; C: MMP-12 mRNA 
fold change. P values correspond to two-way ANOVA comparing UVA-1 with UVC 
across all cell lines. 
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6.13. TIMP mRNA expression; 385nm UVA-1 vs. 254nm UVC 
 
Figure 6.13.1: TIMP expression; 385nm UVA-1 vs. 254nm UVC; mean ±SEM of three separate 
experiments in two control and eight XP cell lines 24h after 52.5J/cm2 385nm UVA-
1 or 10J/m2 254nm UVC at 24 hours; A: TIMP-1, B: TIMP-3. P values correspond to 
two-way ANOVA comparing UVA-1 with UVC across all cell lines. 
 
TIMP mRNA fold change was approximately 10 times lower than MMP mRNA 
expression after both UVR spectra with the same irradiation doses. TIMP-1 was 
more significantly upregulated after 254nm UVC irradiation compared to 
385nm UVA-1 (p<0.0001 by two-way ANOVA, see Figure 6.13.1A). TIMP-3 
expression did not significantly change following irradiation with either UVR 
source (p=0.0935, Figure 6.13.1B). 
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6.14. HO-1 expression; 385nm UVA-1 vs. 254nm UVC 
 
Figure 6.14.1: HO-1 mRNA expression; 385nm UVA-1 vs. 254nm UVC; mean ±SEM of three 
separate experiments in two control and eight XP cell lines 24h after 52.5J/cm2 385nm 
UVA-1 or 10J/m2 254nm UVC at 24 hours. P value corresponds to two-way ANOVA 
comparing UVA-1 with UVC across all cell lines. 
 
HO-1 mRNA was more significantly upregulated by 52.5J/cm2 385nm UVA-1 
than by 254nm 10J/m2 UVC (p<0.0001 by two-way ANOVA, see Figure 
6.14.1A). Mean mRNA fold change (±SEM) in control cells after 385nm UVA-
1 was 8.96 (±3.01), compared to 1.68 (±0.23) after 254nm UVC. In XP-C and 
XP-E cells mRNA fold change after 385nm UVA-1 was 16.57 (±6.49), 
compared to 2.32 (±0.23) after 254nm UVC. For XP-A, XP-D, XP-F and XP-G 
groups, mean (±SEM) mRNA fold change after UVA-1 was 11.52 (±2.70), 
however after 254nm UVC, fold change decreased to 0.25 (±0.03), see Figure 
6.14.1B). This was despite similar initial background levels of HO-1 in all cells 
(see Figure 6.5.2). 
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6.15. MMP expression 24 hours after 52.5J/cm2 385nm UVA-1 
XP cells were grouped according to NER subtype (TC-NER-preserved: XP-C 
and XP-E, versus TC-NER-impaired: XP-A, XP-D, XP-F and XP-G). MMP-1 
was more significantly upregulated in TC-NER-preserved XP cells compared to 
control cells after 385nm UVA-1 (p=0.0089 by one-way ANOVA, see Figure 
6.15.1A). There was no difference in MMP-1 mRNA expression between TC-
NER-impaired XP cells and control cells. There was no significant difference in 
MMP-10 or MMP-12 mRNA expression between XP and control cells (p>0.05, 
Figure 6.15.1B &C). 
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Figure 6.15.1: MMP mRNA expression after 385nm UVA-1; mean ±SEM of six separate 
experiments in two control and eight XP cell lines treated with 52.5J/cm2 385nm 
UVA-1: A: MMP-1, B: MMP-10, C: MMP-12 mRNA fold change at 24 hours. P 
values correspond to one-way ANOVA comparing mRNA fold change across 3 
designated groups. 
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6.16. MMP and HO-1 expression 24 hours after 10J/m2 254nm UVC 
There was no significant difference in MMP-1 or MMP-10 mRNA expression 
between the three groups after 254nm UVC irradiation (see Figure 6.16.1A and 
B). MMP-12 was more significantly downregulated in XP cells compared to 





Figure 6.16.1: MMP mRNA expression after 254nm UVC; mean ±SEM of six separate experiments 
in eight XP and two control cell lines treated with 10J/m2 254nm UVC. A: MMP-1, 
B: MMP-10, C: MMP-12 mRNA fold change at 24 hours. P values correspond to 
one-way ANOVA comparing mRNA fold change across three designated groups. 
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There was no significant difference in HO-1 mRNA expression between the 
three groups after 385nm UVA-1, however after 254nm UVC irradiation HO-1 
was significantly downregulated in TC-NER-impaired XP groups (p<0.0001, 
see Figure 6.16.2B). 
 
Figure 6.16.2: HO-1 mRNA expression; UVA-1 vs. UVC: A: 24h after 52.5J/cm2 385nm UVA-1; 
B: 24h after 10J/m2 254nm UVC; mean ±SEM of three separate experiments in eight 
XP and two control cell lines. P values correspond to one-way ANOVA comparing 
mRNA fold change across three designated groups. 
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6.17. Effect of vitamin E on MMP mRNA expression 
Given that MMP mRNA expression was significantly upregulated by 385nm 
UVA-1 than by 254nm UVC and that UVA is known to induce ROS, I 
postulated that the intracellular antioxidant, vitamin E, might have a dampening 
effect on MMP mRNA expression after 385nm UVA-1. I measured mRNA 
expression in XP and control cells that had either been incubated with media 
containing vitamin E for 24 hours prior to and during irradiation in PBS (pre-
irradiation incubation), or had vitamin E added to the media immediately after 
irradiation for 24 hours until RNA extraction (post-irradiation incubation). 
 
6.17.1. Viability with vitamin E 
Initially I performed dose-response viability experiments incubating XP and 
control cells with media containing vitamin E for 24 hours to identify the highest 
concentration that could be used without affecting cell viability (see chapter 5, 
section 5.5 and Figure 6.17.1A). Based on this and on work by a previous 
student in our laboratory, I identified an optimal vitamin E concentration of 
0.1mM. The addition of 0.1mM vitamin E prior to 385nm UVA-1 irradiation 
also had no exacerbating effect on cell viability (Figure 6.17.1B). 
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Figure 6.17.1: Dose-response viability with vitamin E in XP and control cells; mean ±SEM of three 
separate experiments: A: viability of XP and control cells over vitamin E dose; B: 
cells irradiated in PBS with vitamin E showed no difference in viability compared to 
cells irradiated without vitamin E. 
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Effect of vitamin E without UVR 
To ascertain if incubation of XP and control cells with vitamin E might exert an 
independent effect on MMP mRNA expression, in the absence of UVR, I 
performed experiments measuring mRNA expression for either 24 hours before 
or 24 hours after sham-irradiation incubation with 0.1mM vitamin E (correlating 
to pre- or post-sham-irradiation incubation with vitamin E, respectively). 
6.17.2. Vitamin E effect on MMP-1 mRNA expression without UVR 
 
Figure 6.17.2: MMP-1 mRNA expression with vitamin E, without UVR: Effect of pre- and post- 
(sham)-irradiation incubation; mean ±SEM of three separate experiments in eight XP 
and two control cell lines. 
 
Pre- (sham)-irradiation incubation with vitamin E (48 hour incubation) exerted 
an independent upregulatory effect on MMP-1 expression (Figure 6.17.2), 
significantly different to post (sham)-irradiation (24 hour) incubation 
(p=0.0003). MMP-1 mRNA fold change pre- and post- (sham)-irradiation 
incubation with vitamin E was significantly different to MMP-1 mRNA fold 




6.17.3. Vitamin E effect on MMP-10 mRNA expression without UVR 
 
Figure 6.17.3: MMP-10 mRNA expression with vitamin E, without UVR: effect of pre- and post-
(sham)-irradiation incubation; mean ±SEM of three separate experiments in eight XP 
and two control cell lines 
 
Pre- (sham)-irradiation (48 hour) incubation with vitamin E appeared to exert 
an independent upregulatory effect on MMP-10 mRNA expression in most cell 
lines (Figure 6.17.3). There was a significant difference in MMP-10 mRNA fold 
change with pre and post (sham)-irradiation incubation with vitamin E 
(p=0.0132, p=0.0005 respectively), compared to MMP-10 mRNA fold change 
without vitamin E. 
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6.17.4. Vitamin E effect on MMP-12 mRNA expression without UVR 
 
Figure 6.17.4: MMP-12 mRNA expression with vitamin E, without UVR: effect of pre- and post-
(sham)-irradiation incubation; mean ±SEM of three separate experiments in eight XP 
and two control cell lines. 
 
Pre- (sham)-irradiation (48 hour) incubation with vitamin E exerted an 
independent upregulatory effect on MMP-12 mRNA expression (Figure 6.17.4). 
There was a significant difference in MMP-12 mRNA fold change with pre and 
post (sham)-irradiation incubation with vitamin E (p = 0.0003 for both), 
compared to MMP-12 mRNA fold change without vitamin E. 
 
Therefore I concluded that vitamin E was probably exerting a small independent 
pro-oxidant effect, or it may have activated an alternate pathway resulting in 




6.17.5. MMP-1 mRNA expression with vitamin E after 385nm UVA-1 
Pre-irradiation incubation with 0.1mM vitamin E followed by 385nm UVA-1 
irradiation reduced MMP-1 mRNA expression by an average (±SEM) of 
49.01% (±5.46) in control cells and 48.75% (± 7.29) in XP cells (Figure 6.17.5). 
The effect of post-irradiation incubation on MMP-1 mRNA expression after 
385nm UVA-1 was weaker than pre-irradiation incubation (mean reduction 
23.67% (±8.21) in control cells and 5.49% (±9.59) in XP cells). This dampening 
effect with UVA-1 was inverse to the 2-5-fold increase in MMP-1 mRNA 




Figure 6.17.5: MMP-1 mRNA expression; 385nm UVA-1 with vitamin E; effect of pre and post-
irradiation incubation with 0.1mM vitamin E on MMP-1 mRNA expression as a % of 
UVA-1-induced fold change without vitamin E; mean ±SD of six separate experiments 
in eight XP and two control cell lines. 
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6.17.6. MMP-10 mRNA expression with vitamin E after 385nm UVA-1 
Pre-irradiation incubation with 0.1mM vitamin E reduced 385nm UVA-1-
induced MMP-10 mRNA expression in control cells by 72.9% (±3.04) 
compared to 23.15% (±9.72) with post-irradiation incubation. In XP cells, pre-
irradiation incubation reduced MMP-10 mRNA expression on average by 
68.19% (±5.09) vs. 16.47% (±7.70) with post-irradiation incubation (Figure 
6.17.6). This was inverse to the pro-oxidant effect of isolated vitamin E (without 




Figure 6.17.6: MMP-10 mRNA expression; 385nm UVA-1 with vitamin E; effect of pre and post-
irradiation incubation with 0.1mM vitamin E on in MMP-10 mRNA expression as a % 
of UVA-1-induced fold change without vitamin E; mean ±SD of six separate 
experiments in eight XP and two control cell lines.  
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6.17.7. MMP-12 mRNA expression with vitamin E after 385nm UVA-1 
Post-irradiation incubation with 0.1mM vitamin E reduced UVA-1-induced 
MMP-12 mRNA expression by an overall mean (±SEM) of 54.43% (±6.56) in 
control cells and 36.41% (± 11.10) in XP cells. This was a markedly stronger 
effect than pre-irradiation incubation, which reduced MMP-12 mRNA 
expression by 18.7% (±16.1) in control cells and 15.67 (±15.13%) in XP cells 
(Figure 6.17.7). Looking at individual XP groups, pre-irradiation incubation 
reduced MMP-12 expression more effectively than post-irradiation incubation 
in TC-NER-preserved XP-C and XP-E groups (57.1% vs. 41.9% respectively). 
In TC-NER-impaired groups, post-irradiation vitamin E incubation was more 
effective, whereas pre-irradiation vitamin E incubation in these XP groups was 





Figure 6.17.7: MMP-12 mRNA expression; 385nm UVA-1 with vitamin E; effect of pre and post-
irradiation incubation with 0.1mM vitamin E on MMP-12 mRNA expression as a % of 
UVA-1-induced fold change without vitamin E; mean ±SD of six separate experiments 
in eight XP and two control cell lines. 
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6.17.8. MMP mRNA expression with vitamin E after 254nm UVC 
 
Figure 6.17.8: MMP expression with vitamin E after 254nm UVC: effect of pre and post-irradiation 
incubation with 0.1mM vitamin E on A: MMP-1, B: MMP-10 and C: MMP-12 
expression as a % of UVC-induced fold change without vitamin E, 24 hours after 




Pre-irradiation incubation with 0.1mM vitamin E had a significant effect on 
reducing MMP-1 and MMP-10 mRNA expression 24 hours after 10J/m2 254nm 
UVC (p=0.0048 and p<0.0001 by two-way ANOVA respectively), however it 
had no effect on MMP-12 mRNA expression (p>0.05). It is unlikely that vitamin 
E was acting as a sunscreen as this would have led to a similar effect observed 
on all endpoints.  
 
6.18. MMP-1 protein expression 
MMP-1 protein expression from cell supernatant retrieved after various 
conditions (24 hours pre- and post- 385nm UVA-1 irradiation incubation with 
0.1mM vitamin E, 24 hours post 254nm UVC irradiation and unirradiated) was 
measured by ELISA using two samples per condition from two separate 
experiments, plotted in ng/ml.  
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Figure 6.18.1: MMP-1 protein expression measured after various conditions (24h pre- and post- 
385nm UVA-1 irradiation incubation with 0.1mM vitamin E, 24h post 254nm UVC 
irradiation and unirradiated (UV-); mean (±SEM) of two samples per condition from 
two separate experiments in two control and six XP cell lines. 
 
Highest MMP-1 protein levels were seen in 385nm UVA-1-irradiated XP cells, 
higher than 254nm UVC-irradiated cells, in concordance with mRNA data.  
 
The pattern of MMP-1 protein expression with pre- and post-irradiation vitamin 
E incubation correlated with MMP-1 mRNA fold change in both control and XP 
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cells (Figure 6.18.2) under the same conditions. An approximately 20-fold 
change in MMP-1 mRNA expression correlated with 60ng/mL MMP-1 protein 
in control, XP-A, XP-E and XP-G cells. Vitamin E reduced UVA-1-induced 
MMP-1 protein expression (Figure 6.18.1); pre-irradiation vitamin E incubation 
appeared to have a greater effect on reducing MMP-1 protein expression in XP 
cells, compared to post-irradiation incubation. In control cells, post-irradiation 




Figure 6.18.2: MMP-1 gene and protein expression after UVA-1 exposure: MMP-1 mRNA fold 
change on left panel with corresponding MMP-1 protein levels on right panel in two 




6.19. MMP-10 protein expression 
MMP-10 protein expression from cell supernatant retrieved after the various 
conditions was measured by ELISA using two samples per condition from two 
separate experiments, with results plotted in pg/ml. MMP-10 protein levels were 




Figure 6.19.1: MMP-10 protein expression measured after various conditions; (24h pre- and post- 
385nm UVA-1 irradiation incubation with 0.1mM vitamin E, 24h post 254nm UVC 
irradiation and unirradiated (UV-); mean (±SEM) of two samples per condition from 
two separate experiments in two control and six XP cell lines. 
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Incubation with 0.1mM vitamin E reduced MMP-10 protein expression to 
unirradiated levels or lower (Figure 6.19.1). The pattern of MMP-10 protein 
expression correlated with mRNA expression (Figure 6.19.2); in controls, XP-
A and XP-G cells, an approximate 10-fold mRNA change correlated to 
100pg/mL MMP-10 protein. 
 
 
Figure 6.19.2: MMP-10 gene and protein expression after UVA-1 exposure: MMP-10 mRNA fold 
change on left panel with corresponding MMP-10 protein levels on right panel in two 




6.20. MMP-12 protein expression 
The ELISA kit used to measure MMP-12 protein expression was from a 
different supplier to the MMP-1 and MMP-10 ELISA kits (Thermofisher did 
not supply MMP-12 ELISA kits). Although the MMP-12 ELISA experiment 
generated a standard curve (Figure 6.20.1), unfortunately MMP-12 protein 
levels were below the limit of the assay detection. 
 
Figure 6.20.1: Standard curve generated by MMP-12 ELISA experiment. Results were calculated 




6.21.1. Background MMP and oxidative stress mRNA expression 
In the cells used, I have shown that TC-NER-preserved XP cells (2 XP-C lines 
and 1 XP-E line) had a significantly lower background MMP-1 mRNA 
expression compared to controls. This was opposite to what has been described 
in the literature, where a higher background MMP-1 mRNA and protein 
expression was demonstrated in six primary XP-C fibroblast cell lines (Frechet 
et al., 2008, see Figure 6.21.1) In their study, XP-C cells were also obtained 
from unexposed skin sites of XP-C patients, at a similar age of diagnosis (and 
therefore skin biopsy) to my cohort (see Table 6.3.1); 5/6 (83%) of their XP-C 
cohort had developed KC compared to 2/2 (100%) in my cohort. Their study 
described a significant (3-fold) upregulation of MMP-1 mRNA expression from 
six XP-C cell lines compared to three controls. It is likely that this difference 
was observed from their higher XP-C sample size. However, variable 
background MMP-1 mRNA expression has been demonstrated in individuals 
even without XP (Antony Young, personal communication) and the relative 
sample size (9 cell lines) may have overestimated the observed significance, 
which could be attributed to individual variation. 
 
 
Figure 6.21.1: XP-C patient characteristics in an alternate study: higher background (unirradiated) 
MMP-1 mRNA and protein levels were demonstrated in fibroblasts from these XP-C 
patients (Frechet et al., 2008). 
 
I found that background MMP-10 mRNA expression was significantly lower in 
XP-E cells and background MMP-12 mRNA expression was significantly lower 
in XP-D and XP-G cells compared to controls. There was no difference in TIMP 
or HO-1 background mRNA expression levels between all cells. 
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6.21.2. MMP mRNA and protein expression: 
MMP mRNA and protein was measured 24 hours after UV-irradiation. Initial 
time-response experiments were performed at 6, 12, 24 and 48 hours after 
irradiation, however, retrospectively it would have been prudent to perform 
experiments between 1-4 hours after irradiation, as the literature suggests there 
are bimodal peaks in MMP expression, which are related to the different 
mechanisms of transcriptional activation. The early time point occurs directly 
as a consequence of ROS induction; the 24-hour time point occurs as a result of 
a ROS-initiated cytokine cascade, for example, interleukin 1 (IL-1) can activate 
MMP-1 through NF-κB (Vincenti et al., 1998, Vincenti, 2001). 
 
24 hours after irradiation, I have shown a statistically significant increase in 
MMP-1 expression that was six times greater after 385nm UVA-1 compared to 
254nm UVC irradiation. 385nm UVA-1 caused a significantly higher MMP-1 
expression in TC-NER-preserved XP groups compared to TC-NER-impaired 
groups. MMP-10 mRNA fold change was approximately doubled following 
385nm UVA-1 irradiation compared to 254nm UVC irradiation in both control 
and XP cells. MMP-12 mRNA fold change was similar in control cells after 
both 385nm UVA-1 and 254 nm UVC. In XP cells, MMP-12 mRNA expression 
was three times greater with 385nm UVA-1 compared to 254nm UVC. The fold 
change in MMP-12 mRNA expression for XP and control cells following 
385nm UVA-1 was similar, implying a similar mechanism for upregulation. The 
contrasting fold change following 254nm UVC, coupled with variable 
expression following pre- and post-UVC irradiation incubation with vitamin E 
in XP cells (Figure 6.17.8) suggests a pathway of upregulation independent of 
oxidative stress in UVC-treated cells.  
 
Upregulation of these MMP in vitro correlates to an extent with the observed 
XP phenotype; XP patients, particularly those in TC-NER-preserved groups 
(XP-C and XP-E) have the appearance of coarse wrinkles at exposed sites, 
suggesting breakdown of collagen and elastin. Future in vivo experiments could 
be conducted to confirm if these histological changes are present. 
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6.21.3. Pre- and post-irradiation incubation with 0.1mM vitamin E 
The addition of 0.1mM vitamin E to cultured cells exerted a dampening effect 
on MMP mRNA and protein expression. XP cells expressed less MMP-1 mRNA 
and protein if they were incubated for 24 hours with 0.1mM vitamin E prior to 
385nm UVA-1 irradiation. In control cells, post-irradiation incubation with 
vitamin E reduced MMP-1 protein expression, whereas pre-irradiation 
incubation had little reducing effect on protein, despite a significant reduction in 
mRNA expression.  
 
The pattern of MMP-10 protein expression following pre and post-irradiation 
incubation with 0.1mM vitamin E correlated with MMP-10 mRNA expression; 
pre-irradiation incubation had a stronger reducing effect than post-irradiation 
incubation in all cells (except XP-D (XP135LO) where post-irradiation 
incubation was stronger). MMP-12 mRNA expression after UVA-1 was reduced 
more effectively by post-irradiation incubation with vitamin E than by pre-
irradiation incubation. In conclusion, this data suggest direct photochemical 
mechanisms of MMP-1 and MMP-10 upregulation, as pre-irradiation incubation 
with vitamin E exerted more effective overall reduction in mRNA expression 
than post-irradiation incubation. 
 
When vitamin E was added to cell media for either 48 hours (pre-sham-
irradiation) or 24 hours (post-sham-irradiation) it exerted a small upregulatory 
effect on MMP-1, MMP-10 and MMP-12 mRNA expression UVR in all cases, 
with a more noticeable, time-dependent upregulation that occurred for MMP-1 
across all lines (Figure 6.17.2). This suggests vitamin E was acting as a pro-
oxidant inducer of MMP, in the absence of UVR.  
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6.21.4. Oxidative stress gene expression  
Many of the other oxidative stress genes (SOD-2, NQO-1, OGG-1, NRF-2 and 
APE-1) did not change significantly after 385nm UVA-1. Under normal 
conditions NRF-2 protein is bound to KEAP-1 (Kelch-like-ECH-associated 
protein 1) and it is continuously degraded via ubiquitination, however after 
UVA irradiation and the generation of oxidized phospholipids, NRF-2 protein 
is stabilized, which leads to binding of a transcription factor complex to the HO-
1 gene promoter (Sun et al., 2004, Gruber et al., 2010, Tyrrell, 2012). It is 
therefore unsurprising that no change in NRF-2 mRNA expression was seen 
here, as the main change would be expected to occur at the protein level. 
 
HO-1 mRNA expression was significantly upregulated after 385nm UVA-1 
compared to 254nm UVC. 254nm UVC irradiation significantly downregulated 
HO-1 mRNA expression in TC-NER-impaired groups, suggesting an impaired 
antioxidant as well as CPD repair capacity in TC-NER-impaired XP groups. Or 
it may suggest activation of a repressive transcription factor (Tyrrell & Reeve, 
2006) causing downregulation of HO-1 in these groups.  
 
In view of previous studies demonstrating HO-1 mRNA levels peaked at 2 
hours and HO-1 protein peaked at 6-12 hours after UVA irradiation (Keyse et 
al., 1990, Zhong et al., 2014) it would be prudent to examine shorter time 
periods for HO-1 mRNA and protein levels in XP cells after UVA-1. In 
addition, HO-1 is refractory to upregulation following repeated UVA exposures 
(Zhong et al., 2014), suggesting that the mechanism of suppressed HO-1 may 
in some way be associated with increased oxidative stress and photoageing 
resulting from chronic daily UVR exposure. Experiments measuring the levels 
of HO-1 mRNA (at 2 hours) and protein (at 9 hours) in skin cells after UVA-1 
exposure and potentially in neuronal cells with the addition of a metabolic pro-
oxidant, comparing responses in XP with controls, may further indicate how 









7. CPD & ROS 
 
Part A: CPD repair in 





Phenotypic differences in skin cancer development have been described in the 
previous chapters; several XP patients in our cohort have, remarkably, never had 
a skin cancer. In order to assess if there may be a molecular basis for these 
differences, I analysed the rate and extent of CPD repair in a selection of XP 
patients’ fibroblasts (see Table 7.2.1). XP-A, XP-E, XP-F and XP-G patients 
with no skin cancers were selected to compare with an XP-D patient who had 
developed multiple skin cancers.  
 
The repair rate of UVC-induced CPD over longer time periods has been 
examined in a few XP cases (Zelle et al., 1979, Zelle et al., 1980) and it has 
been shown that UDS levels can vary depending on the time period studied after 
irradiation. However, the rate and extent of CPD repair over time had not been 
systematically analysed in a cohort of XP patients with different mutations in 
different genes. 
 
7.2. Measurement of CPD repair 
I attempted to quantify DNA repair by measuring the removal of CPD over a 
period of 48 hours after UVR exposure in selected fibroblasts from cells with 
different mutations in XP genes and in normal controls. To assess CPD repair I 
used an immunostaining protocol with an anti-CPD antibody (see chapter 5, 
section 5.11.3). Cells were starved prior to irradiation in order to minimize cell 
replication, which could have falsely influenced CPD quantification (a single 
cell division would have effectively mimicked 50% CPD repair). 
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Table 7.2.1: XP lines used to quantify CPD repair. 














XP57BR XP-A c.640dupA p.(Met214fs) 16 1 1 n/a n/a 0 
XP59BR XP-D c.2047C>T p.(Arg683Trp) 
c.1381C>G p.(Leu461Val) 
c.2150C>G p.(Ala717Gly) 
54 24 2 36 BCC 28 
XP115BR XP-E c.1149delG p.(Met383fs) 31 63 1 n/a n/a 0 
XP24BR XP-F c.1765C>T p.(Arg589Trp) 
c.2395C>T p.(Arg799Trp) 
49 4 2 n/a n/a 0 
XP104BR XP-G c.136delC p.(His46fs) 7 2 3 n/a n/a 0 
 
7.3. CPD repair after 254nm UVC 
7.3.1. Cell viability after 10J/m2 254nm UVC in starved cells 
Prior to CPD immunostaining experiments, I measured viability of starved cells 
after 10J/m2 254nm UVC irradiation, using the alamarBlue® viability assay (see 
chapter 5, section 5.10). UVC irradiation in these experiments was performed 
on cells in wells without PBS (described in chapter 5, section 5.11.1). After 
10J/m2 254nm UVC irradiation, mean 24-hour viability of starved XP and 
control cells was 95.88% (similar to viability of non-starved cells (96.33%) in 
chapter 6, section 6.4.2), however it is important to note that the XP cell lines 
used for these experiments were different to those used for MMP (see chapter 
6, Table 6.3.1). At 48 hours after 254nm UVC irradiation, viability for control 
cells was greater than 80%, with XP cell viability ranging from an average of 




Figure 7.3.1: XP and control cell viability after 10J/m2 254nm UVC up to 48 hours. 
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7.4. CPD repair: troubleshooting 
My initial protocol for CPD repair was an assay for alkaline single cell gel 
electrophoresis (comet assay) using T4N5, a highly specific endonuclease, 
cleaving CPD sites within DNA, after UVC exposure. With the application of 
an electric current, fragmented DNA will migrate out of the nucleus to form a 
comet tail that can be visualized with fluorescent propidium iodide staining of 
DNA. The length of DNA migration (comet tail) is proportional to the number 
of DNA strand breaks and therefore to CPD. DNA repair can be calculated by 
measuring post-exposure reduction in tail migration (Alapetite et al., 1996).   I 
attempted to optimize the comet assay for several months, however I found it 
very difficult to obtain good reproducible results and the agarose gels frequently 
dislodged from the glass slides during electrophoresis, meaning that data were 
lost by the time of analysis. Therefore I researched other methods that were 
similar in format to the fluorescent UDS assay (with which I had some prior 
experience, Jia et al., 2015) 
 
In the fluorescent CPD protocol, I trialled two different irradiation methods: The 
first method involved sequential daily irradiation of each plate, starting with the 
48h plate on day 4, the 24 plate on day 5 and the 0h plate on day 6 (see Figure 
5.11.1). The second method involved simultaneous irradiation of all three plates, 
followed by immediate fixation of the 0h plate, fixing of the 24h plate on day 5 
and the 48h plate on day 6, however this method gave inconsistent results and 
therefore I decided that the first method was optimal.   
 
I encountered a separate issue with high background fluorescence in the 
unirradiated wells. I expected the cells in these wells to fluoresce only when 
excited with the blue (DAPI) channel of the microscope (as there were no CPD 
present), however the green channel caused a generalized excitation of wells, 
which created a falsely high background and resulted in a higher value when 
analysed with Cell Profiler. This reduced the numerical difference between 
irradiated and unirradiated wells. I noticed that the value of this background 
appeared to fluctuate between different experiments and even in those 
experiments in which two plates containing identical cell lines, plated at the 
same time, with identical irradiations, were conducted. The exposure settings 
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for each channel on the microscope remained constant for every experiment. I 
tried increasing the number of wash steps and reducing the concentration of goat 
serum to avoid non-specific antibody staining. I replaced the secondary antibody 
for a fresh product; none of these amendments made any difference. I then 
imaged empty, unirradiated, untreated wells in separate experiments where the 
background was low and compared these images to those from experiments in 
which the background had been high; I realised that the backgrounds were 
different even in these wells, leading me to the conclusion that the problem was 
with the 96-well plates rather than the reagents and cells. I remembered using 
plates from two separate batches for the experiments conducted simultaneously. 
Therefore I decided to use black-walled clear-bottomed 96-well plates; this 
completely eliminated all aforementioned problems. I repeated the experiments 
6 times successively and found the unirradiated wells gave consistently similar 
values. 
 
Having finally resolved these issues, I was able to analyse the repair of CPD in 
different cells. Examples of the microscopic images are shown in Figure 7.4.1 
and a summary of the repair data from six experiments is presented in Figure 
7.4.2.  
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7.4.1. CPD staining over time after 10J/m2 254nm UVC 
 
Figure 7.4.1: 48 hour CPD staining in control and XP cells; immunofluorescent single channel images (DAPI and Alexa Fluor 488®) before and after 254nm 10J/m2 UVC irradiation 
at different time points.  
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7.4.2. CPD repair measurement 
 
Figure 7.4.2: 48 hour CPD repair in control and XP cells up to 48h after 10J/m2 254nm UVC 
irradiation, Mean ± SEM of 6 experiments. 
 
In control cells, CPD induced by 10J/m2 254nm UVC were repaired by an 
average (±SEM) of 52.1% (±4.19) in 48BR and 59.38% (±1.01) in 1BR after 48 
hours. Linear regression analysis confirmed a significant deviation from zero in 
both control cell lines (p<0.0001, see Figures 7.4.1 and 7.4.2). 
 
In XP-A, XP-D and XP-G cells, CPD levels even appeared to increase after 48 
hours to an average (±SEM) of 132% (±9.00), 128% (±11.7) and 123% (±14.1) 
respectively. Linear regression analysis confirmed a significant deviation from 
zero in cells from XP-A (p=0.0276) and XP-D (p=0.0224), but not XP-G 
(p=0.187). In XP-E and XP-F cell lines, CPD levels remained constant at 93.4% 
(±8.61) and 101% (±8.65) respectively and linear regression analyses were not 
significant (p>0.05). There was no difference comparing rates of CPD repair 
between different XP groups (p=0.8736 by one-way ANOVA).  
 
Thus no detectable repair was observed in any cells from XP-A, XP-D, XP-E, 








Part B: Photobiological 
effects: 385nm 
UVA-1 vs. 254nm 
UVC
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7.5. Biological relevance of UVA-1 vs. UVC 
The concept of an action spectrum relates to the relative effects of different UVR 
wavelengths for a given photobiological outcome. The induction of DNA 
damage by UVR is proposed to occur both directly, through action of DNA as 
a chromophore, producing CPD, and indirectly through the production of ROS 
by other cellular chromophores.  
 
XP is considered a disease of impaired CPD repair, however the 
neurodegeneration classically manifesting in TC-NER-impaired XP groups has 
been attributed to failure of repair of oxidatively generated lesions (Brooks, 
2002). With this in mind, I sought to identify if the effect of wavelength 
extremes, UVA-1 (385 nm) vs. UVC (254 nm), on XP and control fibroblasts 
over different time periods could help to explain how direct and indirect UVR-
induced DNA damage is repaired. 
 
Repair of CPD (measured as UDS) induced by UVC and UVA in both XP and 
non-XP cells has been measured directly in a limited number of cases (Roza et 
al., 1985), however a spectrally pure UVA source was not used for these studies 
(Figure 7.5.1). It has been subsequently shown that 75% of CPD generated by 
these apparent UVA sources are actually caused by contamination with 0.8% 
UVB (Woollons et al., 1999). Therefore CPD apparently induced by their UVA 
source may actually have been caused by spectral contamination with UVB. 
 
Figure 7.5.1: Spectral emission of Sellas UVA lamp used for historical studies on XP cells (Roza 
et al., 1985): emission spectrum was filtered by 8mm glass to eliminate wavelengths 
below 330nm. The spectrum between 305 and 345nm was plotted at 10-fold higher 
sensitivity (dotted line).  
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The aims of the following experiments were: 
1)  To understand if CPD are generated by spectrally pure UVA-1 
2)  To measure the relative generation of ROS in UVA-1 vs. UVC 
 
Table 7.5.1: XP lines used to measure the rate of CPD repair. 
XP cell line XP 
Group 
Mutation Age UDS 
Level 








XP114BR XP-A c.682C>T p.(Arg228X) 25 8 3 n/a n/a 0 
XP22BR XP-C c.658C>T p.(Arg220X) 39 13 0 11 BCC 7 
XP135LO XP-D c.2047C>T p.(Arg683Trp) 35 25 3 13 BCC 51 
XP98BR XP-E c.161G>A p.(Tyr54X) 63 68 1 15 BCC >200 
XP24BR XP-F c.1765C>T p.(Arg589Trp) 
c.2395C>T p.(Arg799Trp) 
49 4 2 n/a n/a 0 




7.6. CPD staining after 385nm UVA-1 and 254nm UVC irradiation 
These experiments were conducted in tandem with MMP experiments in chapter 
6 to establish if CPD were present after 385nm UVA-1 irradiation. In the earlier 
experiments measuring CPD repair, cells were irradiated without PBS for the 
52.9 seconds, to give a dose of 10J/m2 (see chapter 5, section 5.11). UVC 
irradiations for the following experiments were conducted with cells in PBS. 
This was done because here the 385nm UVA-1 and 254nm UVC irradiations 
were performed on cells within the same 96-well plate (see chapter 5, Figure 
5.13.1) and I did not want to introduce any technical or experimental variability 
in wells irradiated with these different wavelengths. Irradiations were performed 
as per chapter 5 section 5.13.1, using the same doses as those used for MMP 
mRNA and protein expression experiments.  
 
7.6.1. Cell viability 
Cell lines used for these experiments were controls (1BR and 48BR) and one 
cell line from each XP complementation group; TC-NER-impaired: XP-A 
(XP114BR) and XP-D (XP135LO), or TC-NER-preserved: XP-C (XP22BR) 
and XP-E (XP98BR). The cell lines used here (see Table 7.5.1) correspond with 
cell lines used in chapter 6 (see Table 6.3.1). Cell viability after UVR was lower 
in starved irradiated cells compared to non-starved cells irradiated in PBS: 
72.78% vs. 96.33% for 254nm UVC; 61.64% vs. 67.04% for 385nm UVA-1, 




7.7. CPD in control cells 385nm UVA-1 vs. 254nm UVC 
 
Figure 7.7.1: CPD quantification in control cells at time points up to 24 hours after irradiation with 
385nm UVA-1 after two incremental doses and 254nm UVC; A: Control (1BR) and B: 
Control (48BR) plotted as fluorescence intensity in arbitrary units (a.u.); mean ± SEM of 
three experiments.  
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Figure 7.7.1 shows that CPD were induced immediately in both control cell lines 
after 10J/m2 254nm UVC compared to unirradiated cells. 24 hours after 254nm 
UVC irradiation fluorescence intensity gradually reduced to the level of 
unirradiated cells (see Table 7.7.1) indicating that CPD were fully repaired. This 
was confirmed by linear regression analysis: comparing slopes in both 1BR and 
48BR, there was a significant deviation from zero from 0 to 24 hours after 
254nm UVC (p≤0.0001). Analysis by one-way ANOVA showed a significant 
difference between 254nm UVC-irradiated and unirradiated control cells 
(p<0.0001). In addition two-way ANOVA analysis showed this significance 
disappeared at 24 hours, indicating CPD were repaired. Notably the background 
(unirradiated) fluorescence intensity appeared to increase slightly over time.  
 
In 1BR, linear regression analysis for slope change in cells irradiated with both 
doses of 385nm UVA-1 was significant (Figure 7.7.1A), however, the 
fluorescence intensity measured in 385nm UVA-1-irradiated cells (purple lines) 
was actually lower than the fluorescence intensity in unirradiated cells (blue 
line). Therefore this significance is not important and likely artefactual. 
 
For both controls, there was no difference between 385nm UVA-1-irradiated 
cells (at both doses) and unirradiated cells in the 24 hours after irradiation 
(p>0.05 by one-way ANOVA), indicating that CPD were not produced at a 
detectable level by UVA-1, with either 52.5J/cm2 or 105J/cm2 (see Figure 7.7.2). 
 
Table 7.7.1: CPD staining in control fibroblasts; 254nm UVC vs. 385nm UVA-1; mean a.u. (±SEM).
 
UV- 254nm UVC 385nm UVA-1 
Cell line 0h 24h 0h 10J/m2 24h 10J/m2 0h 52.5J/cm2 24h 52.5J/cm2 
1BR 21.32 (±0.81) 23.61 (±0.46) 29.25 (±0.56) 23.25 (±0.40) 23.00 (±0.43) 21.36 (±0.17) 






Figure 7.7.2: CPD staining in control fibroblasts; immunofluorescence single channel images 
(DAPI and Alexa Fluor 488®) at time points up to 24 hours after 385nm UVA-1 with 
two incremental doses and 254nm UVC: 1BR (top panel) and 48BR (bottom panel). 
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7.8. CPD in XP cells 385nm UVA-1 vs. 254nm UVC 
Figure 7.8.1 and Figure 7.8.2 show that CPD were induced immediately after 
10J/m2 254nm UVC in XP-A and XP-D cells, at a similar level to that produced 
in control cells (see Table 7.8.1). Fluorescence intensity remained constant in 
XP-A cells over 24 hours, indicating CPD were not repaired (p=0.781 by linear 
regression). In XP-D cells fluorescence reduced slightly, indicating a small 
amount of CPD repair (p=0.0067). In XP-C and XP-E cells, although the slope 
implies some repair may be occurring 24 hours after 254nm UVC irradiation 
(see Figure 7.8.3 and Table 7.8.1), linear regression suggested it was not 
significant (p=0.0877 in XP-E, p=0.124 in XP-C). One-way ANOVA analysis 
showed a significant difference in all XP cells between 254nm UVC-irradiated 
and unirradiated conditions (p<0.0001). Two-way ANOVA analysis showed 
this significance continued at all time points up to 24 hours, indicating CPD 
persisted. 
 
385nm UVA-1 irradiated cells again produced fluorescence at a similar level to 
unstained cells (lower than unirradiated cells). This was confirmed by one-way 
ANOVA, showing there was no significant difference between 385nm UVA-1-
irradiated cells and unstained cells in XP-A (p=0.568), XP-D (p=0.660), XP-C 
(p=0.134) and XP-E (p=0.249). Therefore CPD were not produced at a 
detectable level with 52.5J/cm2 or 105J/cm2 385nm UVA-1 (see Figure 7.8.2 
and Figure 7.8.4).  
 
Table 7.8.1: CPD staining in XP fibroblasts; 254nm UVC vs. 385nm UVA-1; mean a.u. (±SEM).
 
UV- 254nm UVC 385nm UVA-1 
Cell line 0h 24h 0h 10J/m2 24h 10J/m2 0h 52.5J/cm2 24h 52.5J/cm2 
XP-A 22.16 (±0.35) 22.31 (±0.42) 26.61 (±0.96) 27.69 (±0.50) 17.16 (±0.42) 19.58 (±0.34) 
XP-D 21.05 (±0.44) 20.58 (±0.42) 26.24 (±0.37) 25.15 (±0.61) 21.76 (±0.21) 19.65 (±0.36) 
XP-C 20.39 (±0.39) 21.66 (±0.41) 28.24 (±0.53) 25.73 (±0.62) 22.28 (±0.30) 19.63 (±0.33) 




Figure 7.8.1: CPD quantification in TC-NER-impaired XP cells at time points up to 24 hours after 
irradiation with 385nm UVA-1 after two incremental doses and 254nm UVC; A: XP-
A (XP114BR) and B: XP-D (XP135LO) plotted as fluorescence intensity in arbitrary 




Figure 7.8.2: CPD staining in TC-NER-impaired XP fibroblasts; immunofluorescence single 
channel images (DAPI and Alexa Fluor 488®) at time points up to 24 hours after 
irradiation with 385nm UVA-1 with two incremental doses and 254nm UVC: XP-A 
(XP114BR- top panel) and XP-D (XP135LO- bottom panel). 
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Figure 7.8.3: CPD quantification in TC-NER-preserved XP cells at time points up to 24 hours after 
irradiation with 385nm UVA-1 after two incremental doses and 254nm UVC; A: XP-
C (XP22BR) and B: XP-E (XP98BR) plotted as fluorescence intensity in arbitrary 
units (a.u.); mean ± SEM of three experiments. 
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Figure 7.8.4: CPD staining in TC-NER-preserved XP fibroblasts; immunofluorescence single 
channel images (DAPI and Alexa Fluor 488®) at time points up to 24 hours after 
irradiation with 385nm UVA-1 with two incremental doses and 254nm UVC: XP-C 
(XP22BR- top panel) and XP-E (XP98BR- bottom panel).   
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7.9. Measurement of ROS after 385nm UVA-1 vs. 254nm UVC 
Experiments to measure ROS were performed under exactly the same conditions 
as for CPD experiments (see chapter 5, 5.13.1), however measurement was 
undertaken over 2 hours (instead of 24 hours). Furthermore, 0.1mM vitamin E 
was added to one column of cells immediately prior to 385nm UVA-1 and 
254nm UVC irradiation (see Figure 5.16.1). In order to understand the rate of 
ROS generation after UVR irradiation, I measured fluorescence intensity at 2-
minute intervals. The addition of 0.1mM vitamin E assessed for any dampening 
effect on ROS production after UVR. 
 
Fluorescence intensity measurement in arbitrary units (a.u.) was directly 
proportional to cumulative generation of ROS. Figure 7.9.1 shows the 
measurement of ROS in control and XP cells at 2-minute intervals for 2 hours 
after 52.5J/cm2 385nm UVA-1, 10J/m2 254nm UVC, after incubation with 
TBHT as a positive control and with unirradiated (UV-) cells as a negative 
control.  
 
Table 7.9.1: ROS generation in XP and control cells. 
  











0.1mM vitamin E 
Positive control 
(TBHT) 
Control (48BR) -72,064 -8,741 -166.8 3,837 -31,676 
Control (1BR) -73,637 -15,175 -3,800 244 -21,461 
XP-A (XP114BR) -41,748 -4,178 -4,588 756.2 -21,728 
XP-C (XP22BR) -88,915 -24,824 -7,444 -198.1 -28,669 
XP-D (XP135LO) -243,759 -63,555 -22,564 -7,030 -52,042 
XP-E (XP98BR) -216,425 -84,414 -22,626 -5,952 -34,643 
XP-F (XP24BR) -36,898 -11,060 -9,285 -3,397 -31,740 
XP-G (XP55BR) -146,472 5,692 -1,278 2,808 -44,410 
 
In control cells following 385nm UVA-1 irradiation there was significant 
generation of ROS compared to UV- cells (p<0.0001). There was no significant 
difference between ROS generated by cells after 254nm UVC irradiation versus 
unirradiated cells (see Figure 7.9.1). ROS generation in XP-C, XP-D, XP-E and 
XP-G cells was significantly higher after 385nm UVA-1 compared to 
unirradiated cells (p<0.0001). XP-A and XP-F cells generated less ROS over 2 
hours, compared to the other XP groups. The positive control (TBHT) generated 
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ROS in all lines to similar degrees (see Table 7.9.1) and to a lower extent than 
the level induced by 385nm UVA-1.  
 
The addition of 0.1mM vitamin E to cells immediately prior to irradiation with 
385nm UVA-1 caused a significant reduction of ROS generation (p<0.0001, see 
Figure 7.9.2). There was no significant difference in fluorescence intensity 
between 0.1mM vitamin E-treated cells and UV- cells, confirming a reduction 




Figure 7.9.1: ROS generation in control and XP cells at 2-minute intervals after 385nm UVA-1 and 
254nm UVC irradiation, over 2 hours. 0.1mM vitamin E was added to well buffer 
immediately prior to irradiation in one column of UVA-1 and one column of UVC-




Figure 7.9.2: ROS induced by 385nm UVA-1 with and without vitamin E; Log10 fluorescence 
intensity analysis of area under curve (AUC) from Figure 7.9.2 (cumulative data) in 
two control and six XP cell lines generating ROS over two hours. P value corresponds 
to paired t-test, comparing two conditions. 
7.10. Discussion 
7.10.1. Rates of UVC-induced CPD repair between XP groups 
At comparative cell viabilities, I assessed the rate of CPD repair after 10J/m2 
254nm UVC irradiation over a 48-hour period in control and XP cells from 
patients who had not developed skin cancers (XP-A, XP-E, XP-F and XP-G) 
and compared this to cells from an XP-D patient, XP59BR, who had 23 non-
melanoma skin cancers and 5 malignant melanomas (see page 87). Control 
fibroblasts repaired 60% of CPD after 48 hours. There was no significant 
difference in CPD repair over 48 hours between the different XP groups. For 
XP-E and XP-F cells, fluorescence intensity remained constant over this time; 
for XP-A and XP-D groups, fluorescence intensity significantly increased by 48 
hours after 254nm UVC irradiation. This may indicate that delayed or ‘dark’ 
CPD were being produced, suggesting an alternative pathway of CPD 
generation other than through direct DNA damage by absorption of 254nm UVC 
photons. The recent paper showing generation of dark CPD by chemiexcitation 
of melanin and oxidative damage lends support to this theory (Premi et al. 2015), 
however as my experiments used purely fibroblast cultures, melanin excitation 
could not have played a role here. It is possible that other cellular chromophores 
(heme, porphyrin, flavin) may have been inducing a similar oxidative damage 
effect, contributing to the formation of dark CPD.  
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The lower incidence of skin cancer in XP-F and XP-G patients is therefore not 
related to their DNA repair capacity within the 48 hour time period. Ideally, I 
would have liked to perform staining to see if there were differences in DNA 
repair capacity over an even longer period of time, however the reduction in cell 
viability made this unfeasible. 
 
7.10.2. Effect of 385nm UVA-1 on CPD production 
The 385nm UVA-1 doses caused greater cell lethality than the 254nm UVC 
exposures. 385nm UVA-1 did not induce CPD at any time point up to 24 hours 
in either XP or control cells at doses up to 105J/cm2. In fact the level of 
fluorescence detected in cells irradiated with 385nm UVA-1 was in most cases 
lower than unirradiated cell fluorescence.  
 
Interestingly, the level of CPD repair after 254nm UVC irradiation in the second 
set of experiments for control cells appeared to be 100% by 24 hours, compared 
to 60% repair in the first experiments quantifying CPD repair. On assessment of 
the raw data, the mean level of fluorescence induced immediately after 254nm 
UVC irradiation in the first experiments with 48BR was 59.17 a.u. compared to 
27.28 a.u. in the second set of experiments (conducted a year later). This 
difference can most likely be attributed to experimental variability and different 
antibody batches.  
 
7.10.3. ROS generation 385nm UVA-1 vs. 254nm UVC 
The level of ROS generated by 385nm UVA-1 was significantly higher in most 
XP cells lines compared to control cells and also higher than the positive control. 
These species accumulated for a time after irradiation, suggesting both direct 
photochemical and indirect mechanisms for ROS generation after 385nm UVA-
1 irradiation. There was no significant difference in ROS levels between 
unirradiated cells and 10J/m2 254nm UVC-irradiated cells (XP and controls), 
indicating UVC irradiation (in these conditions) did not induce oxidative 
damage above a basal level.  
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Comparing these results with those from chapter 6, section 6.12, the remarkably 
higher ROS generation after 385nm UVA-1 versus 254nm UVC irradiation in 
all cell lines corresponded with MMP mRNA expression (albeit at a later time 
point): in XP-F cells, low levels of ROS matched low MMP-1 mRNA levels; in 
XP-C, XP-E and XP-G cells higher levels of ROS tallied with high MMP-1 
mRNA levels. The addition of 0.1mM vitamin E immediately prior to 385nm 
UVA-1 irradiation reduced the production of ROS to background levels. In 
chapter 6, sections 6.17.5- 6.17.7 and 6.18- 0, the addition of 0.1mM vitamin E 
caused a dampening effect on MMP mRNA and protein levels respectively. This 
may indicate that vitamin E has a potentially therapeutic role in preventing 
triggers in the cascade leading to MMP mRNA and protein upregulation and/ or 







8. Discussion & future 
prospects
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XP is no longer one disease 
For nearly a century, XP was considered a disease where all affected patients 
exhibited a similar phenotype: acute sunburn on minimal sun exposure, skin 
cancer at an early age, developmental delay and neurodegeneration, resulting in 
death from infection or skin cancer occurring in their third decade of life. The 
mechanism for this phenotype was explained mainly through in vitro 
experiments using UVC-induced DNA damage to demonstrate a lack of DNA 
repair in XP protein-deficient fibroblasts.  
 
Through the initiation and development of the UK National XP clinic, as well as 
through increased dissemination of information and awareness of the disease, a 
large XP patient cohort is now under long-term follow-up. In our cohort, gradual 
differences in clinical presentation and prognosis were recorded; I correlated 
genetic data with careful deep phenotyping of XP patients to increase 
understanding of how their genetic mutation more closely influenced their 
phenotype. 
 
In this thesis I have performed clinical evaluations and laboratory studies on XP 
cells to seek explanations for the varied phenotypes of XP patients and to explore 
molecular mechanisms that may affect their increased susceptibility to 
photoageing and mutation leading to carcinogenesis.  
 
8.1. Variable sunburn and skin cancer phenotype in XP 
Contrary to historical suggestions that all XP patients suffer from severe sunburn 
reactions, in chapter 2, I demonstrated that XP patients with preserved TC-NER 
(XP-C, XP-E and XP-V) had normal sunburn reactions for skin type, whereas 
those with impaired TC-NER (XP-A, XP-B, XP-D, XP-F and XP-G) had severe 
sunburn reactions on minimal sun exposure. This same phenotype has been 
demonstrated in XP mouse models; XPA knockout mice had a low MED, 
whereas XPC knockout mice had an equivalent MED to wild type mice (Berg et 
al., 1998). TC-NER-impaired XP groups were predisposed to 
neurodegeneration, whereas TC-NER-preserved XP groups were neurologically 




Figure 8.1.1: How the molecular defect influences XP clinical phenotype. 
 
Unrepaired DNA photoproducts and/or oxidative damage generated by UVR 
within skin cells may explain severe sunburn reactions and skin cancer 
predisposition; unrepaired oxidative damage of neuronal cells has been 
implicated in neurodegeneration. Overall this suggests that repair of the 
transcribed DNA strand (TC-NER) is fundamental for repairing both direct UVR 
damage (photoproducts) and indirect damage (by oxidative stress), whereas 
repair of the non-transcribed DNA strand (GG-NER) may be more important to 
repair UVR damage implicated in skin cancer development, whether direct or 
indirect. In chapter 7, part B, I explored this further by measuring the rate of 
induction and repair of direct and indirect types of UVR damage, in the forms of 
CPD and ROS respectively (see 8.3.1 and 8.3.2).  
 
The persistence of oxidative damage to guanine (8-oxoGua and 8-oxo-dG) 
within DNA of TC-NER-impaired XP groups may further contribute to an 
impaired antioxidant response; in repair-proficient cells, after their excision from 
DNA, these molecules act as ROS scavengers (Lee et al., 2013). Therefore if 
they are not excised in TC-NER-impaired cells, their antioxidant effect is also 
deficient, which may contribute to a severe sunburn response and 
neurodegeneration (see Figure 8.3.5). 
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8.2. Genotype-phenotype correlations 
8.2.1. Milder XP phenotypes 
It is now possible to cautiously reassure the younger generation of mild XP-A 
patients with the cryptic splice site mutation c.555+8A>G, that they may be 
spared from developing neurodegeneration seen in classical XP-A patients. 
Adherence to meticulous photoprotection will reduce sunburn and skin cancer 
risk, enabling these patients to lead relatively normal lives. This is a very clear 
benefit for quality of life.  
 
Milder phenotypes within the XP-C, XP-D and XP-G complementation groups 
have been identified, with either later presentation of clinical features or sparing 
of neurodegeneration.  In these cases, their XP mutation generates aberrant splice 
products, which may result either in normal read-through, or splicing that results 
in in-frame products, alleviating the anticipated severer phenotype.  
 
8.2.2. XP-C patients are prone to severe ocular disease 
By developing an ocular severity score, I was able to discern further differences 
in XP phenotype, aside from those relating to the skin and brain. XP-C patients 
have significantly higher ocular severity scores compared to the other XP groups 
(p=0.0018, see Figure 8.2.1A). Their severity is mainly as a result of ocular 
surface disease (conjunctival injection and corneal scarring, as opposed to neuro-
ophthalmological disease). One explanation for this may be related to their 
potentially higher cumulative UVR exposure as a result of a later age of 
diagnosis, or less strict adherence to photoprotection due to normal sunburn 
reactions. If this were the case, the number of skin cancers per patient would be 
proportional to ocular score, however there is no correlation (Figure 8.2.1B). 
Even younger XP-C patients who have not developed a skin cancer have high 
ocular scores, versus other XP-E and XP-V patients, who have developed many 
more skin cancers, but have ocular scores comparable to TC-NER-impaired 
groups. Therefore ocular disease severity in XP-C patients appears independent 
of cumulative UVR exposure and even of DNA repair capacity (see Figure 
8.3.1). This suggests an independent role of XPC in maintaining ocular surface 




Figure 8.2.1: Ocular severity scores vs. skin cancers in UK XP patients; A: Individual ocular 
severity scores in XP patients by complementation group; one-way ANOVA 
comparing ocular severity scores across groups (minus XP-C) showed no significant 
difference (p = 0.39); Kolmogorov–Smirnov test compared XP-C against remaining 
groups, showing significance, p = 0.0018; B: Number of skin cancers (KC and MM) 
per XP patient, across complementation groups. 
 
These findings highlight the importance of sequencing both genomic DNA and 
performing functional DNA repair assays to obtain accurate genotype-phenotype 
relationships. I have used these correlations in the largest cohort of XP patients 
under long-term follow-up worldwide, to form a flow diagram that may assist 
with the identification of clinical XP diagnosis in areas where laboratory testing 





Figure 8.2.2: Main XP clinical findings in this thesis, stratified for age of presentation. Flow 
diagram to assist with clinical XP diagnosis (independent of molecular UDS studies).  
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Background to my studies on XP using different UVR sources 
Since 1968, XP has been described as a disease primarily resulting from failed 
DNA repair, defined as the excision of UVC-induced DNA photoproducts 
(Cleaver, 1968). This was demonstrated using a 15W UVC germicidal lamp to 
induce DNA damage, followed by incubation with tritiated thymidine and then 
enumeration of the autoradiographic grains, which was proportional to the 
amount of DNA repair (UDS) occurring over a 3-hour period (see Figure 8.2.3). 
Since that time, the majority of in vitro studies on XP cells have used either a 
UVC source (Lehmann et al., 1975, Zelle and Lohman, 1979, Zelle et al., 1980, 
Mayne & Lehmann 1982) or a UVB source (Petit Frere et al., 1996, Berg et al., 
1998) to induce damage, measure DNA repair and study other photobiological 
responses in XP cells.  
 
 
Figure 8.2.3 Failure of XP cells to repair UVC-induced damage; this graph estimates the number 
of bases inserted in DNA during repair replication, as a function of the number of 
dimers induced by incremental UVC doses (Cleaver, 1968).  
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8.3. Molecular mechanisms of UVR-induced damage and photoageing 
I used the observed differences in sunburn, skin cancer and neurological 
phenotype to separate XP patients into two groups, TC-NER-impaired vs. TC-
NER-preserved, in order to assess for any apparent molecular differences that 
may further explain their clinical phenotype.  
 
Justification for UVR sources and doses in this thesis 
I have assessed the effects of both long-wave 385nm UVA-1 and short-wave 
254nm UVC in control and XP cells on the expression of genes relating to ECM 
degradation and oxidative stress, generation of CPD and ROS. I used an 
environmentally and physiologically relevant dose of 52.5J/cm2 (about 1 MED 
in control skin), similar to sources used in other in vivo and in vitro studies 
(Tewari et al., 2014, Wang et al., 2014) and a spectrally-pure UVA-1 source. 
My UVC lamp had a narrow emission spectrum peaking at 254nm, with no 
spectral contamination of UVB. Primary dose-response experiments showed that 
10J/m2 254nm UVC corresponded with a peak in MMP mRNA expression at 24 
hours, however after 20J/m2, MMP mRNA expression was reduced, even with 
sustained cell viability. 26.25J/cm2 385nm UVA-1 resulted in XP and control 
cell viability above 90%, however initial experiments using this dose showed 
little effect on MMP and oxidative stress mRNA upregulation and therefore the 
higher dose of 52.5J/cm2 was used. XP cell viability was lower with 52.5J/cm2 
UVA-1 than with 10J/m2 UVC (average 67% vs. 96%), suggesting greater 
potency of UVA-1-mediated damage compared to UVC. 
 
8.3.1. Rates of CPD repair in different XP complementation groups 
Measurement of UDS, proportional to the amount of DNA repair of UVC-
induced damage four hours after irradiation, is used to confirm a diagnosis of 
XP in clinically-suspected XP patients. The UDS levels measured by this 
functional assay have been performed in the majority of UK XP patients’ 
fibroblasts taken from a skin biopsy at the time of their suspected diagnosis (see 
section 1.9.3). These results are plotted in Figure 8.3.1.  
 
There was significant variation in UDS levels both within and between 
complementation groups. Highest UDS levels were in XP-V cells, correlating 
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with preservation of NER (their defect lies in post-DNA replication repair 
pathway). Mean UDS levels in XP-D and XP-E cells were 27.6% and 65.3% 
respectively; lowest UDS levels were found in XP-A and XP-G (6.9% and 3.8% 
respectively). Therefore it is apparent that UDS levels did not correlate with 




Figure 8.3.1: UDS levels in UK XP patients, grouped according to complementation group; XP-V 
patients had the highest UDS levels (mean 109%) correlating with their preserved 
NER (see section 1.9.3). Mean UDS in other groups were: XP-E 65.3%; XP-D 27.6%; 
XP-F 18.7%; XP-B 17.5%; XP-C 14.5%; XP-A 6.9% and XP-G 3.8%. 
 
UDS levels were proportional to total DNA repair of UVC-induced DNA 
damage (i.e. mainly CPD, 6-4PP and other lesions repaired by NER). The 
literature describes CPD (rather than 6-4PP) as the more potent mutagen 
involved in carcinogenesis (You et al., 2001, Jans et al., 2005), however UDS 
levels are non-specific for CPD repair and in fact it has been shown that 6-4PP 
are more rapidly repaired than CPD in the first four hours after UVR exposure 
(Mitchell & Nairn, 1989, Muramatsu et al., 1992, Nakagawa et al., 1998, Bykov 
et al., 1999, Riou et al., 2004, de Lima-Bessa et al., 2008), likely as a result of 
greater DNA distortion with 6-4PP compared to CPD (Kim et al., 1995). In vivo 
studies on skin types I and II have demonstrated that the half-life of 6-4PP 
occurred at 2.5 hours compared to 33.3 hours for CPD (Young et al., 1996); 
therefore it is possible that UDS measured in the four hours after UVC irradiation 
is proportional more towards 6-4PP repair than CPD repair (Wood, 1989). 
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None of the XP-F and XP-G patients within the UK cohort has developed a skin 
cancer. I considered that the severity of their sunburn reactions may have 
prompted an earlier XP diagnosis and consequently swifter initiation of more 
rigorous photoprotection. However, I wanted to see if a slower rate of CPD repair 
was potentially occurring over a longer time period, corresponding to a greater 
UDS level than that measured in the 4-hour period at the time of diagnosis 
(Figure 8.3.1). Unfortunately, I found no differences in rate of CPD repair 
between different XP groups in the 48 hours after 254nm UVC irradiation. It is 
possible that repair is occurring over a longer time period than 48 hours; however 
I was unable to examine for longer time periods due to limitations with XP cell 
viability. I used a small sample size (5 XP cell lines), therefore these experiments 
may need to be performed on larger numbers of XP cell lines in order to detect 
any discernable differences between groups. 
 
8.3.2. CPD and ROS generation are wavelength-dependent 
385nm UVA-1 induced ROS without CPD in vitro 
I measured ROS generation in both control and XP fibroblasts immediately after 
52.5J/cm2 385nm UVA-1 irradiation, demonstrating a higher level of ROS 
generated by UVA-1 than by the positive control (TBHT). There was no 
difference in ROS generation between 254nm UVC irradiation and background 
(unirradiated levels), indicating UVC had little immediate effect on ROS under 
these conditions. XP-C, XP-D, XP-E and XP-G cells generated significantly 
greater ROS levels after 385nm UVA-1 compared to XP-A, XP-D and control 
cells. This may indicate an impaired antioxidant defense system in these XP 
cells. The addition of 0.1mM vitamin E to all cells immediately prior to 
irradiation resulted in reduction of ROS to background levels. 
 
Speculatively, if mouse models showing GG-NER is not involved in CPD 
removal (Bohr et al., 1985, Hanawalt et al., 2001) are to be equated with human 
models, then the high levels of ROS generated in XP-C and XP-E cells by UVA-
1 may indicate that failed GG-NER repair of indirect oxidatively-induced 
damage is responsible for the high rate of skin cancer in these XP groups. 
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Notably CS and TTD patients, deficient in TC-NER, suffer from severe sunburn 
reactions but have a normal risk of skin cancer (Leibeling et al., 2006). 
I have shown that 385nm UVA-1 did not generate detectable CPD, but instead 
generated significantly higher amounts of ROS, at a physiologically relevant 
UVA-1 dose. This, together with the observed significant increase in MMP 
expression after the same dose, provides indirect evidence for ROS-mediated 
upregulation of MMP. Furthermore, the higher MMP-1 mRNA and protein 
expression in XP-C and XP-E cells may be related to a likewise greater level of 
ROS generated in these cells after 385nm UVA-1. The biological effects of 
UVR, as observed in this thesis, are summarized in Figure 8.3.2.  
 
 
Figure 8.3.2: Effects of UVR on XP cells depend on the spectrum of the UVR source. 
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Long wavelength UVA-1 has been shown to generate CPD rather than 6-4PP in 
human skin in vivo (Tewari et al., 2012), however DNA is a poor chromophore 
for UVA-1 (see Figure 1.5.1A) and so the DNA damaging effect of UVA-1 is 
more probably attributed to indirect DNA damage; ROS generation of O2*
- and 
NO* causes an increase in peroxynitrite, which excites intranuclear melanin 
derivatives, resulting in the formation of dark CPD (Premi et al., 2015), as 
opposed to ‘light’ CPD caused by direct DNA absorption of UVR photons.  
 
It was thought that 8-oxoGua would be the most ubiquitous type of damage 
induced by UVA, however studies employing high performance liquid 
chromatography-mass spectrometry (HPLC-MS) techniques have shown that 
CPD are the predominant UVA-induced DNA lesions; nine times higher than 8-
oxoGua (Douki et al., 2003, Courdavault 2004, Mouret et al., 2006).  
 
Comparing equimutagenic doses of UVA and UVB, CPD formed after UVA 
exposure, although fewer in number than those induced by UVB, do not initiate 
cell cycle arrest in the same way (Rünger et al., 2012). This may allow 
replication of DNA past CPD, allowing persistence within UVA-irradiated DNA 
(Mouret et al., 2006) and a likely higher rate of C to T transitions arising at these 
sites (Robert et al., 1996, Kappes et al., 2006, Rünger et al., 2008). This is of 
particular relevance in XP cells, where deficiency in NER leads to persistence 
of both UVB and UVA-induced CPD. In NER-proficient (non-XP cells) the 
potential for NER to remove UVA-induced CPD may be adversely affected by 
ROS-induced protein oxidation of RPA, impeding the normal function of NER 
(Guven et al., 2015). 
 
According to work by Mouret et al., there is a linear dose-response with broad-
spectrum UVA irradiation (see Figure 8.3.3). The proportion of UVB radiation 
emission reported in their UVA source represented less than 0.1%, however this 
may still have exerted considerable photobiological effects in terms of CPD 
formation (Woollons et al., 1999), particularly as they have shown generation of 
T<>C and C<>T dimers, which are not generated with spectrally-pure UVA-1 
(Rochette et al., 2003).  
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I did not detect CPD (T-T dimers) at any time point after 385nm UVA-1 
irradiation. My data are in accordance with data from Rünger et al., who showed 
very low levels of CPD, even at doses up to 400J/cm2 of UVA (Figure 8.3.4). 
With the 385nm UVA-1 doses that I used, I might have expected two to four 
CPD per million DNA bases; given that one cell contains approximately 3 billion 
DNA base pairs, I should have expected 6,000- 12,000 CPD per cell at this UVA 
dose range. It is possible that this may have been below the level of detection of 
my immunofluorescence antibody protocol, as the measurement of UVA-
induced CPD in their study used HPLC-MS techniques. However, it is also 




Figure 8.3.3:  CPD formation within human skin exposed to UVA radiation (Mouret et al., 2006) 
showing a linear dose-response in CPD generation after UVA irradiation. N.B. T<>C 
and C<>T dimers are not usually formed by UVA irradiation, which suggests UVB 
contamination of their source.  
 
Figure 8.3.4: UVB induced more CPD than UVA using roughly equimutagenic doses (Rünger et 
al., 2012). N.B. 6.4-PP are not usually formed by UVA irradiation, which also 
suggests UVB contamination of their source. 
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8.3.3. ECM degradation in XP as a marker of photoageing 
The main characteristics of photoaged skin are pigmentary changes in the form 
of lentigines, dryness, wrinkling and ultimately an increased risk of skin cancer 
development (Gilchrest & Rogers, 1993, Berneburg, 2000, Yaar & Gilchrest, 
2007), features that predominate in XP patients from an early age. The precise 
mechanism for XP-induced photoageing had not been previously studied. It has 
been suggested that the persistence of CPD within DNA of skin cells may 
contribute to the cellular effects of photoageing (Dong et al., 2008). However, I 
have shown that UVA-1 did not produce CPD; instead it generated ROS, which 
is known to have damaging effects on collagen and actin fibres leading to 
photoageing from the loss of dermal integrity (Naylor et al., 2011).  
 
UVR exposure has been shown to mediate in vitro collagen degradation (Cooper 
& Davidson, 1965), however, in 2010, Sherratt et al. showed that although 
fibrillin-containing microfibrils changed structure after UVR, neither elastin nor 
collagen were direct targets for UVR irradiation (notably these proteins are 
complex molecules containing multiple chromophores). Crucially, these two 
studies used different UVR sources: Cooper & Davidson used a Hanovia vs220 
lamp with line spectra between 185.0 and 253.7nm (emitting predominantly 
UVC), whereas Sherratt et al. used direct UVB sources at doses between 20-
100mJ/cm2. There have been limited studies identifying the effect of UVA-
induced damage on MMP upregulation and even fewer using wavelengths in 
UVA-1 spectral region (Tewari et al., 2014). 
 
It has been recently suggested that different types of UVA-induced damage other 
than CPD, could be associated with the dermal signs of photoageing exhibited 
by XP patients (Schuch et al., 2017). These lesions may include cyPudNs 
(cyclodeoxyadenosines or cyclodeoxyguanosines) formed by exposure of 
adenosine or guanine to hydroxyl radicals within DNA, respectively (Kuraoka 




Figure 8.3.5:  Implications of ROS-induced oxidative damage in phenotypes associated with XP.  
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1) 385nm UVA-1 significantly upregulated MMP mRNA and protein levels 
I demonstrated that 385nm UVA-1 irradiation induced an average 14-fold 
increase (from unirradiated) in MMP-1 mRNA expression in control cells and 
an average 26-fold increase in XP cells. I showed significantly higher MMP-1 
mRNA and protein expression in cells from TC-NER-preserved groups after 
385nm UVA-1 compared to TC-NER-impaired groups, despite initially lower 
background (unirradiated) levels of MMP-1 mRNA in XP-E cells. Most 
importantly, TC-NER-preserved groups, with normal sunburn reactions, present 
clinically with progressive lentigines and fine wrinkling, in excess of what would 
be expected for their age. These patients tend to have a later age of diagnosis 
than XP patients with severe sunburn reactions, resulting in a greater 
accumulation of UVR-induced damage and more severe skin changes (Sethi et 
al., 2015).   
 
2) UVR exerted wavelength dependent effects on MMP mRNA  
I demonstrated that 52.5J/cm2 385nm UVA-1 caused a six times greater fold 
change in MMP-1 mRNA expression compared to 10J/m2 254nm UVC, with a 
similar pattern for MMP-1 protein expression. I showed that both MMP-10 
mRNA and protein and MMP-12 mRNA expression were more significantly 
upregulated after 385nm UVA-1 compared to 254nm UVC. MMP-10 
(stromelysin-2) cleaves various ECM proteins and is involved in the activation 
of pro-MMP-1. MMP-12 is the most effective elastin-degrading enzyme 
(Taddese et al., 2009) and is known to be specifically upregulated by UVA-1 
(Tewari et al., 2014); therefore both of these enzymes are implicated in the 
mechanism of photoageing. 
 
3) Vitamin E counteracted upregulation of MMP-1 after 385nm UVA-1 
Vitamin E is one of the most abundant endogenous antioxidants found in the 
skin; it has been shown to exhibit photoprotective effects on the skin, both in 
vitro (Fuchs 1998) and in vivo (Norkus et al., 1993), by decreasing UVB-induced 
wrinkling, ROS-mediated lipid peroxidation and interleukin levels after UVA 
exposure (Werninghaus et al., 1994, Fuchs et al., 1998, Offord et al., 2002). 
Chronic UVR exposure has been shown to steadily decrease levels of 
endogenous vitamin E and other antioxidant enzymes in the skin (Maeda et al., 
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1991). An increased level of vitamin E has been observed in mice receiving daily 
topical vitamin E treatments and there was a direct correlation between reduced 
skin wrinkling and a reduced level of ROS generation in this study (Norkus et 
al., 1993).  
 
I showed that 0.1mM vitamin E was non-toxic to XP and control cells in culture. 
Pre-UVA-1 irradiation incubation with vitamin E resulted in approximately 50% 
reduction in MMP-1 mRNA fold change in all cells. In addition, pre-and post- 
irradiation incubation with vitamin E reduced UVA-1-mediated upregulation of 
MMP-10 and MMP-12 mRNA, respectively. These findings were consistent at 
a protein level for both MMP-1 and MMP-10. Vitamin E is known to act as a 
ROS scavenger, therefore lending further support to ROS-mediated MMP-1 and 
MMP-10 upregulation after UVA-1 irradiation.   
 
A similar study conducted by Offord et al. examined the effect of 50J/cm2 UVA 
(using a UVASUN 3000 lamp, with a longer irradiation time than I used) on the 
induction of MMP-1 in normal fibroblasts, with the addition of smaller doses 
vitamin E (0.5-2μM) in nanoparticle form, in combination with beta-carotene 
and vitamin C. They demonstrated a similar 50% reduction in MMP-1 mRNA 
fold change with the addition of 2μM vitamin E and the dampening effect was 
even stronger if vitamin C and beta-carotene were added in combination (Offord 
et al., 2002). This lends more support to the theory that antioxidants may be 
beneficial in counteracting the effects of UVA-induced photoageing and 
potentially in stalling skin cancer invasion, where MMP also play a role. 
 
I examined the isolated effect of vitamin E on control and XP fibroblasts (in the 
absence of UVR) and I demonstrated a small but significant upregulation of 
MMP-1, MMP-10 and MMP-12 mRNA under these conditions. These findings 
were suggestive of vitamin E acting as a pro-oxidant in the absence of UVR, 
particularly for incubation time periods of greater than 24 hours. There is some 
literature to suggest pro-oxidant activity of vitamin E, particularly with inducing 
lipoprotein oxidation (Bowry & Stocker, 1993). The disappearance of the pro-
oxidant effect on vitamin E in the presence of UVA-1 would be an interesting 
subject of further investigation. 
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A summary diagram of the biological effects exerted by UVR demonstrated in 
this thesis and in the literature, is shown in Figure 8.3.6. 
 
 
Figure 8.3.6: Schematic of solar UVR effects to the skin cells, summarising aspects observed from 
this thesis and also from the literature. 
  
 219 
8.3.4. Spectral effects of UVR on HO-1 mRNA expression 
HO-1 mRNA was significantly downregulated by 254nm UVC in TC-NER-
impaired XP groups. As HO-1 is involved in the antioxidant response and 
background HO-1 mRNA levels were equivalent for all XP groups and control 
cells, it suggests UVC-induced damage was affecting the antioxidant defense 
response. 
 
HO-1 mRNA expression was significantly upregulated by 52.5J/cm2 385nm 
UVA-1 at 24 hours after irradiation in control cells, with an average 9-fold 
increase from unirradiated. Mean HO-1 mRNA fold change was highest in XP-
D and XP-E groups (28.5 and 20.2 respectively) and lowest in XP-F (1.91), 
which correlated with levels of ROS generation (see Figure 8.3.7). ROS-induced 
lipid peroxidation is a strong inducer of HO-1 (Basu-modak et al., 1996) and 
therefore this relationship is unsurprising.  
 
There appears to be a trend of variable HO-1 mRNA levels in TC-NER-impaired 
groups after UVR, which may warrant further investigation (see section 8.5). 
 
 
Figure 8.3.7: HO-1 mRNA and ROS levels; how cumulative generation of ROS measured 2 hours 




In the study by Offord et al., 50J/cm2 UVA resulted in a HO-1 mRNA peak at 4 
hours by approximately 40-fold. None of the antioxidants used in their study 
(vitamin E, vitamin C or beta carotene) suppressed UVA-mediated HO-1 
expression, presumably because their dose of vitamin E was 50 times lower than 
the dose I used (2μM vs. 0.1mM, respectively).  
 
8.4. Summary and impact of thesis findings 
8.4.1. Impact on XP 
In this thesis I have identified important genotype-phenotype correlations for XP 
patients, both within and between their assigned complementation groups. I have 
examined sunburn, skin cancer and neurological phenotypes, demonstrating that 
the development of these clinical features is strongly dependent on the causative 
mutation and through preservation of TC-NER. These findings enable the 
provision of personalized prognostic advice for the next generation of XP 
patients and may have an influence on pre-implantation genetic diagnosis 
(although this has not yet been performed in XP patients).  This is a good 
demonstration of the role of stratified medicine in healthcare, especially for rare 
diseases.  
 
From my studies using an extreme UVR spectral range, I believe XP cannot be 
defined as a repair-deficiency exclusive to direct DNA damage; repair of indirect 
(oxidative) UVR-induced damage may also be deficient, providing further 
suggestion for the role of NER proteins in the repair of oxidative stress-induced 
damage (see Figure 8.3.5). Therefore, although UVC may be appropriate for use 
in diagnostic purposes, I have established it is not physiologically relevant for 
biological research in XP, particularly with regard to mechanisms of 
photoageing. There is an increasing realization that all photobiological 
experiments should be done with environmentally relevant UVR spectra.  
 
I have shown that spectrally pure UVA-1 generates significant ROS levels, 
without detectable CPD, that may induce oxidative DNA damage in both XP and 
non-XP cells (in the form of cyPudNs or 8-oxo-Gua/other oxidized guanine 
molecules) leading to upregulation of enzymes associated with ECM 
degradation and skin cancer invasion. Given the higher UVA: UVB ratio in solar 
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radiation reaching the earth’s surface, the importance of adequate UVA-1 
photoprotection cannot be underestimated; strict photoprotection with a 
sunscreen containing SPF50 and a 5-star UVA rating is the mainstay of treatment 
to prevent sunburn, reduce photoageing and skin cancer risk in XP patients. 
Further work on the types of damage formed by oxidative stress, aside from that 
generated indirectly from UVR may also help to explain XP neurological 
phenotypes.  
 
8.4.2. Impact on the general public 
UVA exposure to skin is increasingly becoming a major public health concern. 
In 2009, the WHO registered long wavelength UVA as a class I carcinogen (El 
Ghissassi et al., 2009). Early science demonstrating the deleterious effect of 
short wavelength UVB in inducing direct DNA damage leading to mutations that 
cause KC and MM has initiated the development and use of sunscreens filtering 
out mainly wavelengths of UVB spectrum, with an increasing SPF conferring 
higher protection. These new sunscreens may still only possess moderate 
protection against long wavelength UVA-1 radiation (see Figure 8.4.1). In 
addition, at all latitudes worldwide and regardless of ozone depletion, daily UVA 
irradiance is much higher than UVB (Schuch et al., 2017). This, together with 
use of sunscreens filtering out mainly UVB wavelengths, and the desire to travel 
to sunny climes, has led to an overwhelming increase in the amount of skin UVA 
exposure and more recent research has demonstrated the role of UVA in the 
development of both skin cancer and photoageing.  
 
My studies stress the important role of UVA-1 in oxidative stress-induced MMP 
upregulation, which is attenuated with the addition of vitamin E. This provides 
further evidence to support the use of sunscreens containing antioxidants to 
reduce UVA-1-induced skin wrinkling through elastin degradation and to 




Figure 8.4.1:  Sunscreen effects of SPF15 and SPF50 sunscreens, showing transmission occurring 
in the demarcated UVA-1 range (image kindly provided by Karl Lawrence, British 
Photodermatology Group presentation, 2017).  
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8.5. Future prospectives 
For any future experiments examining the biological role of XP proteins, it is 
necessary to avoid the use of UVC and instead use physiologically and 
environmentally relevant doses of UVA, UVB or SSR. 
 
1) Repeat exposure experiments: chronic UVR exposure results in clinical signs 
of photoageing. I performed single irradiation experiments with 385nm UVA-
1, measuring MMP mRNA and protein 24 hours after irradiation; it would be 
interesting to examine the effect of repeated low-dose UVA-1 or solar-
simulated radiation (SSR) exposures on MMP mRNA and protein levels in XP 
cells.  
 
2) ROS generation SSR in XP cells: Given the relative increase in ROS generation 
by UVA-1 in this study, it would be physiologically relevant to see if ROS 
generation is significantly higher in XP cells after SSR compared to controls. 
 
3) HPLC techniques to measure CPD and oxidative damage: HPLC techniques 
are well established to measure DNA lesions after UVR (Douki et al., 2003, 
Courdavault et al., 2004, Mouret et al., 2006). It would be intriguing to perform 
these techniques on DNA extracted from XP and control fibroblasts after 385nm 
UVA-1 and/ or SSR and correlate this to levels of ROS generation. 8-oxoGua 
and 8-oxo-dG are formed after oxidative stress and excised from DNA by both 
NER and BER. The formation and excision of these lesions in XP and control 
cells after SSR, correlating with XP clinical phenotype, may provide further 
elucidation of mechanisms leading to photoageing, skin cancer and 
neurodegeneration. 
 
4) Measurement of 6-4PP repair: 6-44PP are known to be potent inducers of 
apoptosis and their repair is reported to occur faster than that of CPD; it would 
be interesting to measure the rate of 6-4PP repair after SSR in XP and control 
lines, correlating this data with cell viability, sunburn severity scores and rates 
of skin cancer.  
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5) Photoageing severity score: There are noticeable differences in photoageing 
severity, both within and between XP complementation groups. It would be 
pertinent to conduct applied clinical research to correlate the observed 
molecular differences (MMP mRNA and protein levels) in XP patient skin with:  
a. Histological and computer-enhanced image analysis (% elastic tissue, 
Boyd et al., 1995), 
b. Silicone-based skin surface impressions to assess microtopography  
(Hughes et al., 2012), 
c. Confocal microscopy for real-time histological skin analysis (Haytoglu 
et al., 2014). 
This would more accurately categorize XP photoageing severity, in order to 
better advise on photoprotection strategies. 
 
6) Outcome of NIHR-funded XP photoprotection project: Factors relating to 
adherence to and measurement of photoprotection in XP is currently being 
examined in our XP patient cohort. It will be important to correlate the outcomes 
of that study with the molecular findings in this thesis to further emphasize the 
predisposition of photoageing and photocarcinogenesis in XP patients. 
 
7) Vitamin E (as a model antioxidant) for the prevention of photoageing: I 
demonstrated the significant downregulation of collagenase MMP-1 mRNA 
and protein when vitamin E was added pre- and post-irradiation. Further in vitro 
experiments could be performed with topical vitamin E and SSR on 3D explants 
of XP and control skin to establish photoprotective effects of vitamin E. The 
prevention of UVA-mediated oxidative damage by vitamin E may have 
beneficial effects against the development of photoageing and skin cancer in 






“New possibilities are now emerging as we bring together novel approaches, 
such as whole genome sequencing, data and informatics…it is the 
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